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Despite significant improvements in therapy, ovarian cancer continues to be 
a  leading  cause  of  death  amongst  women  with  gynaecological 
malignancies.  Advanced  stage  at  diagnosis  is  thought  to  be  a  major 
contributor  to  mortality.  Hence,  there  is  considerable  interest  in  early 
detection through screening.
In the 1990s,  Professor Jacobs pioneered the development of a multimodal 
ovarian  cancer screening  (OCS)  strategy  using  serum  CA125  as  the  first 
line  screen  and  pelvic  ultrasound  as  the  second  line  test.  This  thesis 
summarises  the  next  steps  in  the  journey  with  refining  of  the  screening 
algorithm,  feasibility  testing  in  a  pilot  randomised  control  trial  (RCT)  and 
finally setting up and recruiting 200,000 women into the largest ever RCT .
The risk of ovarian cancer in postmenopausal women with elevated CA125 
levels was established through a detailed analysis of 1219 pelvic scans from 
741  women  with  raised  CA125  levels  in  the  completed  trial  of  22,000 
women.  Based  on  this,  the  multimodal  ‘Risk  of  Ovarian  Cancer’  (ROC) 
algorithm  was  refined  and  morphology  instead  of  volume  was  used  to 
interpret the ovarian scans.
The refined ROC algorithm was then prospectively evaluated in a pilot RCT 
of  13,582  postmenopausal  women.  The  trial  established  that  screening
2
MD thesis UMusing the ROC algorithm was feasible and could achieve high specificity and 
positive predictive value.
The improved performance characteristics of the screening strategy and the 
experience accumulated  in  running  and  organising the  pilot trial  led  to the 
design and successful implementation of a RCT - the UK Collaborative Trial 
of Ovarian  Cancer Screening  (UKCTOCS)  - to  assess the  impact of early 
detection  on  disease  mortality.  The  trial  commenced  in  2001  with 
recruitment of 202,638  postmenopausal women  by  September 2005.  The 
issues involved in setting up the trial, recruitment of 202,000 women and the 
baseline characteristics of this population are described.
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8  LITERATURE REVIEW 
8.1  Introduction
Ovarian  cancer  is  the  fourth  most  common  cancer  diagnosed  in 
women  in the UK.  Nearly 6,600  new cases are diagnosed annually12 
with a world wide incidence of over 190,000 new cases.3 The disease 
has  a  high  mortality  rate.  It  is  the  leading  cause  of  death  from 
gynaecological  malignancies  in  the  UK  with  nearly  4500  deaths 
annually  and  a  case  mortality to  incidence  ratio  of 0.68.2  There  has 
been some  improvement in disease outcome over the years with the 
age-standardised 5-year survival rate of patients diagnosed  in the UK 
during  1996-99  rising to 36.4 (95%CI  (35.6 - 37.2) months compared 
to  30.6  (95%CI  30.0  -  31.2)  months  in  1991-9.4  However  there  has 
been  little decrease in the mortality rate especially in women  over 50 
years  of age  (Figure  8-1).  This  is  in  contrast to  breast cancer where 
mortality  rates  have  decreased  by  about 30%  during  the  same  time 
period.5 The data for the US shows similar trends (Figure 8-2)6.
8.2  Rationale for screening
The cancer is typically associated with vague,  non-specific symptoms 
and over 75% of women have Stage III or IV disease at diagnosis.
16
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Figure  8-1:  Age  Standardised  Mortality  Rate  for  Ovarian  and  Breast
Cancer England and Wales 1971-2005
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Figure 8-2  U.S.  Age Adjusted  Mortality  Rate for Ovarian  Cancer 1970- 
2000
The  high  mortality  is  believed  to  be  a  direct  result of  advanced  stage  at 
diagnosis, as early stage disease is associated with a 5-year survival of over
17
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80%/ The link between stage and mortality suggests that early detection of 
ovarian cancer through screening may have an impact on disease mortality 
and  this  has  lead  to  sustained  efforts  to  develop  an  effective  screening 
strategy.
There  is  preliminary evidence that early detection  may  increase  long-term 
survival.  In  a  randomised  control trial  of ovarian  cancer screening  using  a 
strategy  incorporating  sequential  CA125  and  transvaginal  ultrasound 
(multimodal strategy), median survival was significantly increased in women 
with ovarian cancer in the screened group (72.9 months) when compared to 
the  control  group  (41.8  months).8  Follow  up  data  from  prospective  single 
arm  ovarian  cancer  screening  (OCS)  trials  also  provide  evidence  of  a 
possible  survival  benefit.  In  the  Kentucky  trial  involving  nearly  15,000 
women, the survival of patients with invasive epithelial ovarian cancer in the 
annually  screened  population  was  92.9  +/-  6.9%  at 2  years  and  83.6  +/- 
10.8%  at  5  years.9  A  stage  shift  implying  better  survival  has  also  been 
reported from Japan where the authors note that prior to the onset of their 
ovarian  cancer  screening  trial,  29.7%  of  35  cancers  diagnosed  in  the 
department  were  Stage  I  while  after  the  trial  was  initiated,  58.8%  of  85 
ovarian cancers treated were Stage I.10 However,  in such studies,  lack of a 
control group raises the possibility of a "healthy-volunteer effect".  It is also 
important to  note  that the  “ovarian  cancers”   detected  by  screening  in  the 
Japanese  trial  included  granulosa  cell  and  borderline  epithelial  tumours. 
Mortality is unlikely to be reduced significantly by screen detection of these 
tumours, which have a good prognosis.
8-18
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8.3  Precursor lesions
A central principle of cancer screening is detection of a pre-invasive or early 
invasive cancer, thereby reducing disease mortality and treatment morbidity. 
Many  solid  cancers  have  a  pre-invasive  or  intra-epithelial  phase.  The 
cervical  cancer  model  best  represents  this.  About  30%  of  cervical  high 
grade  intraepithelial  lesions  may  progress  to  invasive  disease  if  left 
untreated.1 1   Other  cancers  associated  with  detectable  premalignant 
conditions include oesophagus, large bowel, endometrium, and vulva.
However,  little  is  known  about the  natural  history  of ovarian  cancer.  The 
current  view  is  that  an  unknown  but  probably  predominant  proportion  of 
tumours  arises  de  novo  from  the  surface  epithelium  of  the  ovary  or  its 
inclusion  cysts  in  the  peripheral  ovarian  cortex12.  Pathologists  who  have 
identified  dysplasia  in  the  surface  epithelium  of the  ovary  or  its  inclusion 
cysts13  14  and  who  have  studied  the  relation  of  benign  (and  borderline) 
epithelial lesions to carcinomas within the same specimen15 have presented 
persuasive evidence that benign  and  borderline  lesions  and  dysplasia  are 
precancerous  in  some  cases.  The frequency  and  speed  of their evolution 
into cancer remain  unknown.  It is  likely that they  represent the  minority of 
ovarian cancers.
The  hallmark  of  preinvasive  lesions  in  other  epithelial  cancers  is  the 
presence of an  intraepithelial lesion with the histological features of cancer
8-19
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but the absence of destructive stromal invasion. Borderline ovarian tumours, 
otherwise  called  ovarian  neoplasms  of  low  malignant  potential  or  ovarian 
intraepithelial neoplasms, fulfil the histological criteria of preinvasive lesions. 
However, there is increasing evidence that suggests that borderline tumours 
are  different  from  ovarian  cancers.  Although  they  can  occasionally  be 
multifocal  at  presentation,  in  a  manner  suggestive  of  metastatic  disease, 
recent  studies  have  shown  that while,  the  majority  of  metastatic  invasive 
ovarian cancers are  in fact clonal  in  nature,  metastatic borderline tumours, 
are  truly  multifocal  and  not from  the  same  clone.16  In  addition,  borderline 
and  invasive  ovarian  cancers  do  not  share  similar  genetic  events.  The 
tumour suppressor gene tp53 is mutated in ovarian cancers in up to 75% of 
cases while it is rarely mutated in borderline tumours. K-ras mutations occur 
relatively  frequently  in  borderline  tumours  and  uncommonly  in  ovarian 
cancers, the exception being mucinous cystadenocarcinoma.17-19 Borderline 
tumours  are  rarely  aneuploid  whilst  cancer  is  typically  so.20  So,  although 
borderline  tumours  resemble  intraepithelial  neoplastic  lesions,  they  are 
probably not the major precursor lesion for the majority of invasive ovarian 
cancers.  Borderline  tumours  however,  contribute  to  increase  the  surgical 
intervention rate in screening strategies, as they are phenotypically similar to 
ovarian cancers, making it almost impossible on imaging to differentiate the 
two.
The other possible precursor lesions for invasive ovarian cancer are benign 
ovarian  neoplasms.  If a  large  proportion  of ovarian  cancers  arose  in  this 
way,  removal  of benign  cysts  in  a  screening  programme would  impact on
8-20
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future ovarian cancer incidence. Crayford et al analysed data from a cohort 
of  5479  self-referred,  asymptomatic  women  who  participated  in  ovarian 
cancer screening trial and had been followed up for an average of 15 years. 
202 women had bilateral salpingo-oophorectomies as a result of findings on 
ultrasound  screening.  The  removal  of  persistent  ovarian  cysts  was  not 
associated  with  a  decrease  in  the  proportion  of  expected  deaths  from 
ovarian  cancer.  The  main  limitations  of this study were the  use of ovarian 
cancer mortality  rather than  incidence  as the  end  point,  the  absence  of a 
control  group  and  the  fact  that  59%  of  the  lesions  removed  were 
physiological or simple cysts rather than benign neoplasms.2 1  More recently, 
Hartge  et  al  22  assessed  whether  asymptomatic  complex  ovarian  cysts 
detected on ultrasonography in postmenopausal women were precursors to 
ovarian  cancer.  In  20,000  postmenopausal women  enrolled  in  an  ongoing 
randomised  cancer screening trial,  they compared  the  risk factor profile  of 
women with complex ovarian cysts to the established risk factors for ovarian 
cancer. The women with complex ovarian cysts did not share the same risk 
factor  profile  as  ovarian  cancer,  suggesting  that  majority  of  the  complex 
cysts  and  other  clinically  suspicious  abnormalities  detected  on 
ultrasonography were not immediate precursors of ovarian cancer.
Thus,  a  true  precursor  lesion  for  ovarian  cancer  has  yet to  be  identified, 
limiting  the goal  of screening  to detection  of asymptomatic,  preclinical  low 
volume disease.
8-21
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8.4  Target populations
There are two groups of women who are at risk of ovarian cancer.
8.4.1  High risk population
Hereditary  syndromes  account  for  approximately  5%  of  ovarian  cancers. 
First-degree female relatives of affected members from ovarian cancer only 
or  breast and  ovarian  cancer or  hereditary  non-polyposis  colon  (HNPCC) 
cancer families have a lifetime risk of developing ovarian cancer of 10% or 
more.  Much  of this  risk  in  nonHNPCC  families  is  due  to  mutations  in  the 
BRCA1  and  BRCA2 genes. The average cumulative  risks by age 70 years 
for  ovarian  cancer was  39%  (18%-54%)  in  BRCA1-mutation  carriers  and 
11% (2.4%-19%) in BRCA2 mutation carriers.23 In HNPCC there is a 7-12% 
lifetime  risk of ovarian  cancer24  In  such  populations,  the  ovarian  cancers 
occur somewhat earlier with the median age at diagnosis of ovarian cancer 
in BRCA1  carriers being 51  years and in BRCA2 carriers 57 years.  In such 
high  risk  populations,  the  most  effective  method  of  risk  reduction  is  risk 
reducing  bilateral  salpingo-oophorectomy  when  women  have  completed 
their families  and  are  in  their forties.15 25" 29.  In  those  unwilling  to  undergo 
surgery, screening is an option, although the efficacy of such surveillance is 
not yet established.30
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8.4.2  General population
90% of ovarian  cancers are sporadic and  occur in the general  population,. 
Age  is  a  strong  determinant  of  risk  with  over  90%  of cases  occurring  in 
women aged over 451. Age specific rates peak in the ages of 74-85 (Figure 
8-3)2 The age adjusted rate for ovarian cancer in women over the age of 50 
based  upon  1996-2000  US cancer registry data was 44.97 (95%CI 44.01  - 
45.95)  per  100,000  while  that  in  women  below  the  age  of  50  was  6.16 
(95%CI  5.94  -   6.39).3 1   General  population  screening  trials  are  usually 
limited to women over 50 years of age.
1,000  T T  80
Female cases —  Female rates
60  £ 750  -
0
1
40  ©
E 3
z
-  20 250  -
^   »   5   o  
cm  cm  rt  n
Age at diagnosis
Figure  8-3:  Numbers  of  new  OC  cases  and  age  specific  incidence 
rates, UK 20032
Other risk factors for targeting  women  at increased  risk within  the general 
population  are  menopausal  status,  years  of  oral  contraceptive  use  and 
parity.  Various  groups  are  investigating  the  role  of  single  nucleotide 
polymorphisms  in  low  and  moderate  penetrance  genes  and  their
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interactions with  environmental  and  lifestyle factors.  It  may  be  possible  in 
the  future  to  identify  women  with  increased  susceptibility  for  sporadic 
ovarian cancer based on their genetic profile and lifestyle factors.
8.5  Screening tests
A variety of screening tests based on  biochemical,  morphological, vascular 
and  cytological  tumour  markers  have  all  been  explored  with  varying 
success.
8.5.1  Tumour markers
Circulating  antigens released  by the tumour predominate in this group, the 
best known being CA125.
CA125
CA125 is an antigenic determinant on a high-molecular-weight glycoprotein 
recognised  by  the  murine  monoclonal  antibody  OC125  which  was  raised 
using  an  ovarian  cancer cell  line  as  an  immunogen.32.  It  is  expressed  by 
amnion and coelomic epithelium during foetal development. In the adult, it is 
found in structures derived from coelomic epithelium (the mesothelial cells of 
the  pleura,  pericardium,  and  peritoneum)  and  in  tubal,  endometrial  and 
endocervical  epithelium.  Curiously,  the surface epithelium  of normal foetal 
and adult ovaries do not express the determinant, except in inclusion cysts, 
areas of metaplasia and  papillary excrescence.33 More  recently expression
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has been  identified outside the female genital tract in epithelial cells of the 
lung, breast, conjunctiva and glandular epithelium of the prostate gland.34
Although  CA125  antigen  was  first  detected  in  1981,  very  little  is  known 
about its biochemistry and genetics. In the late 1990s, molecular analysis of 
the  CA125  antigen  identified  a  mucin-type  glycoprotein  which  is  highly 
glycosylated with the protein  moiety  rich  in  serine,  threonine and  praline.35 
Possibly because of the mucinous nature of CA125  its peptide moiety has 
been very difficult to clone. In 2001, molecular cloning of the CA125 ovarian 
cancer antigen  led  to the  identification  of a  new  mucin,  MUC16.36 37 The 
gene has been localized provisionally to chromosome 19 p13.3.
The CA125 antigen carries two major antigenic domains classified as A, the 
domain  binding  monoclonal  antibody  OC125  and  B,  a  domain  binding 
monoclonal  antibody  M1138.  Immunoassays  for measuring  serum  CA125 
levels are now usually based on a heterologous assay (CA125II) using both 
monoclonal  antibodies  (M11  and  OC125),  as  opposed  to  the  original 
homologous  assay  done  with  monoclonal  antibody  OC125  alone.  The 
CA125II  assay  is  sensitive  and  reliable  for measuring  serum  CA125,  and 
fully retains the cut-off values of 35 and 65  units/ml that were defined with 
the original CA125 immunoradiometric assay.39 The serum value of 35U/ml, 
representing  1%  of  healthy  female  donors,  is  a  widely  accepted  as  the 
upper  limit of  normal40  It should  be  noted  that this  is  an  arbitrary  cut off 
which  may  not  be  ideal  for  some  applications  of CA125.  For example  in 
postmenopausal women or in patients after hysterectomy CA125 levels tend
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to be lower than  in the general population and  lower cut-offs may be more 
appropriate; 20U/ml and 26U/ml have been suggested.4142
Approximately  83%  of  patients  with  epithelial  ovarian  cancer  will  have 
CA125  levels  >35U/ml40  43  50%  of  patients  with  Stage  I  disease  have 
elevated  levels while raised  levels are found  in  >90% of women with  more 
advanced  disease.44  Lower  incidences  of  CA125  elevation  are  found  in 
mucinous, clear cell and borderline tumours 45_47. Elevation of serum CA125 
may also  be  associated  with  other malignancies  (pancreas,  breast,  colon, 
bladder,  liver,  lung)48  as  well  as  benign  disease  (diverticulitis,  uterine 
fibroids,  endometriosis,  benign  ovarian  cysts,  tubo-ovarian  abscess, 
hyperstimulation  syndrome,  ectopic  pregnancy)49  and  physiological 
conditions  (pregnancy  and  menstruation).50  Many  of these  non-malignant 
conditions are not found in post-menopausal women, thereby improving the 
diagnostic accuracy of an elevated level in this population.
Various  refinements  in  the  last  decade  have  lead  to  improvements  in 
sensitivity  and  specificity  of  ovarian  cancer  screening  using  CA125.  Key 
among them are:
(1)  Pelvic ultrasound as a second line test
Specificity of screening with CA125 was initially improved by the addition of 
pelvic  ultrasound  as  a  second  line  test  to  assess  ovarian  volume  and 
morphology.  Using  multimodal  screening  incorporating  sequential  CA125 
and pelvic ultrasound, a specificity of 99.9% and positive predictive value of
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26.8% (approximately 4 operations for each cancer) for detection of ovarian 
and fallopian tube cancer was achieved  in 22,000 postmenopausal women 
5 1   52.  With  the  accumulation  and  analysis  of  data  (as  part  of  the  work 
undertaken  in  this  thesis),  ovarian  morphology  has  been  used  to  refine 
algorithms for the interpretation of ultrasound in postmenopusal women with 
elevated CA125 levels 53 64.
(2)  Risk  of  Ovarian  Cancer  Algorithm  (ROCA)  to  interpret  CA125 
results
The CA125 based screening strategy was further improved by incorporating 
a  more  individualised  approach  rather  than  absolute  cut-off  levels  to 
interpret  CA125  results.  Detailed  analysis  of  over  50,00  serum  CA125 
values involving 22,000 volunteers followed up for a median of 8.6 years in 
the study by Jacobs et al  revealed 851 that elevated CA125 levels in women 
without  ovarian  cancer  are  static  or  decrease  with  time  while  levels 
associated with malignancy tend to rise. This finding has been incorporated 
into  a  computerised  algorithm  that  uses  an  individual’s  age  specific 
incidence of ovarian cancer and serial CA125 profile to estimate her risk of 
ovarian  cancer  (ROC)  55 56.  The  closer  the  CA125  profile  to  the  CA125 
behaviour of known cases of ovarian cancer, the greater the risk of ovarian 
cancer.  The  final  result  is  presented  as  the  individual’s  estimated  risk  of 
having  ovarian  cancer so that a  ROC of 2%  implies a  risk of 1   in  50.  The 
ROC algorithm increases the sensitivity of CA125 compared to a single cut­
off value  because  women  with  normal  but  rising  values  are  identified  as 
being at increased risk. At the same time, specificity is improved as women
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with  static  but  elevated  levels  are  classified  as  low  risk.  For  a  target 
specificity  of  98%,  the  ROC  calculation  achieved  a  sensitivity  of  86%  for 
preclinical  detection  of ovarian  cancer.55  This  approach  forms  part  of the 
multimodal  screening  strategy  in  the  recently  completed  pilot  randomised 
control trial of ovarian cancer screening at Bart’s London 57 and is part of the 
ongoing  UK  Collaborative  Trial  of  Ovarian  Cancer  Screening 
(www.ukctocs.ora.uk).  The  ROC  algorithm  is  also  being  evaluated 
prospectively as part of the OCS strategy in two trials in ‘high risk’ women in 
USA -  one under the auspices of the Caner Genetics Network and the other 
by the Gynaecology Oncology Group (GOG199 study protocol). In the UK, it 
is to be used in Phase II of the UK Familial Ovarian Cancer Screening Study 
(UKFOCSS).
New tumour markers
Certain tumours (e.g.  mucinous and  borderline carcinomas) are  less  likely 
to  be  associated  with  elevated  CA125  levels  than  invasive  serous 
cancers.44  In  the  past  decade,  significant  progress  has  been  made  in 
developing novel tumour markers for use in OCS. While some like CA72-4 
or  TAG  72  47 5M0,  O V X I^and  LPA64  have  not  lived  up  to  their  initial 
promise. Novel markers undergoing current evaluation are listed in 
Table 8-1 55  It is important to appreciate that most of these have been so far 
studied using samples from women with clinically diagnosed ovarian cancer 
(i.e.  differential  diagnosis  of ovarian  cancer)  as  opposed  to  asymptomatic 
women with pre-clinical disease (i.e. early detection of ovarian cancer). They
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therefore need to undergo significant further evaluation before their potential 
in OCS can be determined.
In  the  new era  of proteomics,  in  addition  to  individual  markers,  there  has 
been a great deal of interest in identifying global patterns of serum proteins 
and peptides that relate to cancer risk. A wide range of techniques are now 
available for protein identification and characterization where high sensitivity 
and  specificity  is combined with  high  throughput.  Surface-Enhanced  Laser 
Desorption  Ionization  Time-Of-Flight  (SELDI-TOF)  analysis  and  Matrix- 
Associated  Laser  Desorption  Ionization  Time-Of-Flight  (MALDI-TOF) 
technology have the potential to identify patterns or changes in thousands of 
small  proteins  (<20  kd).  When  combined  with  matrices  that  selectively 
absorb  certain  serum  proteins,  these  approaches  can  globally  analyze 
almost all small proteins in complex solutions, such as serum or plasma.66 67 
Combination  of  mass  spectra  generated  by  these  new  technologies  and 
artificial-intelligence-based  bioinformatics  algorithms  have  been  used  to 
discover  small  sets  of  key  protein  values  that  discriminate  normal  from 
ovarian cancer patients. A preliminary study reported that using SELDI-TOF 
to analyze the proteomic spectra patterns of serum, a discriminatory pattern 
correctly identified all 50 ovarian cancer cases in the masked set including 
all 18 stage I cases with a specificity of 95% (87-99), and positive predictive 
value of 94% 68. The results of this study have not so far been validated and 
the limitations of the study design and data analysis have been discussed in 
some detail in the literature 69-75 While there are challenging  issues related 
to  sample  processing,  study  design  as  well  as  the  reproducibility,
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sensitivity,  and  specificity of this  new technology,  the implications of such 
proteomic spectrum analysis for the identification of novel tumour markers is 
huge..76  It is possible that in the future, the early detection of ovarian  (and 
other) cancers will involve high throughput proteomic profiling either alone or 
in combination with markers already in use.
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Table 8-1: Tumour markers currently undergoing evaluation for OCS
Tumour marker Description
M-CSF
Serum  macrophage  colony-stimulating  factor  is  a  cytokine  produced  constitutively  by  normal  as  well  as 
neoplastic ovarian epithelium. Levels are elevated in 68% of patients with ovarian cancer compared to 2.5% 
of apparently,  healthy controls77.  Elevated  levels have  been  found  in ovarian cancer patients with  normal 
levels of CA125 77. While CA  125 alone was elevated  in 67% of 46 patients with stage I ovarian cancer, 
CA125 or  M-CSF was elevated in 91% 78.
Prostasin
Prostasin  is  a  serine  protease  normally  secreted  by  the  prostate gland.  It was  identified  as  a  biomarker 
following identification of gene over-expression using micro array technology on RNA pooled from OC and 
normal human ovarian surface epithelial cell lines. The combination of CA 125 and prostasin in 37 patients 
with  non-mucinous  ovarian  cancer  and  100  control  subjects,  resulted  in  a  sensitivity  of 92%  (95%  Cl  = 
78.1% to 98.3%) and a specificity of 94% (95% Cl = 87.4% to 97.7%) for detection of ovarian cancer79.
Osteopontin
Osteopontin  is  another  bio-marker  that  has  been  identified  by  exploiting  gene  expression  profiling 
techniques.  Plasma  levels  of osteopontin  were  significantly  higher  in  patients  with  EOC  compared  with 
healthy  controls,  patients  with  benign  ovarian  disease  and  with  other gynaecologic cancers.80  However, 
Stage  IV  OC  patients  and  those  with  ascites  had  higher  plasma  osteopontin  levels  than  those  without 
ascites and with early stage disease.  The sensitivity in detecting OC was 81.3% compared to 84.4% with 
CA125  alone  and  specificity  was  moderate.  Sensitivity  increased  to  93.8%  when  the  markers  were 
combined.8 1  In urine samples from OC patients, urinary osteopontin fragments have been described.82
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Table 8-1: Tumour markers currently undergoing evaluation for OCS (contd)
Kallikreins
The human kallikrein gene family currently consists of 15 members which includes prostate-specific antigen 
(hK3).  Preliminary  reports  indicate  that  two  kallikreins  (hK6.  hK5  and  hK10)  may  be  useful  serum 
biomarkers for diagnosis of ovarian83-85
HE4
Among  the genes  most commonly  identified  in  gene  expression  profiles of epithelial  ovarian  carcinomas 
(EOC) is the gene for human epididymis protein 4 (HE4).86 On immunohistochemical assessment,  normal 
ovarian  surface  does  not  express  HE4,  while  cortical  inclusion  cysts  lined  by  metaplastic  Mullerian 
epithelium  abundantly  express  the  protein.  Its  expression  in  tumours  is  restricted  to  certain  histological 
subtypes:  93% of serous and  100% of endometrioid  EOCs expressed HE4, whereas only 50% and 0% of 
clear cell carcinomas and mucinous tumours, respectively, were positive87 Although the function of the HE4 
protein  is  unknown,  it is a  member of a family of stable 4-disulfide core proteins that are secreted at high 
levels.  In a  blinded  study on  sera from postmenopausal patients with ovarian carcinoma and controls, the 
specificity and sensitivity of the HE4-based ELISA was found to be equivalent to that of the CA125 assay. 
However, the HE4 assay may have an advantage over the CA125 assay in that it is less frequently positive 
in patients with non-malignant disease.88
Mesothelin
Mesothelin is a cell surface glycoprotein that is present on normal mesothelial cells and over expressed  in 
several cancers including ovarian tumours.89 Using a sandwich ELISA developed in the laboratory, the level 
of circulating antigen was found to be significantly elevated in sera from patients with ovarian carcinoma, as 
compared with  healthy controls and  patients with other tumours.90 9 1   One of the current focuses is to use 
mesothelin as a target for immune-based therapies.
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Table 8-1: Tumour markers currently undergoing evaluation for OCS (contd)
Soluble EGF 
receptor
EGF receptor (ErbB1) over expression is common in human OC-derived cell lines and tumours.  Recently, 
an  immunosorbent  assay  that  detects  an  approximately  110-kDa  soluble  analogue  of  EGF  receptor 
(sEGFR) has been described. Serum sEGFR concentrations in stage I/ll and stage lll/IV EOC patients have 
been found to be significantly lower than in healthy women.  Logistic regression models showed that lower 
serum  sEGFR  concentrations  are  associated  significantly  with  a  greater  risk  of  EOC  and  age  or 
menopausal  status-specific cut-off values for sEGFR  concentration are appropriate.  By maintaining a test 
specificity  of approximately  95%  across  the  strata  of age  or  menopausal  status  with  appropriate  cut-off 
values, sEGFR concentrations had a sensitivity for detecting stage I/ll of 64-67% and stage lll/IV of 75-81%) 
in young, premenopausal women.92 93
Inhibin
Serum inhibin is an ovarian product, which decreases to non-detectable levels after menopause.  However, 
certain  ovarian  cancers  (mucinous  carcinomas  and  sex  cord  stromal  tumours  such  as  granulosa  cell 
tumours)  continue to  produce  inhibin,  which  provides  a  basis for a  serum  diagnostic test.  Available  data 
show that inhibin assays which detect all inhibin forms,  i.e.  assays which detect the alpha subunit both as 
the free form and as an alphabeta subunit dimer provide the highest sensitivity/specificity characteristics as 
an ovarian cancer diagnostic test94
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Use of marker panels
Use  of multiple  markers  may  increase the sensitivity for early detection  of 
ovarian  cancer.  However,  increased  sensitivity  is  usually  associated  with 
decreased  specificity.  A  panel  of  8  different  markers  (CA  125,  M-CSF, 
OVX1,  LASA,  CA15-3,  CA72-4,  CA19-9,  CA54/61)  improved the sensitivity 
for discriminating malignant from  benign  pelvic masses 9S .  Using the same 
data set, a subset of four markers (serum CA-125II, CA 15-3, CA 72-4, and 
M-CSF) analysed  using an artificial neural network demonstrated  improved 
sensitivity  over  CA125  alone  (87.5%  versus  68.4%)  while  maintaining 
comparable  specificity.  Estimates from  the  training  set were  applied  to  an 
independent validation  set of 60  stage  I  to  II  OC  patients  and  98  healthy 
controls from two other centres. Combining information on CA-125II, CA 72- 
4,  and  M-CSF  significantly  increased  preoperative  early-stage  sensitivity 
from  45%  with  CA-125II  alone  to  70%,  while  maintaining  98%  first-line 
specificity.  In  addition,  greater specificity  using  multiple  markers  might  be 
attained if serial values are employed.96 Preliminary data on a panel of five 
serum  tumour markers  (CA125,  HER-2/neu,  urinary gonadotropin  peptide, 
lipid-associated  sialic  acid,  and  Dianon  marker  70/K)  obtained  during  6 
years  of follow-up  of  1257  healthy  women  at  high  risk  of ovarian  cancer 
suggests that, individual-specific screening rules may be developed with the 
potential to improve early detection of ovarian cancer.97
8.5.2  Imaging
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Real time  ultrasound screening  is used  in an attempt to detect the earliest 
possible architectural changes in the ovary that accompany carcinogenesis. 
Transvaginal  ultrasound  (TVS)  is  preferred  because  of the  more  detailed 
images obtained.  Both  ovarian  volume and  morphology are assessed with 
cut-offs for volume  ranging from  8mls to 20mls depending  on  menopausal 
status.98"100  The  lack  of  physiological  changes  in  ovarian  volume  in 
postmenopausal  women  helps  decreases  the  number  of  false  positives 
when compared to premenopausal women.  However even  in older women 
there is a  high  prevalence of benign  ovarian  lesions.  In  an  ultrasound  and 
histopathological autopsy study of 52 consecutive postmenopausal women, 
(mean  age  79,  range  64-96  years),  who  died  from  causes  other  than 
gynaecological or intraperitoneal  cancer,  56% were found to have a <_50 
mm  benign  adnexal  lesion.1 0 1   In  a  more  recent  autopsy  study  of  234 
postmenopausal  women  who  had  died  from  non-gynaecological  diseases 
ovarian  cysts were found  in  15.4%.  All  cysts were  benign,  except for one 
woman,  who  had  bilateral  borderline  serous  cystadenoma.102 
Ultrasonography can therefore lead to the detection of many benign ovarian 
tumours and hence unnecessary surgery in healthy, asymptomatic women.
Other issues with  ultrasound  screening  for adnexal  masses  is  the  lack  of 
standard definitions and  classification.103  The  International Ovarian  Tumor 
Analysis  (IOTA)  group  have  attempted  to  provide  standardised  terms  and 
procedures to describe anatomical features by B mode imaging. They have 
provided definitions for morphological features such as septum, solid areas, 
papillary  projections,  cyst  wall  irregularity.  All  lesions  have  been  divided
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qualitatively into a total of six categories that include  unilocular,  unilocular- 
solid, multilocular, multilocular-solid, solid and non-classifiable tumours.104
An  additional  issue  is  subjective  assessment  of  images  which  leads  to 
significant  inter observer variability.  In  a  prospective  study of 300  patients 
whose  pre-operative  recorded  images  were  independently  reviewed  by  5 
ultrasonographers with different qualifications and degree of experience, the 
most  experienced  investigator  obtained  an  accuracy  of  92%  while  less 
experienced observers obtained significantly lower accuracy (between 82% 
and 87)105 . Another prospective study based on 173 women who were also 
scanned  preoperatively  showed  that  with  experienced  sonographers, 
subjective  evaluation  of  the  gray-scale  ultrasound  image  is  the  most 
accurate method for distinguishing between  benign  and  malignant adnexal 
lesions.106 Self-teaching computer models such as neural networks that may 
increase  the  reproducibility  of  results  are  being  investigated  in  order  to 
address the problem of the subjectivity of ultrasound.107
Given the high incidence of benign adnexal lesions, it is crucial to be able to 
characterise  ovarian  cysts  detected  on  scanning  in  order  to  reduce  false 
positive rates. As data regarding outcome accumulates with long-term follow 
up of the  participants of the early screening  trials,  it  has  been  possible to 
correlate  the  risk  of  ovarian  cancer with  various  ultrasound  findings.  The 
work  done  in  the  initial  chapters  of  this  thesis  established  that  use  of 
complex  ovarian  morphology  to  interpret  pelvic  ultrasound  increases  the 
sensitivity and  positive predictive value  in  multimodal screening.54 Similarly
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follow  up  of  participants  in  the  Kentucky  ultrasound  based  OCS  trial 
established  that  unilocular  ovarian  cysts  <10cm  in  diameter  are  found  in 
18% of asymptomatic postmenopausal women aged over 50 years and are 
associated with  an  extremely  low risk of malignancy.108'110  In  cysts with  a 
mean  diameter  of  >5  cm,  however,  there  is  a  chance  that  papillary 
formations or solid  parts may be  missed  by TVS.1 1 1   Hence  conservative 
management  is  often  limited  to  smaller cysts.  In  contrast to  unilocular or 
simple  cysts,  complex ovarian  cysts with  wall  abnormalities or solid  areas 
are  associated  with  a  significant  risk  for  malignancy.109  Based  on  gross 
anatomic  changes  at  the  time  of  surgery,  papillary  projections  have  the 
highest and simple cysts and septal thickness the lowest correlation with a 
diagnosis  of  ovarian  malignancy.112  Numerous  weighted  morphological 
indices based on ovarian volume,  outline,  presence of papillary projections 
and  cyst  complexity  (i.e.  number  of  locules,  wall  structure,  thickness  of 
septae  and  echogenicity  of  fluid)  have  been  proposed  to  improve 
discrimination  of benign and malignant masses  .  There  is  no standardised 
index  as  yet  with  systems  varying  on  the  number  and  type  of  variables 
evaluated.113-116  On  prospective  testing  none  of  the  current  models  have 
been  found  to  beat  an  expert  sonologist.117  118  Further  refinement  of 
mathematical  models  and  review  of  results  of  multicentre  trials  are  need 
before clinical use of these mathematical models can be advocated.
In  the  recently  reported  prospective  clinical  study  by  the  IOTA  group 
involving nine European ultrasound centres, 1,066 symptomatic women with 
an adnexal mass underwent TVS gray scale and colour Doppler ultrasound
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examination  by  a  skilled  examiner  before  surgery.  A  standardized 
examination  technique  and  predefined  definitions  of  ultrasound 
characteristics were used. The 1,066 masses included 55 ovarian borderline 
tumours,  144  primary  invasive  epithelial  ovarian  cancers  (42  stage  I,  102 
stages 2-4), 25  rare malignancies,  and 42  metastatic tumours.  Most (56%) 
metastatic tumours  and  most  (60%)  rare  types  of tumour were  solid  and 
richly  vascularised  at  colour  Doppler  ultrasound  examination.  Borderline 
ovarian tumours and stage I primary invasive EOC differed significantly from 
stages ll-IV primary invasive EOC in that they were  larger (median volume 
375  ml  and  695  ml  vs.  209  ml),  more frequently  had  papillary  projections 
(64%  and  67%  vs.  41%),  were  multiloculated  without  solid  components 
(18%  and  14% vs.  2%) and  less often  purely solid  (5%  and  7% vs.  38%). 
With increasing degree of invasiveness, ascites became more common and 
the  proportion  of  solid  tissue  increased.119  Diagnostic  difficulties  were 
particularly  related  to  borderline  tumours,  papillary  cystadenomas,  struma 
ovarii and some myomas. Logistic regression models did not seem to solve 
the  diagnostic  problem  in  difficult  pelvic  masses.120  Similar data  on  large 
numbers  of adnexal  masses detected  by  screening  asymptomatic  healthy 
women is not yet available.
One of the main strategies to  decrease false positives in TVS screening is 
repeat scanning 4-6 weeks following initial detection to check for persistence 
or  change  in  the  morphology  or  size  of  the  detected  abnormality.100  108 
Among postmenopausal women  in the Kentucky ultrasound screening trial, 
49%  of  unilocular  cysts  and  55%  of  complex  tumours  resolved
8-38
MD thesis UMLITERATURE REVIEW
spontaneously within 60 days of the initial scan.108 In the ultrasound based 
European  Randomised  Control  Trial  Of Ovarian  Cancer Screening  (which 
recruited about 15,000 postmenopausal women before it was discontinued), 
multicystic  and  multilocular  cysts  in  addition  to  unilocular  cysts  were 
managed  conservatively if the morphology remained  unchanged  on  repeat 
scanning.1 2 1   This  parallels  the  move  in  clinical  practice  of  conservative 
management  of  adnexal  cysts  judged  to  be  benign  at  transvaginal 
ultrasound  examination  when  they  are  incidentally  detected  in 
postmenopausal women.117 Follow up data on such women will be important 
in refining optimal strategies for operative intervention in screening.
Neovascularisation  is  an  obligate  early  event  in  tumour  growth  and 
neoplasia. Fast growing tumours contain many new vessels which have less 
smooth muscle in their walls and therefore provide less resistance to blood 
flow when compared to vessels within benign ovarian tumours.  Colour-flow 
Doppler  imaging  uses  these  altered  blood  flow  patterns  as  markers  to 
differentiate malignant from physiologic and benign lesions. However while it 
has  been  demonstrated  that  the  mean  PI  of  vessels  supplying  ovarian 
cancers is lower than that of vessels supplying  benign ovarian tumors, the 
overlap  in  vascular resistance between these two groups prevents  reliable 
separation  of  malignant  from  benign  ovarian  tumors.  The  optimal 
parameters  and  cut-off  levels  (pulsatility  index  (PI)  <1.0,  resistance  index 
<0.4  or  0.6,  or  peak  flow  velocity)  with  the  highest  predictive  value  for 
malignancy have been difficult to define. The IOTA group have attempted to 
provide  standardized  terms  and  procedures  to  describe  the  vascular
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features detected by colour flow Doppler imaging. The vascular features are 
assessed  by  examination  of  the  entire  tumour  by  colour  flow  Doppler 
imaging.  Scores of 1   to 4 are given dependent on the degree of blood flow 
visualized,  score  of  1   being  absence  of  blood  flow  and  4  being  highly 
vascular lesion with marked blood flow and 2 and 3 are in between.104
Colour  Doppler  has  been  used  both  as  a  first  line  screening  test  in 
combination  with  transvaginal  ultrasound122  123  as  well  as  a  second  line 
test1 2 1   124  in  screening  both  general  and  high  risk  populations.  The  initial 
promise  of Doppler to differentiate  between  malignant and  benign  ovarian 
masses  and  therefore  improve  the  specificity  of  ultrasound122  123  has  not 
been  sustained.125  It  was  initially  reported  that  lack  of  blood  flow  in  an 
ovarian tumor as detected by color Doppler could preclude cancer. This has 
not been  substantiated  by data  from  either clinical  studies116  or screening 
trials.  In  the  Kentucky  ultrasound  screening  trial,  6%  of  ovarian  tumors 
without blood flow were malignant.  Even when  Doppler examinations were 
simplified  and  limited  to  the  expression  of  internal  color  flow,  gray-scale 
sonography  was  a  more  sensitive  indicator  of  malignancy  than  Doppler 
sonography.106  116  Key  issues  with  regard  to  Doppler  examination  as  a 
possible  second-line  study for  ultrasound-based  ovarian  cancer screening 
protocols  are  whether  the  examination  should  focus  on  quantitative  or 
qualitative differences in blood flow within complex masses,  difficulties with 
interobserver  variation  and  lack  of  standardisation.  At  present  the 
consensus  of  opinion  is  that  colour  flow  Doppler  evaluation  of  ovarian
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masses will not significantly improve the accuracy of gray-scale sonography 
except perhaps in a few highly selected cases.
Three-dimensional  (3D)  power Doppler ultrasound  provides a  new tool to 
evaluate  features  of  tumor  vascularity  Combined  evaluations  of 
morphology  and  neovascularity  using  3D  ultrasound,  3D  power  Doppler 
and  contrast-enhanced  3D  power  Doppler  helps  delineate  overall  vessel 
density  and  branching  patterns  within  an  intratumoral  abnormality. 
Preliminary  studies  on  symptomatic  patients  suggest  increased  accuracy 
in  differentiating  benign  from  malignant  adnexal  lesions.  126-130  in  a 
prospective  study  of  656  consecutive  women  with  adnexal  masses 
scheduled for surgery in two European university centres, TVS had a false- 
positive  rate  of  18%  while  the  false-positive  rates  of  colour  Doppler  and 
power  Doppler  imaging  were  4.6  and  7.4%,  respectively.  Although  the 
overall  diagnostic  accuracy  of  the  two  techniques  seemed  comparable, 
colour  Doppler  imaging  showed  a  higher  false-negative  rate.1 3 1   In  the 
screening  context,  3D  ultrasonography  with  power  Doppler  has  recently 
been  used  as  a  second  line  test  in  a  TVS  based  OCS  study  of  3,201 
asymptomatic women aged >50 years.  Twenty-five patients with  persistent 
abnormalities after primary and secondary screening underwent surgery and 
five  Stage  I  EOC  were  detected.  3D  ultrasonography  and  power  Doppler 
were indicative of malignancy in all 5 patients whereas colour flow Doppler 
was negative in 2 of the patients with stage I disease.132 
Magnetic  resonance  imaging  (MRI),  computerised  tomography  (CT)  and 
positron emission tomography (PET)  have been  used as third  line tests to
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improve discrimination between benign and malignant adnexal lesions in the 
ovarian  arm of the  Prostrate  Lung Colon  Ovary Screening Trial  (PLCO)133. 
There  are  as yet  no  formal  reports  analysing  their specific  contribution  in 
reducing surgical intervention rates. Clinical studies exploring the role of CT 
and MR imaging in the diagnosis of OC seem to suggest that where there 
is  uncertainty on  ultrasound  assessment,  MRI  may  provide  more  specific 
information  and  help  to  better  distinguish  benign  from  malignant.134 
Accuracy  is  particularly  high  with  regard  to  mature  cystic  teratomas, 
endometriotic  cysts,  and  leiomyomas.  CT  however  is  not  useful  for 
differential  diagnosis  of  adnexal  masses  because  of  poor  soft  tissue 
discrimination, except for fatty tissue and  calcification.135'138 However,  it is 
to  be  noted that negative  MRI  or PET  results do  not rule  out early-stage 
ovarian cancer or borderline malignancies.139
The tumour marker serum CA125 is frequently used to asses the malignant 
potential of a persistent adnexal mass detected on  ultrasound screening.133 
140 The Risk of Malignancy Index (RMI) which incorporates the CA125 value 
and an  ultrasound  scoring system and  menopausal status  is often  used  in 
the clinical context to triage management in women with suspicious adnexal 
masses.141'146  However,  it  is  crucial to  note  that most screening  trials do 
report  EOC  that  were  detected  on  ultrasound  but  had  normal  CA125 
levels.132133147
8.6  Screening Strategies
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The main screening tests,  serum  CA125 and TVS have been  incorporated 
into three distinct screening strategies:
(1) Multimodal  based  on  measurement  of  the  serum  tumour  marker 
CA125  as  the  first  line  test  with  TVS  if  the  level  is  abnormal. 
Increasingly  the  serum  CA125  is  interpreted  using  the  Risk  of 
Ovarian Cancer (ROC) algorithm
(2) Ultrasound  based  on  primary  screening  using  TVS  followed  by  a 
repeat scan in 6-8 weeks if the first detects an abnormality
(3) Combined where both serum CA125 and TVS are done as first line 
tests.
Currently the first two strategies are being investigated  in  UKCTOCS which 
is the subject of part of this thesis and the third strategy has been adopted in 
the  ovarian  arm  of the  PLCO trial  and  in  many  of the  reported  ‘high  risk’ 
screening studies.
8.7  Screening interval
Most  general  population  trials  to  date  have  empirically  chosen  annual 
screening.  If the screening interval is too short, this will lead to higher false 
positive rates with its resultant cost and morbidity.  If however the screening 
interval  is too long then one may miss the opportunity of detecting women 
with early stage disease.  Based  on  an  analysis of follow up data from the 
Bart’s  trial  of 22,000,  Skates  et  al  estimated  the  preclinical  phase  of the 
disease in the general population to be about 1.9 years.50 The large serum 
banks with serial blood samples resulting from all the trials will help establish
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lead time for OC with some degree of accuracy.  In the high-risk population, 
studies  are  underway  which  use  much  smaller screening  intervals  of  3-4 
months. It is however likely that familial OC in the younger high-risk patients 
is a somewhat different disease from the sporadic disease.
8.8  Completed trials in the general population
Numerous  trials  have  been  completed  and  reported  in  the  general 
population. They are detailed  in Table 8-2 and Table 8-3.This includes the 
prevalence screen of the pilot RCT reported in section 11  of this thesis. The 
only large general population study not included  in the table is the recently 
reported OC prevalence screen in the PLCO trial (Figure 8-4).  In this trial a 
combined  strategy  using  both  serum  CA125  and  ultrasound  as  first  line 
tests was adopted for the first three years of screening.  Of 39,115 women 
randomised to receive screening, 28,816 received at least 1   test. Abnormal 
TVS  was  found  in  1338  (4.7%),  and  abnormal  CA-125  in  402  (1.4%). 
Twenty-nine  neoplasms  were  identified  (26  ovarian,  2  fallopian,  and  1  
primary peritoneal neoplasm).  Nine were tumors of low malignant potential 
and 20 were primary invasive.  133 The positive predictive value for invasive 
EOC  was  3.7%  for  CA125,  1.0%  for TVS,  and  23.5%  if both  tests  were 
abnormal.  This  equals 41.2  operations  per  invasive  EOC  detected  if TVS 
alone as used versus 4.1  if serum CA125 alone was used as a first line test. 
The data confirms the findings of the  large  prospective studies of OCS  in 
the  general  population  listed  in  Table  8-2  and  Table  8-3.  Sequential 
multimodal screening with  serum  CA125 as the first line test has superior
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specificity  and  leads  to  about  4-5  operations  per  case  of  invasive  EOC 
detected when compared to strategies based on TVS alone which result in 
20-40 operations per case detected.
TVS
28506
Serum CA125 
28803
Both CA125 or TVS 
28506
Either TVS & Serum 
CA125 28816
28.5
NO OF OPERATIONS PER INVASIVE EOC DETECTED 
41.2  4.1 3.4
570
NO OF OPERATIONS UNDERTAKEN 
535  62
PRIMARY INVASIVE OVARIAN CANCERS
Figure 8-4: Prevalence screen in the ovarian arm of the PLCO trial
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Table 8-2: Prospective OCS studies in the general population using the multimodal strategy
Authors Main features Screening  No.  screened No. of No. of No.  of operations
strategy Primary  invasive positive EOC detected
EOC detected  () screens
SERUM CA125 ALONE
Einhorn et al Age >40 years Serum CA125 5550 6 175a 29b
1992 2 stage I
MULTIMODAL APPROACH - CA125 (LEVEL 1 SCREEN), then USS (LEVEL II SCREEN)66
Menon  et al Age >50 years Serum  CA125 6532 3 16 5.3
200557 Postmenopausal interpreted  using 2 Stage I
RCT ROC (1)a
TVS, if ROCt
Jacobs et al Age >45 years Serum CA125 10958 6 29 4.8
1999 (median 56)TAS/TVS, if CA125t 3 stage I
Postmenopausal 3 screens
RCT
Jacobs et al Age >45 years Serum CA125 22000 11 41 3.7
1988,  1993, (median 56) TAS, if CA125t 4 stage I
1996 Postmenopausal
Adonakis  et al Age >45 years Serum CA125 2000 1 15 15
1996 (mean 58) TVS, if CA125t 1 stage I
(1)a
Grover et al Age >40 years Serum CA125 2550 1 16 16
1995 (median  51)  or  withTAS/TVS, if CA125f 0 stage 1
family history (3%)
TOTAL 44040 22 (2)a 117 5.3
RCT  =  randomised  controlled  trial;  TAS  =  transabdominal  ultrasound;  TVS  = transvaginal  ultrasound;  ROC=  risk  of 
ovarian cancer.a Borderline/granulosa tumours detected are shown in parenthesis;b  Not all of these women underwent 
surgical investigation as the study design involved intensive surveillance rather than surgical intervention
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Table 8-3: Prospective OCS studies in the general population using ultrasound as the primary test
Authors Subjects Screening strategy No.
screened
No.  of  primary 
invasive  EOC 
detected ( )a
No  of
positive
screens
No  of  positive 
screens/  EOC 
detected
USS ONLY APPROACH -USS (LEVEL 1 SCREEN), then reseat USS (LEVEL II SCREEN)
van  Nagell  et 
al  1995, 
2000149269 
De  Priest  et  al 
1997,  2003147
150
Age  >50  years 
and
postmenopausal 
OR >30 with family 
history
TVS
Annual screens Mean 
4 screens /  woman
14,469 11
5 Stage I
(6)a
180 16.3
Sato  S  et  al 
20001 °
Part  of  general
screening
programme
TVS 51,550 22
17 Stage I
324 14.7
Hayashi  et  al 
19991 5 1
Age >50  years TVS 23,451 3
0 Stage I
(3)a
258
b
Tabor  et  al 
1994152
Aged 46-65 years TVS 435 0 9 -
Campbell  et  al 
1989153
Age  >45  years 
(mean  53)  or  with 
family history (4%)
TAS  3  screens  at  18 
monthly intervals
5479 2
2 stage I
(3)a
326 163
Millo  et  al 
1989154
Age  >45  years  OR 
postmenopausal 
(mean 54)
US (not specified)
500 0 11 -
Goswamy et al 
1983155
Age  39-78 
Postmenopausal
TAS 1084 1
1 stage I
TAS = transabdominal ultrasound; TVS = transvaginal ultrasound.a Borderline/granulosa tumours detected are shown 
in parenthesis.b  Only 95 women consented to surgery and there are no follow up details on the remaining.
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Table 8-3: Prospective OCS studies in the general population using ultrasound as the primary test (contd.)
Authors Subjects Screening strategy No.
screened
No.  of  primary 
invasive  EOC 
detected ( )a
No  of
positive
screens
No  of  positive 
screens/ EOC 
detected
USS and CDI (LEVEL I SCREEN)
Kurjak  et  al 
1994122
Aged 40-71  years 
(mean 45)
TVS and CDI 5013 4
4 stage I
38 9.5
Vuento  et  al 
1995123
Aged  56-61  years 
(mean 59)
TVS and CDI 1364 0
(1)a
5 -
USS (LEVEL 1) and other test (LEVEL II SCREEN)
Kurjak  et  al 
2005132
Aged >50 TVS then  3D  USS and 
power  Doppler  if  TVS 
positive
TVS  then  CDI  if  TVS 
positive
TVS  then  CA125  if 
TVS positive
TAS,  then  aspiration/ 
biopsy
3201 5
5 stage 1
25 5
Parkes  et  al 
19941 2 1
Aged 50-64 
RCT
2953 1
1 stage I
15° 15
Holbert  et  al 
1994156
Postmenopausal, 
Aged 30-89 years
478 1
1 stage I
33° 33
Schincaglia  et 
al 1994
Aged 50-69 3541 2
0 stage I
98 9.5
TOTAL (including studies on prev ous page) 113,518 52 (30) 1322 25.4
RCT  =  randomised  controlled  trial;  TAS  =  transabdominal  ultrasound;  TVS  =  transvaginal  ultrasound;  CDI  =  colour 
Doppler
a Borderline/granulosa tumours detected are shown in parenthesis 
c  86 women had abnormal USS prior to CDI. 
d  Only 11 of these women underwent surgery.
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With regard to apparent sensitivity for detection of ovarian cancer, very few 
trials  have  reported  on  follow  up  and  interval  (false  negative)  cancers. 
Published  data  is  only  available  for  prevalence  screening  in  two  of  the 
multimodal trials (including the one detailed  in  chapter 8 of this thesis)52 57 
and  for  both  prevalence  and  incidence  screening  in  the  Kentucky  trial9 
(Table 8-4). In addition, in the PLCO trial, although no interval cancers have 
been reported in the year following the prevalence screen, some estimates 
of  highest  possible  sensitivity  can  be  derived  for  the  multimodal  and 
ultrasound strategy as both TVS and CA125 were used as first line tests.
The apparent sensitivity at 1   year for both strategies seems to in the range 
of 70-80%.  Such  conclusions  are  however  very  preliminary  for  given  the 
numbers involved, confidence limits are wide.
The  data  with  regard  to  detection  of  early  stage  cancers  is  extremely 
disappointing  in  the  recent  PLCO  prevalence  screen  where  all  detected 
cancers  were  advanced.  However  in  the  previously  reported  studies 
detailed in Table 8-2 and Table 8-3, over 50% of the cancers detected were 
early  stage  with  an  ultrasound  based  strategy  possibly  offering  greater 
sensitivity for early stage disease.
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Table 8-4: Apparent sensitivity for detection of primary invasive EOC in general population OCS trials
Authors
Screening
strategy
Type of screen
Number
of
women
No. of
primary
invasive
EOC
detected
No of interval 
invasive EOC in one 
year from screen
Apparent 
sensitivity at 
one year for 
detection of 
EOC (%)
Multimodal strategy using CA125 as the first line test
Menon  et  al 
2005
CA125
interpreted  using 
ROC algorithm
Prevalence 6532 3
2 Stage 1
0 100
Jacobs  et  al 
1996
CA125
interpreted  using 
cut-off
Prevalence 22000 11
4 Stage 1
3 78.6
Buys et al 2005
If  serum  CA125 
with  cut-offs  was 
used  as  first  line 
test
Prevalence 28803
15
0 Stage 1
Not  reported  but  in  all 
20  invasive  EOC  were 
detected  using  the 
combined strategy
75
Ultrasound strategy using TVS as the first line test
Van  Nagell  et al 
2003
USS using TVS
Both  prevalence and 
incidence
7705b
11
5 Stage 1
3 78.6
Buys et al 2005
If TVS  was  used 
as first line test
Prevalence 28506
13
0 Stage 1
Not  reported  but  in  all 
20  invasive  EOC  were 
detected  using  the 
combined strategy
65
b  Restricted to the cohort of women aged  >50 who were postmenopausala A combined strategy using  both serum 
CA125 and TVS was used
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8.9  Current trials in the general population
With the screening strategies well defined and  refined over the  1990s 
and the performance characteristics established, the next step was to 
establish  if  OCS  did  in  fact  save  lives.  Two  large  randomised 
controlled trials are now underway in the general population to assess 
the impact of screening on ovarian cancer mortality.
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening 
Trial  has  completed  enrolment  of  78,000  women  aged  55-74  at  10 
screening  centres  in  the  U.S.A.  with  balanced  randomization  to 
intervention  and  control  arms.158  For  ovarian  cancer,  women  are 
screened  using  both  CA125  and  transvaginal  ultrasound  for  three 
years and CA125 alone for a further two years. Follow-up will continue 
for at least  13 years from  randomisation  to assess  health  status and 
cause of death (Figure 8-5).
The  United  Kingdom Collaborative Trial of Ovarian  Cancer Screening 
(UKCTOCS) which  is detailed in chapters12,  13,  14 of this thesis has 
also  completed  recruitment of over 200,000  postmenopausal women 
who have been randomised to either control, screening with ultrasound 
or multimodal screening (www.ukctocs.ora.uk).  The primary end  point 
is ovarian cancer mortality. The trial will also comprehensively address 
the  issues  of  physical  and  psychological  morbidity  of  screening, 
acceptability,  and  compliance  of  the  target  population  and  health
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economics.  There  is  a  direct  comparison  of  the  two  screening 
strategies. The trial is expected to report in 2012.
All women will  be followed  up till 2013 by postal questionnaire 
Power 88% to detect 35% mortality benefit
Figure  8-5:  Design  of the  OCS  arm  of the  Prostrate  Lung  Colon 
Ovary trial
8.10  Trials in a high risk population
In  women  with  strong  evidence  of  a  hereditary  predisposition, 
screening  is  recommended  although  there  is  no  conclusive  evidence 
available that screening has an impact on ovarian cancer mortality. As 
a result, a randomised control trial of screening in this population is no 
longer feasible or ethical. Screening is problematic in this population as 
it  includes  premenopausal  women  who  have  a  higher  incidence  of 
false  positive  CA125  elevations  and  ultrasound  abnormalities.  In 
addition,  recent  reports  suggest  that  multifocal  peritoneal  serous
4913 previous oopherectomy 
5386 withdrew
STUDY GROUP (28816 women) 
Annual CA 125 for 5 years 
Annual TVS for 3 years
WOMEN
> 55 -74 years 
78, 237
CONTROL GROUP  39122 women 
(not known  no who had oopherectomy)
Primary end point 
Ovarian Cancer Mortality
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papillary  carcinoma  may  be  a  phenotypic  variant  of familial  ovarian 
cancer and may be difficult to detect using current screening tests.2 1  
In  order  to  develop  an  optimal  screening  strategy  in  the  high  risk 
population,  a  multicentre  National  Familial Ovarian  Cancer Screening 
Study (UK-FOCSS) involving 5000 ‘high risk’ women is being set up in 
the  UK.  This  is  a  prospective  study  using  a  standard  screening 
protocol  based  on  annual  CA125  measurement  and  transvaginal 
ultrasound. The trial design includes collecting and storing serial serum 
samples for retrospective  analysis of CA125 and  other markers.  The 
intention is to derive a Familial Risk of Ovarian Cancer Index (FROC), 
similar  to  the  ROC  in  use  in  the  general  population,  which  will 
incorporate  in  addition  to  the  serial  CA125  profile,  data  on  family 
history  and  mutation  analysis.  A similar trial  is underway  in the  USA 
under the  auspices  of the  Cancer  Genetics  Network  of the  National 
Cancer Institute with the scope for meta-analysis in the future.
8.11  Conclusion
There are numerous answered questions and many aspects of ovarian 
cancer screening are still poorly understood,  including whether or not 
there  are  precursor  lesions,  the  rate  of disease  progression,  and  to 
what extent transvaginal  ultrasonography and  CA125  detect different 
cancers.  There  is  also  concern  about  the  morbidity  associated  with 
unnecessary  surgery  resulting  from  false  positive  screening  results. 
Acceptability  and  compliance  are  crucial  issues  if  ovarian  cancer
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screening were to become a national  programme. While the levels of 
compliance  reported  in  the  literature  are  encouraging,  one  must  be 
cautious about extending it to the wider population as recruitment into 
most  trials  are  by  self-referral5 22 23Large  randomised  trials  are  now 
underway in the general population to provide definitive data on impact 
of screening on mortality and address morbidity, health economics and 
psychosocial  issues.  High-risk women  who  request screening  should 
be  counselled  about the  current  lack  of evidence  of  its  efficacy  and 
encouraged to participate in research trials.
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9  OVARIAN  CANCER  RISK  IN  POSTMENOPAUSAL  WOMEN 
WITH CA125 ELEVATION 
9.1  Introduction
Although the definitive role of serum CA125 in screening remains to be 
ascertained,  there  is  evidence  that  elevation  is  associated  with  an 
increased risk of ovarian cancer. Based on data collected in the course 
of the initial Bart OCS trial of 22,000 women, it was previously reported 
that  asymptomatic  postmenopausal  women  with  a  CA125  >30  U/ml 
have  a  36  fold  increased  risk for diagnosis  of ovarian  cancer  in  the 
subsequent year.5 1   A further analysis was carried  out to quantify the 
value  of  pelvic  ultrasound  in  refining  the  risk  of  cancer  amongst 
asymptomatic women with CA125 elevation.
9.2  Methods
9.2.1  Subjects
Women,  aged  >45  years  and  with  12  months  of amenorrhoea  were 
invited in  1986 to participate in a multimodal ovarian cancer screening 
programme.8 5 1   52  148  Exclusion  criteria  included  previous  history  of 
ovarian cancer,  bilateral oophorectomy,  active malignancy or a family 
history of ovarian  cancer involving two or more first degree  relatives.
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Approval  was  obtained  from  the  local  ethics  committee  and  all 
volunteers gave written consent.
9.2.2  Trial design
22,000  postmenopausal  women,  aged  >45  years  underwent 
prevalence  screening  using  CA125  between  1986  and  1989. 
Volunteers  with  a  CA125  level  >30  U/ml  were  referred  for  an 
ultrasound scan and a gynaecological evaluation if an abnormality was 
detected.  Subsequent  to  the  prevalence  screen,  the  women  were 
randomised to control and study arm. The 10,958 randomised to study 
arm underwent 3 annual incidence screens
Study 
Group 
10,958 
Annual 
screening 3y screening
Control
Group
10,977
Follow up ■  Mean 8y 
Questionnaire & Cancer Registry
22,000
postmenopausal
women
prevalence
screen
SCREENING STRATEGY
CA 125
I
CA125>30 U/ml
I
USS + CA125
I
Ovarian volume 
>8.8ml
\
Surgery
Jacobs et al 1990,1993,1996
Figure 9-1: Trial design of the Bart’s initial OCS trial (A)
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9.2.3  Screening tests 
CA125
The women were posted venepuncture equipment and asked to visit 
their  general  practitioners  for  venepuncture.  Blood  samples  were 
sent  by  first  class  mail  to  the  Ovarian  Cancer  Screening  Unit.  On 
receipt at the laboratory, the samples were centrifuged at 4,000 rpm 
for  10  minutes  and  the  serum  separated,  aliquot  prepared  and
stored  at  -20°c.  All  blood  samples  over  56  hours  since 
venepuncture  were  discarded.  Serum  CA125  levels  were 
determined  by  commercial  radioimmunoassay  within  two  weeks  of 
receipt of the blood sample.
Ultrasound
Ultrasonography was  performed  using  a  transabdominal  approach  in 
the  prevalence  screen  and  the  first  incidence  screen.  Subsequently 
transvaginal scanning  became available and was the preferred  route. 
Irrespective of the mode of scanning, the intention was to measure the 
diameter  of  each  ovary  in  three  planes  and  to  document  ovarian 
morphology.  Ovarian volume was calculated  using the formula for an 
ovoid7.  Ovarian  morphology was regarded as normal if the ovary was 
of uniform hypoechogenecity and smooth outline. All other morphology 
was regarded as abnormal.
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9.2.4  Screening strategy
All  women  in  the  prevalence  screen  and  those  in  the  screen  arm 
following  randomisation  underwent  an  annual  serum  CA125 
measurement.  If the serum  CA125 was  <30U/ml,  it was  regarded  as 
normal.  If  the  serum  CA125  was  >30  U/ml,  it  was  regarded  as 
abnormal and the women were asked to attend for an ultrasound scan. 
The  interpretation  and  management  protocol  following  ultrasound 
assessment was as follows:
(1)  Normal  scan  -  (a)  Ovarian  volume  <8.8ml  with  normal 
morphology (uniform  hypoechogenecity and  smooth  outlines)  or 
(b)  Ovaries  not  visualised  but  no  pelvic  abnormality  apparent: 
repeat CA125 estimation every three months for a year and then 
return to annual screening.
(2)  Equivocal  scan  -  Ovarian  volume  <8.8ml  and  abnormal 
morphology:  repeat  scans  at  intervals  of 6  weeks  until  a  scan 
could be classified as normal or abnormal.
(3)  Abnormal scan - Ovarian volume >8.8ml,  irrespective of ovarian 
morphology:  referral  to  a  gynaecologist  for  assessment  and 
advice.  Management  including  surgical  intervention,  was  at the 
discretion of the specialist receiving the referral.
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9.2.5  Follow Up
In  December 1997, all volunteers were traced via the National Health 
Service  Central  Register  to  document  cases  of  cancer  which  had 
occurred  in this population12.  In addition,  all volunteers were followed 
up  annually  during  the  study  by  a  questionnaire  which  specifically 
enquired about any hospital visits in the previous year. When a  reply 
suggested  a  possible  gynaecological  malignancy,  histopathological 
and  clinical  information  was  obtained  from  the  general  practitioner 
and/or hospital.
9.2.6  Case Ascertainment
An  independent  pathologist  who  had  no  knowledge  of  the 
randomisation status reviewed all reports and histological slides.  Only 
women  confirmed  to  have  primary,  invasive  epithelial  ovarian  or 
fallopian tube cancer (index cancers) were included as cases.
9.2.7  Analysis
As part of the work undertaken in the course of this thesis, a database 
was  built  and  all  the  details  documented  on  the  ultrasound  scans 
performed  in  women  with  elevated  serum  CA125  in  the  course  of 
Bart’s  trial  A  were  entered.  The  scans  were  classified  as  per  trial 
protocol. In addition, ovarian morphology was reclassified into normal if
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the ovary was of uniform hypoechogenecity and smooth outline, simple 
cyst  if a  single,  thin  walled,  anechoic  cyst with  no  septa  or  papillary 
projections  was  detected  or  complex  which  included  all  abnormal 
ovarian morphology other than simple cysts.
Index cancers were defined as primary invasive epithelial carcinomas 
of the  ovary  and  fallopian  tube.5 1   The  risk  of  index  cancer  at  time 
interval t from the date of ultrasound in volunteers with scans satisfying 
a  particular  ultrasound  criterion  (abnormal  ovarian  morphology  and 
volume over a specified cut-off) was calculated by dividing the number 
of volunteers with scans satisfying that criterion who developed  index 
cancers  within  time  t  by  the  total  number  of volunteers  with  scans 
satisfying  the  criterion.  Cumulative  risk  curves  were  constructed  by 
plotting  the  calculated  risk values  against time.  The  observed  risk of 
index  cancer  for  all  22,000  study  volunteers  as  well  as  for  all 
volunteers with  CA125  >  30U/ml at a given  time  interval  t  had  been 
previously calculated.5 1   The  relative  risks of cancer at  1   and  5 years 
were computed by dividing the calculated  risk for women  satisfying a 
specified ultrasound criterion at I and 5 years by the observed risk for 
the entire study population at  1   and  5 years  respectively.  Confidence 
intervals  for  the  risk  estimates  and  the  relative  risk  estimates  were 
calculated using the Taylor series method.
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9.3  Results
Of  the  22,000  study  participants,  741  had  a  CA125  >30  U/ml  and 
underwent  a  scan.  A  further  26  volunteers  with  a  CA125  >30  U/ml 
declined  an  ultrasound  (n=15)  or  were  found  to  be  premenopausal 
(n=11) and were therefore not included  in the analysis.  Twenty index 
cancers were diagnosed amongst the 741  women with a CA125  >30 
U/ml during a median follow up of 6.8 years. The index cancers were 
invasive  epithelial  cancers  of the  following  histological  types;  serous
(7),  endometroid  (6),  clear cell  (2),  undifferentiated  (1),  fallopian  tube 
(3). The number of index cancers at FIGO (International Federation of 
Gynaecology and Obstetrics) stages I,  II,  III and  IV were 7,  1, 9 and 2 
respectively.  The histological type and  precise stage were  not known 
for one patient whose diagnosis was on the basis of imaging findings, 
clinical  assessment,  and  an  ascitic  tap  which  revealed 
adenocarcinoma cells.
Of the  741  women,  662 women  had  normal  ovarian  morphology  on 
scan and only one had a subsequent diagnosis of an index cancer (at
2.3  years  of  follow  up).  Of  the  79  women  with  abnormal  ovarian 
morphology, 19 had a subsequent diagnosis of an index cancer. Of the 
women with abnormal morphology and an ovarian volume >20ml and 
>100ml,  15/41  and  10/17 respectively had a subsequent diagnosis of 
an  index  cancer.  Figure  9-2  shows  the  relation  between  cumulative 
risk of developing an index cancer according to CA125 and ultrasound
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findings.  Compared  to  the  entire  study  population  (curve  A),  women 
with a CA125 >30U/ml (curve  B) had an  increased  risk of developing 
an  index cancer.  However,  the subgroup of women with  an  elevated 
CA125  but  normal  ovarian  morphology  (curve  C)  had  a  similar 
cumulative  risk  to  the  entire  study  population  (Jacobs  et  al,  1996) 
(0.15%  vs.  0.22%,  95%  confidence  intervals  [Cl]  0.02-1.12  vs.  0.18- 
0.30).  In  contrast  the  cumulative  risk  of developing  index  cancer  in 
women  with  a  CA125  >30U/ml  and  abnormal  morphology  (curve  D) 
was  24%  (Cl:  15-38).  Further  stratification  of  risk  assessment  was 
achieved  by  incorporating  volume  measurements  in  addition  to 
morphology.  The  cumulative  risk  for  index  cancer  in  women  with 
CA125  >30U/ml  associated  with  abnormal  morphology  and  ovarian 
volume of >20mls (curve E) and  >100mls (curve  F) was 37%  (Cl  22- 
SI) and 59% (Cl 32-111) respectively.
The relative risk (RR) of an index cancer at 1   and 5 years follow up for 
various  criteria  are  shown  in  Figure  9-2.  Among  volunteers  with  a 
raised  CA125  and  abnormal  ovarian  morphology,  the  relative  risk  of 
index  cancer  at  one  year  was  327  compared  to  the  entire  study 
population  (RR  1.0).  The  highest  relative  risk  at  one  year follow  up 
was  for women  with  a  CA125  >30U/ml  whose  ultrasound  revealed 
abnormal  morphology and  ovarian  volume  >100ml  (RR  809,  Cl  302- 
2165).  Further  stratification  of  women  with  abnormal  ovarian 
morphology  on  the  basis  of  CA125  level  revealed  that  the  29  with
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CA125  >50U/ml  had  a  RR  of 664  (Cl  277-1590)  and  the  10  with  a 
CA125 >100 U/ml had a RR of 1682 (Cl 486.5-5816).
O v a r ia n  can cer r is k
S  0.0100
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0.0000
7 0 1 2 3 4 5 6
A = Entire study population of 22,000 women;
B = all women with a CA125 >30 U/ml;
C = CA125 >30 U/ml and normal ovarian morphology;
D = CA125 >30 U/ml and abnormal ovarian morphology;
E =  CA125 >30  U/ml,  abnormal ovarian  morphology and  ovarian 
volume >20mls;
F =  CA125 >30  U/ml,  abnormal  ovarian  morphology and  ovarian 
volume >100mls.
The  cumulative  risk curves  for all  women  with  CA125  >30  U/ml 
and  the  entire  study  population,  shown  in  dotted  lines,  are 
reproduced  from  a  previous  analysis  involving  the  same  study 
population.5 1
Note that no index cancers developed in the women with a CA125 
>30  U/ml and  normal ovarian  morphology on  scan  in the  initial 2 
years  following  the  scan  episode.  As  a  result,  this  curve 
commences at 2.3 years
Figure  9-2:  Cumulative  risk  of  developing  an  index  cancer 
according  to  CA125  and  ultrasound  in  asymptomatic 
postmenopausal women
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Table 9-1: Relative risk of index cancer at 1 and 5 years follow up 
for various ovarian ultrasound criteria
Population
criteria
USS
criteria
Relative 
risk 
1 year3
Relative 
risk 
5 years3
Serum CA125 
(U/ml) 
Median 
(range)
Entire
population5
1 1
CA125 
<30 U/mlb Not applicable
0.13
(0.03-0.58)
0.54
(0.32-0.91)
CA125 
>30 U/mlb
36
(18-70)
14.3
(8.5-24)
Normal
morphology
c
0.76
(0.09-5.96)
35.6
(30-318)
Abnormal
morphology
327
(150-708)
119
(56-244)
39.2
(30->500)
CA125 
>30 U/ml
Abnormal 
morphology & 
volume >20 ml
503
(218-1164)
183
(83-402)
Q
(30->500)
Abnormal 
morphology & 
volume >50 ml
617
(254-1495)
224
(97-518)
40.6
(30-134)
Abnormal 
morphology & 
volume >100 ml
809
(302-2171)
294
(114-756)
40.6
(30-108)
a 95% confidence limits shown in parenthesis. 
b  Previously published.5 1
cThe  figure  could  not  be  calculated  because  no  index  cancers 
occurred in this group until 2.3 years of follow up.
9.4  Discussion
We  have  previously  reported  that  asymptomatic  postmenopausal 
women with  a  CA125  level  >30U/ml  have a  36 fold  increased  risk of 
ovarian  cancer  compared  to  the  general  population.5 1   This  finding
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justified  close surveillance  of all  postmenopausal women  undergoing 
ovarian cancer screening who were found to have an elevated serum 
CA125.  In  the  Bart’s  A  trial  this  surveillance  was  undertaken  using 
pelvic ultrasonography.  The incidence of ovarian cancer on  long term 
follow  up  and  the  details  of ultrasound  findings  in  the  study  made  it 
possible  to  assess  the  impact  of  ultrasound  on  ovarian  cancer  risk 
stratification. The findings indicate that women at increased risk on the 
basis of an elevated CA125 can be further stratified for ovarian cancer 
risk according to ultrasound findings.
The  majority  (89%)  of women  with  an  elevated  CA125  had  normal 
scan findings. None of these women developed an index cancer within 
one year and only 1/662 during the full duration of the study follow up. 
This  group  of women  were  not at  increased  risk  of an  index cancer 
compared to the general  population despite their CA125 elevation.  In 
contrast,  women  with  a  raised  CA125  and  abnormal  ultrasound 
findings are at a  markedly increased risk of an  index cancer. The risk 
of index cancer during the subsequent year for women with a CA125 
>30U/ml and abnormal ovarian morphology on scan was 300-fold that 
of the  entire  population.  This  risk  is  significantly  higher than  the  risk 
associated  with  an  elevated  CA125  alone6.  In  view  of  the 
documentation  of this  high  risk,  the  combination  of CA125  elevation 
and abnormal ovarian scan findings justifies prompt investigation even 
when found in asymptomatic women.
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Further risk stratification was possible on the basis of ovarian volume 
measurements  at ultrasound.  Asymptomatic postmenopausal women 
with a CA125 >30 U/ml, abnormal ovarian morphology and an ovarian 
volume >100ml were at 800 fold increased risk of developing an index 
cancer during the subsequent year. Risk stratification, according to the 
details of morphological findings may be valuable but was not feasible 
within  the  size  of our dataset.  Further analysis suggested  that within 
the small group of women with abnormal ovarian morphology, the risk 
of ovarian  cancer  could  be  further categorised  according  to  CA  125 
level.
The  impact  of  screening  for  ovarian  cancer  on  mortality  is  still 
uncertain.  Furthermore,  screening  has  a  well  documented  false 
positive rate which can  result in anxiety and morbidity associated with 
surgical  investigation.  For  these  reasons,  ovarian  cancer  screening 
should  be  limited  to women  at  high  risk  because  of a  strong  family 
history  and  women  participating  in  research  trials.  Nevertheless, 
inappropriate  screening  is  performed  and  clinicians  are  increasingly 
faced with the problem of CA 125 elevation  in asymptomatic women. 
The results of this analysis provide some guidance for management of 
postmenopausal women in this situation.  It is clear that ultrasound can 
separate  asymptomatic  postmenopausal  women  with  raised  CA125 
levels into those who have normal scans and are not at increased risk 
of  ovarian  cancer  and  those  with  abnormal  scans  who  are  at 
substantially increased risk of ovarian cancer.
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10  REFINING THE ULTRASOUND ALGORITM 
10.1  Introduction
The  group  had  previously  demonstrated  that  the  poor  performance 
characteristics  of  serum  CA125  and  pelvic  ultrasound  as  individual 
tests  in  ovarian  cancer  screening  can  be  overcome  by  a  sequential 
screening  strategy  (multimodal  strategy)  using  serum  CA125  as  the 
primary screen  and  ultrasound  as the  secondary test  in  the  Bart’s A 
trial. Using this multimodal strategy to screen postmenopausal women 
from  the  general  population,  positive  predictive  values  of  26%  and 
21%  were  achieved  at  initial  prevalence  screening  and  on  annual 
incidence screening respectively.8 52  When these trials were initiated, 
no  data  was  available  regarding  ultrasound  findings  in 
postmenopausal women with elevated serum CA125. The definition of 
a normal scan was therefore based on ovarian volume criteria reported 
by Campbell et al in a study which used ultrasound to measure ovarian 
volume in normal postmenopausal women.159 The current project was 
undertaken in order to assess the performance characteristics of pelvic 
ultrasound  and  to  refine  the  crude  criteria  used  for  interpretation  of 
ultrasound findings in this multimodal screening strategy.
10.2  Method
The  data  from  the  Bart’s  A  trial  was  collated  and  databased  as 
described in the preceding chapter (Chapter 9)
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Analysis
Scans  were  grouped  into  episodes  for  the  purpose  of  analysis.  An 
episode was defined as a single or series of scans initiated by a raised 
CA125 and ending in  referral for a gynaecological opinion or return to 
annual CA125 screening. Study participants underwent a maximum of 
four  CA125  screens  (1  prevalence  and  3  incidence)  and  hence  a 
maximum  of  4  episodes  were  possible  per  volunteer.  For  analysis, 
each scan episode was classified on the basis of last scan  result into 
normal, equivocal or abnormal. Index cancers were defined as primary 
invasive  epithelial  carcinomas  of  the  ovary  and  fallopian  tube.52 
Sensitivity,  specificity,  and  positive  predictive  value  for  detection  of 
index cancer were calculated as shown in Table 10-3.
10.3  Results
Of the 22,000 study subjects who participated in the trial, a total of 741 
subjects with  an  elevated  CA125  underwent a total of 1219 scans. A 
further 26  subjects with  a  CA125  >30  U/ml  are  not included  as they 
declined a scan (n=15) or were found to be pre-menopausal (n=11). Of 
the  741  subjects,  475,  128,  87  and  51  had  1,  2,  3  or  >  3  scans 
respectively.  918  of  the  1219  scans  (75.3%)  were  performed 
transabdominally,  103  (8.4%)  transvaginally  and  198  (16.2%)  both 
transabdominally and transvaginally.
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25  of  the  741  women  had  previously  undergone  unilateral 
oophorectomy.  44  of  the  1219  scans  were  performed  on  these  25 
women.  As  a  result,  the  overall  number of ovarian  scans  attempted 
was 2394. The ovary was visualised in 2129 (89%) of the 2394 scans. 
Ovarian  dimensions  were  documented  in  1839  (86%)  of  the  scans 
where visualisation was possible. The mean ovarian volume calculated 
from  the  1663  scans  of ovaries  that were  normal  on  follow  up  was 
2.57cm3  (standard  deviation  3.1cm3).  A total  of 1027  scan  episodes 
resulted of which 97 (9.4%) were abnormal or equivocal Table 10-1.
Table 10-1: Number of scans and classification of scan episodes 
in women with elevated CA125 levels
Classification  of 
scan episodes
No.  of 
women
No.  of  scan 
episodes
No. of 
scans
Normal 645 930 1072
Equivocal 16 17 27
Abnormal 80 80 120
Total 741 1027 1219
Ultrasound findings and outcome on follow up are summarised  below 
(Table 10-2).
Normal  scan  episodes:  There  were  a  total  of 930  normal  episodes. 
Thirteen  subjects  underwent  surgical  investigation  despite  normal 
ovarian  findings.  In  nine  cases,  this  was  for  incidental  findings  of a 
thickened  endometrium  (n=4),  uterine  fibroids  (n=4)  and  a  bladder 
abnormality  (n=1)  which  resulted  in  the detection  of one endometrial
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and one bladder carcinoma. A further four subjects were referred for a 
specialist  opinion  and  eventually  underwent  surgery  as  they  were 
anxious  following  CA125  elevation.  Surgery  revealed  no  abnormality
(3)  and  pelvic  adhesions  (1).  Only  one  woman  with  a  normal  scan 
episode  developed  ovarian  cancer which  was  diagnosed  2.25  years 
after her last scan.
Equivocal scan episodes: There were 17 equivocal scan episodes. All 
the  women  were  referred  for  a  gynaecological  assessment.  In  9/17 
episodes, volunteers with  persistent simple cysts,  elected  not to have 
surgery.  They continued to undergo annual CA125 screening and did 
not develop  index  cancers  on  follow  up.  Two women  with  equivocal 
results died before a repeat scan, one from pneumonia and the other 
from ovarian cancer (diagnosed on the basis of clinical findings and an 
ascitic  tap).  The  remaining  six  volunteers  with  equivocal  episodes 
underwent surgical investigation which revealed ovarian cancer in one 
case and benign pelvic pathology in the five other cases.
Abnormal  episodes:  There  were  80  abnormal  episodes.  In  17/80 
episodes,  abnormal  ovarian  volume  was  associated  with  normal 
morphology (22 scans,  17 volunteers). Only one of these 17 volunteers 
underwent surgery and she had a benign ovarian thecoma. The other 
16  subjects  did  not  undergo  surgical  investigation  following  clinical 
decisions  based  on  borderline  increases  in  ovarian  volume  (n=10), 
falling  CA125  levels  (n=3),  diminishing  ovarian  volume  on  serial
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scanning  (n=2)  and  anaesthetic  risk  (n=1).  None  of  these  subjects 
developed ovarian carcinoma.  In 63/80 episodes, both ovarian volume 
and  morphology  were  abnormal  (98  scans,  63  volunteers).  Five  of 
these  63  episodes  involved  volunteers  with  stable  CA125  levels  on 
serial  measurements  and  simple  cysts  (ovarian  volume  10.24- 
29.7cm3).  In these cases, a clinical decision was made not to proceed 
to surgery and all these volunteers have remained well. The remaining 
58/63  episodes  resulted  in  surgical  referral  which  revealed  index 
cancer in 17 cases. The remaining 41  subjects had adenocarcinoma of 
unknown primary (2), benign pelvic pathology (31) and no abnormality
(8)
Table 10-2: Ultrasound episodes and outcome on follow up.
Episodes
(morphology)
Outcome
Index
cancer
Other
cancers
Benign
ovarian
lesions
Other
benign
pelvic
lesions
Normal Total
Normal 1* 2 0 8 920 930
Equivocal
(Simple cyst) 1 0 3 0 10 14
(Complex mass) -| ** 0 0 2 0 3
Abnormal
(Normal 0 0 1 0 16 17
morphology)
(Simple cyst) 2 0 10 1 10 23
(Complex mass) 15 2*** 15 5 3 40
Total 20 4 29 16 959 1027
‘ Developed ovarian cancer 2.25 years after normal scan 
“ Died before surgery was undertaken;
***Both were adenocarcinomas of unknown primary.
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The  performance  of different  ultrasound  criteria  for  detecting  the  19 
index  cancers  diagnosed  within  1   year of an  ultrasound  is  shown  in 
Table  10-3.  Abnormal  morphology achieved  higher sensitivity  (100%) 
than  abnormal  volume  (89.5%)  or  complex  morphology  (84%). 
However, the differences were not statistically significant. Similarly, the 
positive  predictive  value  of  37.2%  achieved  by  using  complex 
morphology  was  not  significantly  higher  than  that  achieved  by 
abnormal morphology (23.8%) or abnormal volume (21.3%).
Table  10-3:  Performance  characteristics  of  ultrasound  for 
detection  of  index  cancers  diagnosed  within  one  year  of 
screening in women with elevated serum CA125.
Index
cancer
No index 
cancer
Sensitivity, specificity, 
positive  predictive 
value (PPV)
Criteria abnormal a c Sensitivity  = a / a+b 
Specificity  = d / c+d
Criteria normal b d PPV  = a / a+c
Abnormal  volume 17 63 Sensitivity = 89.5%
Normal volume 2 945 Specificity = 93.75% 
PPV  =21.3%
Abnormal morphology 19 61 Sensitivity = 100%
Normal morphology 0 947 Specificity = 93.95% 
PPV  = 23.75%
Complex morphology 16 27 Sensitivity = 84.2%
Normal  morphology 
OR simple cyst
3 981 Specificity = 97.32% 
PPV  =37.21%
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10.4  Discussion
This is the first detailed  report of ultrasound findings in  asymptomatic 
postmenopausal women with  an elevated serum CA125.  A limitation 
of the  current study  was  the  use  of transabdominal  scanning  in  the 
initial  phase.  It  is  possible  that  the  sensitivity  for  detection  of 
morphological  abnormalities  was  underestimated  as  a  result. 
Nevertheless, the findings have important clinical implications and are 
valuable for the design of future ovarian cancer screening trials.
The  performance  of  ultrasound  in  the  prospective  study  was 
encouraging  and  a  variety  of  ultrasound  criteria  achieved  an 
acceptable  positive  predictive  value.  Strict  application  of  the  study 
criteria  (ovarian  volume  >  8.8  ml)  without  clinical  input  would  have 
resulted  in  surgical  referral  following  80  scan  episodes,  with  a 
sensitivity  of  89.5%  and  a  positive  predictive  value  of  21%.  Using 
abnormal  morphology  as  the  discriminating  criterion  increased 
sensitivity  to  100%  with  minimal  change  in  specificity  and  positive 
predictive  value  but  this  improvement  did  not  reach  statistical 
significance.  It is,  however, worth noting that both the 2 index cancers 
that had normal ovarian volume had abnormal morphology.
The  use  of  complex  morphology  further  increased  specificity  and 
positive  predictive  value  but  again  statistical  significance  was  not 
achieved.  Using complex morphology,  sensitivity fell to 84%  as three
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index  cancers  appeared  to  be  simple  cysts  on  transabdominal 
scanning. This may be attributable to the lower resolution of the older 
generation transabdominal scanning techniques used in the early part 
of the study compared to the transvaginal approach now in use. This is 
consistent  with  the  observation  that  5  of  the  12  ovarian  cancers 
detected on primary transabdominal ultrasound screening in the study 
by Campbell et al160 were found to  have simple  morphology on  scan 
while none of the ovarian cancers detected by transvaginal scanning in 
the  more  recent  ultrasound  screening  trials114  1 2 1   had  simple 
morphology. In the Kentucky study, 256 postmenopausal women were 
detected to have simple ovarian  cysts  <10cms  in  diameter and  none 
developed an ovarian malignancy.108
The use of ultrasound assessment as a secondary test maintains the 
sensitivity of the  CA125  algorithm  and  enables the  overall  screening 
programme  to  achieve  a  high  positive  predictive  value.  Clearly,  a 
variety of ultrasound  criteria can  achieve  high  sensitivity and  positive 
predictive value for index cancers in women with an elevated CA125. 
The balance of evidence suggests that ovarian morphology is the most 
sensitive criteria. Larger studies are needed to definitively establish the 
criterion with the  best performance characteristics.  As a  result of this 
analysis,  the  ultrasound  algorithm  in  the  Bart’s  B  trial  (detailed  in 
chapter  11) was  refined  to  incorporate  both  ovarian  morphology  and 
volume,  with  the  major  emphasis  on  morphology.  In  the  current 
definitive trial,  United  Kingdom  Collaborative  Trial  of Ovarian  Cancer
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Screening  (UKCTOCS),  the  ultrasound  algorithm  is  solely  based  on 
morphology, although volume is recorded.
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11  A PILOT TRIAL USING THE ‘ROC’ ALGORITHM
11.1  Introduction
In  1993,  the  group  demonstrated  in  the  prospective  trial  of  22,000 
postmenopausal  women  (Bart’s  A)  from  the  general  population  that  a 
multimodal  OCS  strategy can  achieve  a  sensitivity of 78.6%,  specificity of 
99.9%  and  positive  predictive value  of 26.8%  for detection  of OC1.  In  this 
trial,  the  serum  CA125  was  interpreted  using  a  fixed  cut-off  of  30  U/l. 
Analysis of the data revealed that serial CA125 values prior to detection of 
ovarian cancer exhibited increasing levels following a change-point while for 
almost all  other subjects  CA125  values  had  a  flat  profile which  fluctuated 
around  an  individual’s  own  baseline  level.  Interpreting  this  additional 
information  in  serial  CA125  values  using  longitudinal  statistical  models 
retrospectively increased the sensitivity for detection of ovarian cancer from 
70% to 86%55, while maintaining a high level of first line specificity (98%) for 
referral to ultrasound exceeding that of the fixed CA125 cut-off. The model 
estimates  an  individual’s  ‘Risk  Of Ovarian  Cancer1   (ROC)  starting  with  an 
estimate based on  age and  modified  by the relative fit of the serial CA125 
profile to the change-point model estimated from known cases compared to 
the  flat  profile  model  estimated  from  known  controls161.  The  screening 
algorithm  interprets  an  individual’s  CA125  values  by  calculating  the  ROC 
and  making  screening  decisions,  such  as  returning  to  annual  screening, 
repeating  the  CA125  test  within  a  shorter  period  of  time,  or  referral  to 
ultrasound, on the basis of the ROC value.
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Parallel  to  this  effort,  analysis  of  the  ultrasound  data  from  the  trials 
established  that  refining  the  ultrasound  criteria  could  increase  specificity 
(chapters  10)53 54.  Complex ovarian  morphology was the  best predictor of 
ovarian cancer in asymptomatic postmenopausal women found to have an 
elevated serum CA125 level. This was incorporated into the new strategy.
A  prospective  pilot  screening  trial  using  the  new  Risk  of Ovarian  Cancer 
Algorithm  (ROCA)  incorporating  the  ROC  calculation  for  CA125 
interpretation and refined ultrasound criteria was set up to inform the design 
of a  definitive  RCT.  The  chapter describes the  outcome  of the  prevalence 
screen in this trial and provides the first data on prospective use of the ROC 
algorithm in ovarian cancer screening.
11.2  Methods
11.2.1  Subjects
Approval  was  obtained  from  the  local  ethics  committee.  Women  from 
England,  Scotland,  and Wales were  invited  to volunteer via  articles  in  the 
press  and  leaflets  distributed  through  collaborating  general  practices  and 
occupational health departments of major companies. In addition, invitations 
were sent to those who had participated in our previous screening studies.8 
62  Women  who  expressed  interest  were  sent  a  detailed  fact  sheet 
describing the study and a recruitment appointment at the Ovarian  Cancer 
Screening  Unit  at  Bart’s  Hospital  or  at  their  general  practice.  At  these
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appointments, the study design was explained and volunteers completed a 
questionnaire  and  gave  written  consent.  Volunteers  were  eligible  if  they 
fulfilled  the  following  criteria:  (a)  Age  >50  years,  and  (b)  >12  months 
amenorrhoea following  a  natural  or surgical  menopause  or >12  months of 
hormone replacement therapy commenced for menopausal symptoms. The 
exclusion  criteria  were:  (a)  History  of  bilateral  oophorectomy,  (b)  Active 
malignancy  (women with  a  past history of malignancy were eligible  if they 
had  no  documented  persistent or  recurrent disease),  (c)  Increased  risk of 
ovarian cancer due to familial predisposition -  exclusion criteria were entry 
criteria  for the  UK  Familial  Ovarian  Cancer  Screening  Study  (d)  Previous 
history of ovarian cancer.
11.2.2  Trial design
Eligible volunteers were randomised with equal chance to either the control 
or  screening  group  using  a  computerised  random  number  generator.  All 
volunteers randomised to the screening group underwent primary screening 
(Level  I)  with  CA125.  If  an  abnormality  was  detected  the  women  had 
secondary  screening  (Level  II)  using  CA125  and  transvaginal  ultrasound 
(TVS) of the ovaries (Figure 11-1). A customised database was built for the 
trial that assessed eligibility and  undertook randomisation,  ‘Risk of Ovarian 
Cancer’ calculation, classification of results and letter printing.
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postmenopausal 
Volunteers >50 yrs
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Annual screening Low Risk
Group Screen
Intermediate
Risk
Repeat serum CA125 & 
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Level I Screen 
Serum CA125 & 
ROC
Elevated
Risk
Level II screen 
CA125 + TVS
Abnormal
screen
Abnormal
screen
Referred to gynaecological oncologist
Figure 11-1: Design of Bart’s B pilot RCT
11.2.3  Screening tests
The  women  in  the  screening  group  were  posted  venepuncture  equipment 
and  asked  to  visit  their  general  practitioners  for  venepuncture.  Blood 
samples were sent to the Ovarian Cancer Screening Unit by first class mail, 
centrifuged  at 4,000  rpm for 10 minutes and the serum separated,  aliquots
prepared  and  stored  at -20°C.  All  blood  samples  received  >56  hours after 
venepuncture were discarded and repeat samples requested. Serum CA125 
levels  were  determined  by  commercial  radioimmunoassay  (CA  12511  kit, 
Centocor, Malvern PA) within two weeks of receipt of the blood sample. The 
CA125  values  were  entered  into  the  trial  database,  which  calculated  the
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‘Risk  Of  Ovarian  Cancer*  (e.g.  a  risk  of  2%  implied  a  risk  of  1   in  50  of 
ovarian cancer), and then generated the appropriate letter.
TVS  was  performed  either  at the  Ovarian  Cancer Screening  Unit  or at  a 
collaborating  centre  by  a  consultant  radiologist  or  experienced 
ultrasonographer.  Where  TVS  was  not  possible  or  acceptable,  a 
transabdominal scan was performed.  Ovarian  morphology and  dimensions 
were assessed and volume determined using the formula for an ovoid (d-j  x
d2 x d3 x 0.532). Ovarian morphology was classified as normal if the ovary
was of uniform hypoechogenecity and smooth outline, simple cvst if a single, 
thin  walled,  anechoic  cyst  with  no  septa  or  papillary  projections  was 
detected  and  complex if there was  non-uniform  echogenicity due to  cystic 
and solid areas in the ovary,  multiple cysts or ascites. The larger of the two 
ovaries with the most abnormal morphology was used to classify scans as 
shown in Table 11-1.
Table 11-1: Classification of scans
SCAN CLASSIFICATION
Volume Morphology
Normal* Simple  cyst Complex
<10ml Normal Equivocal Equivocal
10 to 60m Is Equivocal Equivocal Abnormal
> 60 mis Abnormal Abnormal Abnormal
Not  visualised  due  to 
poor view of pelvis
Unsatisfactory
*  Scans where  the  ovaries  were  not visualised  but  a  good  view of the 
pelvis and iliac vessels was obtained and  no abnormality was seen were 
included under normal.
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11.2.4  Screening strategy
Level  I  screen  (CA125):  Women  in  the  screen  arm  underwent an  annual 
serum  CA125  assay  interpreted  using  the  ‘Risk  Of  Ovarian  Cancer’ 
calculation.  On the basis of the risk value, volunteers were allocated to one 
of three groups and managed as detailed below:
(1)  Normal  Risk (<1  in  2000):  Volunteers were  informed that their results 
were normal.
(2)  Intermediate Risk (1  in 2000 -  1   in 500): Volunteers were recalled for a 
repeat  venepuncture.  The  interval  of  recall  varied  between  6  weeks 
and  6  months  and  was  inversely  related  to  the  risk  estimate. 
Management  following  repeat  testing  depended  on  the  recalculated 
risk value which incorporated the latest CA125 result.
(3)  Elevated  Risk  (>1  in  500):  Volunteers  were  recalled  for  a  Level  II 
screen.
Level  II  screen  (TVS  and  CA125):  Women  underwent  a  scan  of  their 
ovaries and serum CA125 assay.  Based on the  results of these tests, they 
were managed as shown in Table 11-2:
(1)  1 H H I I H H I  (Green) - Volunteers were  informed 
that their results were normal.
(2)  Normal scan  and  risk 1  in  25 - 1   in 5 (  ) - Serum CA125 was
repeated  and  the  risk  reassessed.  Subsequent  management  was 
determined  by the  same  risk  criteria  as  described  above  for  Level  1  
screens.
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(3)
Equivocal  or  Unsatisfactory  scans  irrespective  of  the  risk 
value or Normal scan with risk >1  in 5
(Orange)  -   TVS  and  CA125  were  repeated  after  ruling  out  other 
conditions  associated  with  a  CA125  elevation.  The  volunteer  was 
referred for surgery if the scan findings were persistently equivocal or 
became abnormal.
(4)  Abnormal scans irrespective of the risk value (  ) - The volunteer
was  referred  to  a  gynaecological  oncologist  for  assessment  and 
possible surgical investigation.
Table 11-2: Management of women following Level 2 screen
ROC value Classification of scans
Abnormal Equivocal Unsatisfactory Normal
<1 in 25
1  in 25 -1 in 5 Referral Repeat CA125 and TVS Repeat CA125
>1 in 5
11.2.5  Confirmation of diagnosis
Operative notes and histology reports of those who underwent surgery were 
reviewed  to  confirm  diagnosis  and  the  stage,  grade  and  histology  of any 
cancer diagnosed.  Further information regarding the women diagnosed with 
ovarian  cancers  was  obtained  from  the  surgeon,  medical  oncologist,  and 
general practitioner.
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11.2.6  Follow up
All volunteers who did  not undergo surgery or had  not withdrawn from the 
study  were  contacted  a  year  later for further  screening  and  were  sent  a 
postal follow up questionnaire 3 years after recruitment.
11.2.7  Analysis
The end  point  of the  prevalence  screen  was  defined  as  surgery following 
referral to a specialist or return to annual screening. The prevalence screen 
therefore consisted of a single or series of serum CA125 / scans culminating 
in  surgery  or  return  to  annual  screening.  Index  cancers  were  defined  as 
primary invasive epithelial  carcinomas of the ovary and fallopian tube.  For 
the  purpose  of this  analysis,  all  volunteers  have  been  censored  one  year 
after  the  date  of  the  final  blood  or  scan  test  related  to  their  prevalence 
screen.  Their  status  with  regard  to  a  diagnosis  of  an  index  cancer  was 
determined  on  the  date  of  censorship.  Specificity  and  positive  predictive 
value for detection of index cancer has been calculated as shown in Table 
11-7.
11.3  Results
A total of 13,582 women were recruited  in the UK between  1995 and 2000 
(Figure  11-2).  50  women  provided  incomplete  data.  66  women  were 
ineligible,  the  majority  (51)  because  they  were  pre-menopausal.  Of  the
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remaining,  6682  were  randomised  to  the  screen  arm.  Table  11-3 
summarises their baseline characteristics.
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Figure 11-2: Recruitment in the Bart’s B trial 
Table 11-3: Baseline characteristics of study population
Median (25th  -75th  centiles)
Age 59.65 (55.57-64.17)
Years since last period 10.1 (5.5-16.08)
Duration of HRT use in those who 
were currently on HRT (yrs)
5.02 (2.58-7.52)
Duration of OCP use (yrs) in those 
who had used it
4(1-10)
Miscarriages 1  (1-2)
No. of children 2 (2-3)
Height (cms) 162.56(157.48-167.64)
Weight (kg) 64.86 (59.42-73.03)
Number (%)
Ever use of OCP 4746 (35.3%)
Current use of HRT 4671 (34.7%)
Personal history of cancer 689 (5.1%)*
Personal history of breast cancer 315(2.3%)
Maternal history of ovarian cancer 283 (2.1%)
Maternal history of breast cancer 483 (3.6%)
Hysterectomy 2580(19.2%)
Ethnicity
White 12232  (90.9%)
Black 33 (0.3%)
Asian 24 (0.2%)
Other** 1171 (8.7%)
* includes those with personal history of breast cancer 
** includes women who did not fill in ethnicity
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11.4  Screen results
Following  randomisation  to  the  screen  group,  150  participants  did  not 
provide  a  blood  sample  because  they  had  both  ovaries  removed  (7), 
developed  a  new  cancer  or  other  illness  (11),  withdrew  (46)  or  did  not 
respond (86).
11.4.1  Level 1 screen
Of the 6532 women who had a blood test, the risk calculation was normal in 
5213,  intermediate  in  1228  and  elevated  in  91  (Figure  11-3).  The  1228 
women  with  intermediate  risk values  (i.e.  1  in  2000 -   1   in  500)  had  repeat 
CA125 testing.
  >  6344
Returned to 
annual screening
  ►   44 withdrew
144 Referred for 
Level II screen 
(see figure 2)
IR = Intermediate Risk, W = Withdrew
Low Risk (6344)
T  f  t  t  t  t
5213 671  233  98  61  68
W 18
Level I 
screen 
6532
IR1228
W 5
IR 504
W 6 W 2 W 13
IR 252 -►   IR 146-*  IR 83-
91 35  14
Elevated Risk (144)
Figure 11-3: Results following Level I screen
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Of  the  women  in  the  intermediate  group,  1131  were  returned  to  annual 
screening,  44  withdrew,  and  53  were  found  to  have elevated  risk.  All  144 
women  (91  +  53) with  an  elevated  risk (i.e.  risk >1  in  500) were offered  a 
Level  II  screen.  If  a  fixed  cut-off of  CA125  >30U/ml  had  been  used,  413 
women would have required a Level II screen.
11.4.2  Level II screen and further management
Six of the  144 women  in  the elevated  risk group were found  to  have  non- 
ovarian  malignancies  -  myeloma,  hepatocellular  carcinoma,  colon,  breast, 
endometrial cancer,  and  adenocarcinoma of unknown  primary.  In the latter 
case the woman had a  risk estimate of >1 in  5 with normal ovaries on scan. 
On  CT,  she  had  ascites  with  a  large  splenic  mass,  extensive  upper 
abdominal lymphadenopathy, a 2cm right external iliac mass and masses in 
the  upper  body  of  stomach  and  lower  lobe  of  right  lung  but  no  pelvic 
abnormality.  Biopsy of a lymph  node confirmed metastatic adenocarcinoma 
and  the  diagnosis  on  multidisciplinary  review  was  of  abdominal 
carcinomatosis of unknown primary origin.
The  results  of  the  Level  II  screen  in  the  remaining  138  women  were 
classified as shown in Table 11-4 with the overall outcome summarised in 
Figure 11-4.
(1) (Green):  All  39  participants  in  this
group returned to annual screening.
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(2)  Normal scan and  risk 1  in 25 -1  in 5 (  ) : All 28 women  had a
further CA125 and were then returned to annual screening.
Equivocal  or  Unsatisfactory  scans  irrespective  of  the  risk 
^   value or Normal scan with risk >1  in 5
(Orange): All 58 had a repeat CA125 and TVS. Six underwent surgery 
as the  repeat TVS was abnormal (2) or persistently equivocal (4).  52 
returned to annual screening
(4)  Abnormal  scans  irrespective  of the  risk  value  (  ):  13  women
were  assessed  clinically  and  10  underwent  surgery.  Three  women 
(RISK  values  <1%)  were  managed  conservatively;  one  had  a 
diagnosis of uterine fibroids,  a second  had a biloculated small ovarian 
cyst with  no sinister features and the third had multicystic ovaries with 
the diameter of the largest cyst <2cms. The latter was followed up with 
repeat scans and  bloods for 6  months during  which  time the  ovarian 
size decreased.
Table 11-4: Results of Level II screen
ROC value
Classification of scans
Abnorma Equivocal Unsatisfactory Normal Total
<1  in 25 4 2 21 39 66
1  in 2 5 - 
1  in 5 1 2 1 28 32
>1  in 5 7 2 4 26 39
No blood test 1 1
Total 13 6 26 93 138
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11.5  Surgery in screen positives
Overall,  16 women  underwent surgery as a  result of prevalence screening. 
11  had  surgery  at  Bart’s  Hospital,  London  and  5  had  surgery  in  other 
hospitals  following  referral  by  their  general  practitioner.  Seven  had  a 
laparotomy,  4  a  diagnostic  laparoscopy  and  5  a  laparoscopic  salpingo- 
oophorectomy.  Two  of the  latter  had  completion  laparotomy  as they were 
found to  have ovarian  cancer.  Postoperatively one woman  (without ovarian 
cancer)  developed  bowel  obstruction  and  had  to  undergo  a  further 
laparotomy, with drainage of a pelvic abscess and resection of small bowel, 
caecum, and ascending colon.
95
Level II screen 
TVS and CA125
Returned to 
annual screening
Referral to
gynaecological
oncologist
144 women had elevated 
ROC values
6 were diagnosed to have non 
ovarian cancers
16  — ►
4 had laparoscopy 
12 had oophorectomy
I
Primary EOC  3
Borderline EOC  1
Metastatic OC  1
Benign ovarian lesion  11
Figure 11-4: Summary of management of women with elevated ROC 
values on Level I screen
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11.5.1  Final diagnosis in screen positives
Ovarian malignancy was detected in 5 women. One had ovarian recurrence 
of a  breast  cancer  16  years  after  initial  diagnosis,  one  had  a  borderline 
papillary  serous  ovarian  carcinoma,  and  3  had  primary  invasive  epithelial 
ovarian  cancers  (Table  11-5).  The  details  of  the  benign  findings  in  the 
remaining 11 women are summarised in Table 11-6.
Table  11-5:  Details  of  women  with  diagnosis  of  ovarian  cancer 
following surgery
No First
CA125
Final
CA125
result
Final
ROC
value
(%)
Final
scan
result
Stage Grade Histology
1 34 248 98.82 A IC 3 Invasive serous papillary 
cystadenocarcinoma
2 169 160 100 A IIA Mixed Mullerian tumour
3 190 190 100 A IC 3 Invasive
cystadenocarcinoma
4 71 91 97.71 E IA Borderline micropapillary 
serous
cystadenocarcinoma
5 125 145 100 E Metastatic ovarian 
adenocarcinoma - 
recurrence of primary 
breast cancer after 10 
years
A= abnormal; E = equivocal
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Table 11-6: Details of women without a diagnosis of ovarian cancer following surgery
No Final scan 
result
Final CA125 I ROC value Histology of removed ovaries Other pelvic findings
1 A 54 10.24 Not removed Pelvic adhesions
2 E 135 100 Normal ovaries Dense adhesions -diverticulitis
3 E 53 10.89 Not removed Pelvic adhesions
4 A 124 99.26 Bilateral serous 
cystadenofibroma
5 A 25 0.47 Serous cystadenoma
6 A 100 100 Serous cystadenoma
7 A 62 99.98 Not removed Fibroids, adhesions
8 A 88 93.04 Serous cystadenoma Adhesions
9 A 117 100 Bilateral ovarian endometriosis
10 A 65 34.67 Not removed Pelvic adhesions - diverticulitis
11 E (4th scan) 60 0.02 Serous cystadenoma
A = abnormal; E = equivocal
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11.5.2  Follow up
Follow up data at 1   year after the final test related to the prevalence screen 
was available in 97.5% (6369) of the screened women. No additional cases 
of ovarian cancer were documented during follow up.
11.5.3  Screening Performance
The screening strategy achieved a positive predictive value of 19%  (Table 
11-7) for detection  of primary invasive epithelial ovarian cancer.  Specificity 
was 99.8% if all participants are included. If only those individuals who were 
followed for at least one year are  used to calculate specificity,  then  it was 
99.7%.
Table  11-7:  Specificity and  positive  predictive value of the screening 
strategy
Result of screen and 
clinical assessment
Primary
Invasive
Epithelial
OC
Not Primary 
Invasive 
Epithelial 
OC
Specificity 
(95% Cl)
PPV 
(95% Cl)
Abnormal 3 13* 99.8% 
(99.7- 99.9)
19%
(4.1-45.6)
Normal 0 6498
‘includes  one  serous  papillary  borderline  carcinoma  and  one  secondary  ovarian 
carcinoma due to breast cancer recurrence.
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11.6  Discussion
This  chapter  describes  the  first  prospective  use  of  the  Risk  of  Ovarian 
Cancer algorithm  in  screening for ovarian  cancer.  The  results demonstrate 
that  ovarian  cancer  screening  using  the  algorithm  is  feasible  and  can 
achieve  high  specificity  (99.8%,  95%CI  99.7%-99.9%)  and  positive 
predictive  value  (19%,  95%CI  4.1%-45.6%).  The  initial  algorithm  was 
developed  using  stored  serum  from  apparently  healthy  women  in  the 
Stockholm ovarian cancer screening study, six of whom were found to have 
ovarian cancer162.  Retrospective analysis estimated it achieved a specificity 
of  99.7%  and  positive  predictive  value  of  16%  for  detection  of  ovarian 
cancers diagnosed within  a year of the assay161.  The algorithm was then 
applied retrospectively to 33,621  CA125 results from 9,233 women from the 
Bart’s A screening trial. When compared with  a fixed cutoff for CA125,  the 
area  under the curve  significantly  improved  from  84%  to 93%  (p  =0.01 )55. 
The  results  reported  here  demonstrate  for the  first  time  in  a  prospective 
study that this novel screening strategy can achieve the high specificity and 
PPV  required  for  ovarian  cancer  screening.  These  are  essential 
characteristics  as  positive  screens  result  in  surgical  investigation,  with  its 
attendant morbidity.
The trial was undertaken to inform the design of a definitive ovarian cancer 
screening  trial  with  mortality  as  a  primary  end  point  and  to  assess  the 
feasibility  and  logistic  implications  of  this  approach.  Based  on  the  initial 
blood  test,  18.8%  of  women  had  an  intermediate  risk  value.  On  repeat
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testing,  92% with  an  intermediate value were  recalculated  to be at normal 
risk and returned to annual screening. The initial protocol did not specify the 
number of repeat tests and 252 women were referred for 4 or more tests. Of 
the  women  recalled  for  4  or  more  tests  6%  (15/252)  withdrew  from  the 
study,  compared  to  1.5%  (18/1228)  who  withdrew  after  their  first 
intermediate risk result (Figure  11-3).  It was noted that the  15 women who 
withdrew after multiple  tests  gave  the disruption  and  stress  resulting  from 
repeat  testing  as  their  primary  reason  for  withdrawing.  For  the  definitive 
UKCTOCS trial  it was therefore decided that a  maximum  of three CA  125 
tests would be requested and that women who remained in the intermediate 
group would then be offered an ultrasound scan. Assessment of anxiety and 
worry  resulting  from  repeat  testing  is  one  of  the  core  objectives  of  the 
psychosocial study that accompanies UKCTOCS.
The  overall  rate  of  referral  for  ultrasound  assessment  of the  ovaries was 
2.2% (144/6514), compared with a rate of 6.3% (413) had a fixed cut-off for 
CA125  (>30U/ml)  been  used.  Ultrasound  is  an  expensive  and  labour 
intensive procedure and the higher rate would  have a significant impact on 
cost and  logistics of a definitive trial and  if successful, a national screening 
programme.
In the course of the study 6 non-ovarian cancers were diagnosed as a result 
of  elevated  CA125  levels.  These  included  a  case  of  adenocarcinoma  of 
unknown  primary  (ACUP).  The  findings  on  imaging  in  this  particular 
individual  made  it unlikely that the  primary site was ovarian.  However,  the
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classification  of ACUP  raises  a  difficult  issue  in  ovarian  cancer screening 
trials.  Ovarian  cancer  if diagnosed  at an  advanced  stage  may wrongly  be 
classified as ACUP  resulting  in  a  lower numbers of ovarian cancers cases 
(true positives).  This can cause under reporting of ovarian cancer cases in 
the control arm of a screening trial.  It is important that as much information 
as  possible  is  gathered  about such  cases  and  that the  number of ACUP 
cases in the screen and controlled arm are monitored -  the numbers should 
not be significantly different.
Sixteen operations were undertaken following the Level II screen and clinical 
assessment of which  11  did not have ovarian malignancy. The major cause 
for  false  positive  surgery  was  benign  ovarian  cystadenomas  and  the 
presence  of pelvic adhesions.  In  2  cases,  this was  related  to diverticulitis, 
which  is  a  known  cause  for  raised  CA125  levels.  Initial  laparoscopic 
assessment made it possible to avoid oophorectomy in women with normal 
ovaries but dense pelvic adhesions, where the risk of surgical complications 
may be increased.
Of the five women  found to  have ovarian  malignancy,  one had  a stage  IA 
borderline  serous  micropapillary  ovarian  cancer.  There  is  controversy 
amongst  trialists  about  inclusion  of  borderline  tumours  (tumours  of  low 
malignant  potential)  as  ‘true  positives’  in  ovarian  cancer  screening  trials. 
Recently it has been proposed that the serous borderline tumors should be 
classified as micropapillary serous carcinoma or atypical proliferative serous 
tumor. The former have a higher incidence of bilateral ovarian involvement,
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recurrence  with  shorter  progression-free  interval  and  invasive  implants. 
However,  the  overall  survival  of patients  in  both  groups  appear to  be the 
same163 and both these tumours have an overall good prognosis. We have 
therefore  continued  our  practice  of  not  including  borderline  ovarian 
carcinomas as ‘true positives’ irrespective of their histology as the aim is to 
develop a strategy that impacts on ovarian cancer mortality.
Ovarian recurrence of a primary breast cancer was detected in one patient. 
Women who had previously been diagnosed with a malignancy and were in 
remission  were  allowed  to  join  the  study.  5.12%  (689)  women  in  the 
screened arm had a personal history of cancer, mainly breast and bowel. As 
CA125 can occasionally be elevated in recurrences of such malignancies48, 
the  detection  of  occasional  asymptomatic  recurrences  is  inherent  in  the 
study design. The benefits of such detection are uncertain and women with 
a previous history of cancer should be counseled about this at recruitment.
The prevalence screen  reported  here involved 6532 women. Three women 
were diagnosed with primary invasive epithelial ovarian cancer, two Stage I 
and one Stage  II.  No other primary ovarian cancers were reported  in these 
women during the year following their screen. The numbers are too small to 
comment on  sensitivity or stage shift but are consistent with the data from 
retrospective evaluation  of the  Risk of Ovarian  Cancer algorithm.  There  is 
preliminary  evidence  from  our  previous  RCT  that  early  detection  may 
increase  long-term  survival8.  Follow  up  data  from  prospective  single  arm 
ovarian  cancer screening  (OCS) trials also  provide evidence of a  possible
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survival benefit910. It is however important to note that the “ovarian cancers”  
detected  by  screening  in  the  latter  trials  included  granulosa  cell  and 
borderline ovarian carcinomas that have a good overall prognosis.
The algorithm  is also being  used for screening ‘high risk’ women in the US 
Cancer Genetics Network trial, and in the screening arm of the Gynecology 
Oncology Group study of women at high  risk in the US.  In the UK Familial 
Ovarian Cancer Screening Study efforts are underway to revise the current 
screening strategy to  incorporate the ‘Risk of Ovarian  Cancer’ algorithm.  If 
screening were shown to be effective in these various trials, it is highly likely 
that the ‘Risk of Ovarian Cancer’ algorithm that will be part of future ovarian 
cancer screening programmes across the world.
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12  UK COLLABORATIVE TRIAL OF OVARIAN CANCER SCREENING -  
TRIAL DESIGN AND ORGANISATION
12.1  Introduction
Despite  advances  in  both  surgery  and  chemotherapy for the treatment of 
ovarian cancer, there has been  little mortality benefit. The relative five-year 
survival rate for women diagnosed in England and Wales in 1991-1993 was 
29%,  compared  with  23%  for  women  diagnosed  1971-1975 
(www.statistics.aov.ukT In the late nineties, preliminary data from OCS trials 
seemed  to suggest that screening  and  early detection  may  impact on  OC 
outcome.  In  1999,  follow  up  of 22,000 women  in  the  initial  Bart’s  RCT  of 
ovarian cancer screening (Bart’s A) showed a significantly improved median 
survival (72.9 months) in women with ovarian cancer in the screened group 
as  compared  to  the  control  group  (41.8  months).  The  difference  was  not 
biased  by  lead  time;  ascertainment  of  cancers;  treatment  in  specialist 
centres  or  follow  up  8.  Data  from  single  arm  prospective  studies  also 
suggested  a  possible  survival  benefit.  The  University of Kentucky Ovarian 
Cancer  Screening  Program  involving  nearly  15,000  women  reported  92.9 
+/- 6.9% survival at 2 years and  83.6 +/-  10.8% at 5 years in  patients with 
screen  detected  epithelial  ovarian  cancer 9.  A stage  shift implying  better 
survival was also reported from Japan where authors noted that prior to the 
set  up  of  a  10  year  ovarian  cancer  screening  trial  29.7%  of  35  cancers 
diagnosed in the department were Stage I while after the trial was initiated, 
58.8% of 85 ovarian cancers treated were Stage 110. The latter trials lack a
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control group and hence are prey to a significant "healthy-volunteer effect", 
lead  time  bias,  reporting  bias  etc.  Moreover,  none  of  the  trials  were 
designed or powered to answer definitively whether screening would have a 
mortality effect.  With  data  emerging  from  the  pilot randomised  control trial 
(Bart’s B) confirming feasibility of using the ROC algorithm in ovarian cancer 
screening  (Chapter  7),  the  stage  was  set  to  conduct  a  large  definitive 
screening trial with ovarian cancer mortality as the primary end point.
In  1999,  a number of professional groups (the NIH Consensus Conference 
1995,  the  Society  of  Gynaecologic  Oncologists  1998  and  the  National 
Screening  Committee  in  the  UK  1999)  were  of  the  view  that  a  large 
randomised  controlled  trial  was  required  to  unequivocally  establish  the 
impact of ovarian  cancer screening (OCS) on disease mortality.  In addition 
the  Exceptional  Cases  Advisory  Committee  in  the  UK  on  the  basis  of an 
economic  analysis  and  detailed  systematic  review164  concluded  that  a  well 
designed trial of OCS would be of value to the National Health Service.  Lay 
groups  like OVACOME and  the  National  Federation  of Women’s  Institutes 
urged the government to support research  into OC screening.  In parallel,  it 
was clear that that there was need to perform a randomised controlled trial 
on the effectiveness of screening  before media  publicity and demand from 
individuals,  lay  groups  and  sectors  of  the  medical  profession  led  to 
widespread implementation of OCS.
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To  address  these  issues  the  UK  Collaborative  Trial  of  Ovarian  Cancer
Screening  (UKCTOCS)  was  set  up  and  in  2001  commenced  recruitment.
This chapter describes the design of the trial and its organisation.
12.2  Aims and Objectives
The overall aim of the  UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS)  is  to  provide  data  so  that  an  informed  decision  about  the
introduction of population screening for ovarian cancer can be made.
Primary objective
To  establish  the  impact  of  screening  on  ovarian  cancer  mortality  by
comparing disease mortality in the screen and control arms.
Secondary objectives
1.  To  assess  and  compare  the  performance  characteristics  of  the  two 
screening strategies (serum CA125 versus ultrasound)
2.  To  determine the  physical  morbidity  resulting  from surgical  intervention 
attributable to screening
3.  To assess the psychological consequences of screening
4.  To  determine  the  resource  implications  of screening  and  the  resulting 
interventions
5.  To assess feasibility of screening, as reflected by compliance rates with 
annual screening.
6.  To  establish  a  serum  bank  for  future  assessment  of  novel  tumour 
markers.
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12.3  Trial design
The  design  involves  a  randomised  controlled  trial  of  200,000 
postmenopausal women aged 50-74 years allocated in a 2:1:1  ratio to: (1) A 
control group (no screening) (2) A multimodal group (annual screening with 
CA125  as  a  primary  test  and  ultrasound  as  a  secondary  test)  (3)  An 
ultrasound  group  (annual screening with transvaginal  ultrasound).  Women 
in the screened arms have 6 annual screens (Figure 12-1).
M ULTIM O DAL 
GROUP 
Annual CA 125-ROCA
Postmenopausal 
women 
> 50 -74 years 
200,000
CONTROL GROl P 
100,000
6 annual screens
Primary end point 
Ovarian Cancer Mortality
All women followed up via Office of National Statistics as well as postal questionnaires
Figure 12-1: Trial design of UKCTOCS
12.4  Subjects
As this is a general population trial, the aim was to include women with the 
highest risk of sporadic OC.
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12.4.1  Inclusion criteria
(1)  Age  50-74  years:  The  lower cut off was  chosen  as  primary  invasive 
OC is uncommon below 50 years after which the incidence rises steeply165. 
An upper limit was fixed a
as over 74 years, mortality from other causes during the follow up is likely to 
be high and confound interpretation of the end point of OC mortality.
(2)  Postmenopausal:  This  was  defined  as  either  (a)  >12  months 
amenorrhoea  following  a  natural  menopause  or  hysterectomy,  or  (b)  >12 
months  of  hormone  replacement  therapy  commenced  for  menopausal 
symptoms.  The  restriction  was  because  pre-menopausal  women  have  a 
greater  incidence  of  benign  and  physiological  conditions  associated  with 
false positive findings on  multimodal and  ultrasound screening. The criteria 
does not entirely exclude pre-menopausal women, but it was not feasible to 
determine FSH  levels in all volunteers and such an approach would not be 
applicable to women taking hormone replacement therapy.
12.4.2  Exclusion criteria
(1)  Previous ovarian malignancy
(2)  History of bilateral oophorectomy:
(3)  Active  non-ovarian  malignancy:  Women  who  had  a  past  history  of 
malignancy were only eligible  if (a)  they  had  no documented  persistent or 
recurrent disease and  (b)  had  not received treatment for >12  months.  The 
intention  was  to  minimise  false  positive  CA125  results  due  to  advanced
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stages of previously diagnosed  malignancy.  This exclusion did  not include 
premalignant disease such as cervical intraepithelial neoplasia or treatment 
with Tamoxifen for breast cancer that was not clinically active.
(4)  Increased risk of familial ovarian cancer: There are ethical difficulties in 
randomising  high-risk women  between  a screened  and  a control group.  In 
the  UK,  such  women  are  eligible  for a  separate trial,  the  United  Kingdom 
Familial Ovarian Cancer Screening Study (UKFOCSS). Women at high-risk 
were defined  by the eligibility criteria for UKFOCSS. They were first degree
(1°) relatives (mother, sister or daughter) of a cancer affected member of a 
“high  risk” family.  The  high-risk family was defined  by one of the following 
criteria:
1.  Two or more individuals with OC who were 1° relatives
2.  One  individual with  OC  and  1   individual with  breast cancer diagnosed
under 50 years who are 1° relatives
3.  One individual with OC and 2 individuals with breast cancer diagnosed
under 60 years who are connected by 1° relationships
4.  An  affected  individual  with  a  mutation  of  one  of  the  known  ovarian 
cancer predisposing genes (BRCA1, BRCA2, MSH1)
5.  One person with OC and three individuals with colorectal cancer with at
least  one  case  diagnosed  before  50  years,  all  connected  by  1° 
relationships.
6.  Affected relatives fulfilling criteria  1,2 or  3 who were related by second 
degree  through  an  unaffected  intervening  male  relative  who  had  an 
affected sister.
12-102
MD thesis UMUKCTOCS -  TRIAL DESIGN AND ORGANISATION
(5)  Participation in other ovarian cancer screening trials: It should be noted 
that after the start of UKCTOCS, other general population OCS trials in 
the  UK stopped  recruitment and  discontinued screening.  These were 
the  pilot  randomised  control  trial,  Bart’s  B  and  the  ultrasound  based 
European  Randomised  Control  Trial  Of  Ovarian  Cancer  Screening. 
Both had recruited about 15,000 postmenopausal women each.
12.5  Screening regimen in the trial
The OCS strategies in  UKCTOCS utilises the two screening tests -  serum 
CA125 and/or transvaginal ultrasound (TVS) of the ovaries. The ultrasound 
strategy  uses  TVS  as  a  first  line  test  with  repeat  screening  after a  fixed 
period  if  an  abnormality  is  detected  on  initial  testing.  The  multimodal 
strategy uses serum CA125 as the primary screening modality with TVS as 
a second line test if levels are abnormal.  The algorithms were derived from 
the  data  collected  in  the  numerous  large  prospective  screening  studies 
undertaken  in  the  90s  and  discussed  in  the  literature  review.8  9  5 1   52  57 
Women  are  screened  annually  for 6  years.  It  is  anticipated  that  ongoing 
refinement of the screening algorithms will occur in the future  in a manner 
analogous to  refinement of the screening  algorithms for Downs syndrome, 
cervical cancer and breast cancer.
12.5.1  Ultrasound Algorithm
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All  OC  screening  and  diagnostic strategies incorporate TVS of the ovaries 
with  the  aim  to  detect  the  earliest  morphological  changes  that  could  be 
linked to ovarian cancer. The main issue with use as a first line test is that a 
significant  proportion  of  women  require  further  investigations  and 
unnecessary surgery for benign masses.
The  UKCTOCS  ultrasound  algorithm  takes  into  account  some  of the  key 
issues raised in literature. Features include
(1)  Use of grey-scale  ultrasound  morphology to characterize the adnexal 
mass with ovarian volume playing a lesser role.
(2)  Repeat scanning of adnexal masses detected on the first screen in 6-8 
weeks by a more experienced ultrasonographer
(3)  Classification  of simple  (unilocular)  cysts  less  than  60mls  in  size  as 
normal.1 1 1
(4)  Possibility  of conservative  management of adnexal  masses with  less 
suspicious features (multicystic, multiloculated) after clinical evaluation.9108
(5)  Collection of Doppler data but no use of it in the screening algorithm as 
it is proven to be subjective and prone to significant interobserver variation.
(6)  Use of subjective pattern recognition as opposed to a weighted scoring 
system or morphological index. Data is collected on ovarian volume, outline, 
presence of papillary projections and cyst complexity but the final decision is 
driven by the clinician.
Ultrasonography  is  performed  by  about  90-100  ultrasonographers  at  13 
regional centres (RC). The method of choice is transvaginal ultrasonography
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(TVS)  but  where  this  is  not  possible  or  acceptable  to  a  volunteer, 
transabdominal ultrasonography is performed.
Annual  or  Level  I  scans  are  performed  by  ultrasonographers  and  Level  II 
scans  by  senior  ultrasonographers,  gynaecologists  or  radiologists  with 
particular experience  in  transvaginal  ultrasonography.  For each  ovary,  the 
ultrasonographer first decides if the ovary is visualised and the view is good
(S), not visualised but a good view is obtained of the iliac vessels (N) or not 
visualised  due to  a  poor view (P)  resulting from  bowel gas or other pelvic 
structures  such  as  fibroids.  In  the  latter  case,  if  possible  transabdominal 
ultrasonography  is  undertaken  after  bladder  filling.  Two  aspects  are 
assessed in the visualised ovary:
(1)  Ovarian  Size:  Ovarian  diameter  is  measured  in  3  dimensions.  The 
software  calculates ovarian  volume  using the formula for an  ellipsoid 
(d1 x d2 x d3 x 0.523). If it is not possible to measure the 3 dimensions 
of the ovary, the ovarian volume is not calculated.  Instead the system 
calculates a mean diameter.
(2)  Ovarian  Morphology:  Ovarian  echogenicity  is  assessed  for  the 
presence of cysts and solid areas.
Morphology is classified as
Normal: Uniform ovarian echogenicity with or without single inclusion cyst or 
spots  of  calcifications.  To  classify  as  normal  the  inclusion  cyst  must  be 
single, less than 10mms and should not distort the outline of the ovary. 
Simple cvst: Single cyst distorting the outline of the ovary, with no septae or 
papillations and thin wall with regular internal outline.
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Complex morphology: All non-uniform ovarian echogenicity excluding single 
simple cyst. If there is more than one cyst with no septae or papillations and 
thin  wall  with  regular  internal  outline,  this  is  classified  as  complex 
morphology.  Detailed  description  of all  features  -  the  number and  size  of 
cysts, wall regularity,  presence and thickness of septae, size of papillations 
and echogenicity of the fluid contents are recorded. Definitions of ultrasound 
features and classification of cysts are as per International Ovarian Tumour 
Analysis (IOTA) group.104
Scans are classified based on findings in both ovaries into:
Normal:  If  both  ovaries  have  either  normal  morphology  or  simple  cysts 
<60cc or <5cms in diameter or or both ovaries are not visualised despite a 
good view of the iliac vessels.
Abnormal:  If one or both ovaries have complex morphology or simple cysts 
>60cc  or >5cms  in  diameter or ascites  (vertical  pool  in  Pouch  of Douglas 
>10mms)  is  present.  If  any  abnormality  is  detected  on  Level  II  scans, 
presence and site of colour flow Doppler is recorded.
Unsatisfactory:  If one or both ovaries are not visualised due to a poor view. 
The exception will be those scans where one ovary is not visualised due to a 
poor view but the  other ovary  has  abnormal  morphology  or a  simple  cyst 
>60cc  or  >5cms  in  diameter.  In  the  latter  case,  the  scan  is  classified  as 
abnormal.
Level I screen
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In UKCTOCS, women randomised into the ultrasound group have an annual 
TVS  at  their  RC.  Depending  on  the  results  of  the  scan,  there  are  five 
possible courses of action (Figure 2):
(1)  Normal scan or a scan  abnormality that was managed conservatively 
in the past and  has not changed  in appearance since the last annual 
scan:  Routine  screening  with  an  annual  TVS  (Level  1)  on  the  next 
anniversary (one year) of the date of randomisation.
(2)  Unsatisfactory scan: A repeat level I scan in 12 weeks
(3)  Abnormal  scan:  Level  II  screen  in  6-8  weeks.  Earlier  scans  are 
arranged where there is a high index of suspicion.
Level II screen
Depending  on  the  results  of the  Level  II  screen,  there  are  four  possible 
courses of action:
(1)  Normal Scan:  Routine screening with an annual TVS (Level  1) on the 
next anniversary (one year) of the randomisation date.
(2)  Unsatisfactory  scan:  Repeat  Level  II  screen  in  6  weeks  with  earlier 
screens arranged where there is a high index of suspicion.
(3)  Abnormal scan -  Referral for clinical assessment.
Women  who  have  repeat  Level  II  screens  are  similarly  triaged  based  on 
their findings to annual screening, clinical assessment with a view to surgery 
and in a minority of women, clinical management.
Scan  images  are  centrally  archived  in  the  CC.  RCs  are  able to  request a 
second opinion from the senior PI at the CC with ultrasound expertise
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Level I screen - TVS
Complex
morphology
Simple cyst Normal
morphology
Volume > 60ml Volume < 60ml
Level II screen - TVS in 6-8 weeks
Normal morphology 
OR
Simple cyst < 60ml
Complex morphology 
OR
Simple cyst > 60cc
Return to annual screening Referral to gynaecological oncologist
Figure 12-2: Ultrasound algorithm 
12.5.2  Multimodal Algorithm
This algorithm  is  based  on the work done  previously  in the  Bart’s A and  B 
trials. The ‘Risk Of Ovarian Cancer’ (ROC) algorithm tested prospectively in 
the  Bart’s  B  pilot  trial  is  used  with  a  few  logistics  modifications.  These 
include fixing the interval for a repeat blood after an intermediate ROC result 
at 12 weeks rather than the varied interval of 6 weeks to 6 months adopted 
in  the  pilot  trail  (Bart’s  B)  and  restricting  number  of  repeat  bloods  to  a 
maximum of three in any year before a woman has a TVS.  Interpretation of 
the  ultrasound  findings follows the  same  rules  as described  above.  Based 
on  the  results  of the  analysis  of data  from  Bart’s trial  A,  complex  ovarian 
morphology is used for classifying scans as abnormal.
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Level I screen
In UKCTOCS, women who are randomised to the multimodal group have an 
annual level I screen which involves venepuncture for CA125 estimation and 
calculation  of the  ROC.  The  blood  sample  is taken  at the  regional  centre 
(RC)  and  transported  overnight  at  room  temperature  to  the  central 
laboratory at the co-ordinating centre (CC). All blood samples received >56 
hours after venepuncture are discarded and repeat samples requested. The 
samples are initially centrifuged at 4,000 rpm for 10 minutes and the serum 
separated.  Excess serum  is aliquoted and stored.  Serum CA125 levels are 
determined by commercial enzyme immunoassay (EIA) (Roche EIA Elecsys 
2010  system).  The  CA125  values  are  directly  uploaded  electronically  into 
the trial database management system (DMS), which calculates the ‘Risk of 
Ovarian  Cancer’.  The  first  ROC  determination  is  based  upon  a  single 
measurement of CA125.  Subsequent ROC determinations are based  upon 
both the absolute CA125 level and the rate of change in CA125 levels. The 
approach summarises in one number,  the information about risk of ovarian 
cancer,  thus  simplifying  the  practical  implementation  of  the  screening 
protocol.
On  the  basis  of  the  ROC,  subjects  are  allocated  to  one  of three  groups 
(Figure 3):
(1)  Normal ROC: Routine screening with an annual blood test (Level 1) on 
the next anniversary (one year) of the randomisation date.
(2)  Intermediate  ROC:  Volunteers  in  this group  are  recalled  for a  repeat 
venepuncture for CA125  measurement in  12 weeks.  After the  repeat
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CA125  the  ROC  is  recalculated  and  management determined  as for 
the  initial  ROC.  The  majority will  require  1-2  repeat venepunctures to 
be reclassified as normal or elevated. The small proportion of subjects 
who  remain  in  the  intermediate  group  after three  CA125  estimations 
will have a level II screen.
(3)  Elevated  ROC:  Women  will  be  recalled  for  a  level  II  screen  in  6-8
weeks.  For  initial  serum  measurements,  a  CA125  level  of  35  U/ml 
would correspond approximately to a ROC of 1   in 500.
Level II screen
Women  have  venepuncture  for  repeat  CA125  assay  and  a  transvaginal
scan.  The scan  results are classified as detailed  above.  Depending  on the
results of the Level II screen, there are four possible courses of action:
(1)  Scan  normal and the ROC  normal or intermediate:  Routine screening 
with an annual blood test (Level  1) on the next anniversary (one year) 
of the randomisation date.
(2)  Scan  normal  and  the  ROC  elevated  OR  scan  unsatisfactory 
irrespective  of ROC:  Repeat Level  II  screen  in  12 weeks with  earlier 
screens arranged where there is a high index of suspicion.
(3)  Scan  abnormal  irrespective  of  the  ROC  -   Referral  for  clinical 
assessment with a view to surgery.
(4)  Women  who  have  the  Level  II  screen  repeated  are  again  triaged 
based on their findings to annual screening, clinical assessment with a 
view to surgery and in a minority of women, clinical management.
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MULTIMODAL SCREENING ALGORITHM (UKCTOCS)
Level I screen - CA125
CA125 repeated in 12 weeks
CA125 repeated in 12 weeks
Annual screening
Normal ROC Intermediate ROC
Intermediate ROC
Intermediate ROC
Abnormal scan 
irrespective of ROC
Normal scan with 
normal or 
intermediate ROC
Clinical assessment with a 
view to surgery
Level II screen in 6 weeks
Normal Level II scan with elevated ROC 
Or
Unsatisfactory Level II scan
Repeat Level II screen in 6 weeks
i
Management
ROC  |
Abnormal scan Unsatisfactory scan Normal scan
Very high* Clinical assessment with a 
view to surgery
Clinical assessment with a 
view to surgery
Elevated* Clinical assessment 
with a view to surgery
Clinical decision Clinical decision**
Intermediate* Clinical decision**
Annual screen
Normal Annual screen
Rule out other causes of raised CA125 
Usually repeat Level II screen in 3 months
ROC -  risk of ovarian cancer
Figure 12-3: Multimodal algorithm
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12.6  Clinical assessment and further investigation
Where the protocol requires clinical assessment the RC refers the woman to 
a  designated  NHS  clinician  who  carries  out  the  initial  clinical  evaluation 
(history and physical examination) and arranges for further investigations as 
appropriate. These may include
(1)  Serum CA125 in women in the ultrasound arm
(2)  Repeat  Ultrasound  and  Doppler  with  a  senior  consultant  radiologist
with a specialist interest in gynaecological oncology
(3)  CT / MRI of abdomen and pelvis
(4)  Serum FSH / oestradiol if multiple cysts present  and  hysterectomy  has
been  performed  in  the  past  to  establish  if  patient  is  pre-  or  peri- 
menopausal and still ovulating
(5)  Mammogram -  to  rule out breast cancer if CA125 profile is abnormal 
and no ovarian abnormality is detected on TVS.
(6)  Assessment of CEA and  CA19.9  levels:  CEA though  mainly elevated 
in colorectal cancer,  maybe elevated in other malignancies. CA19-9 is 
a  tumour  marker  detected  in  serum  of  healthy  individuals  at 
concentrations  <  40  U/ml,  with  the  highest  levels  in  excretory  ductal 
pancreatic  adenocarcinoma,  biliary,  hepatocellular  and 
cholangiocellular  cancer.  Levels  may  also  be  elevated  in  gastric, 
colorectal  and  ovarian  cancer  and  occasionally  in  lung,  breast  and 
uterine cancer.
In  multimodal  group women,  other causes of CA125 elevation  need  to  be 
ruled out.  In the ultrasound group,  some scan features are associated with
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lower risk and others with significant risk.  Following consultation and clinical 
evaluation, if there is a high index of suspicion; women undergo surgery with 
a  named consultant gynaecological oncologist following case discussion  in 
the  local  gynaecological  oncology  multidisciplinary  meeting.  If  on  clinical 
assessment the  risk  of a  cancer  is  considered  to  be  low or  if the  patient 
refuses surgery, then conservative management with follow up is arranged.
12.7  Surgery
The nature and timing of surgical intervention is decided at the consultation 
between  the  participant and  the  gynaecological  oncologist / gynaecologist 
receiving  the  referral.  Patients  undergo  routine  investigations  that  are 
deemed  appropriate  for  assessment  of fitness  for surgery.  Some  centres 
may  use  pre-operative  assessment  scoring  systems  to  assess  possible 
morbidity.  It  is to  be  noted  that in  the  ultrasound  arm,  women  referred  for 
surgery  include  a  higher proportion  who  have  had  previous  hysterectomy 
and/or  endometriosis.  The  guidelines  below  represent  appropriate 
management  in  the  majority  of  cases.  However,  it  is  acknowledged  that 
there  are  circumstances  where  they  cannot  be  adhered  to  and  in  such 
situations,  management  depends  upon  the  considered  judgement  of  the 
clinician involved.
The  primary aim of surgery  is to  remove both ovaries for histopathological 
examination.  Supposedly,  ‘normal’  looking  ovaries  will  be  removed  as 
malignancy has been detected in such ovaries in the pilot trial (unpublished
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data).  However,  there  will  be  exceptions  based  on  clinical  grounds.  One 
such occasion is where there are dense pelvic adhesions with increased risk 
of significant morbidity if dissection  is undertaken. The clinician  may opt to 
only remove the ovary found to have an abnormality on ultrasound and not 
dissect the contralateral ‘normal’ ovary.  Hysterectomy adds to morbidity and 
will be avoided unless there are clear clinical indications.
The  approach  to  surgery  depends  on  the  results  of  any  pre-operative 
investigations and  local surgical expertise. The primary intervention in most 
cases is laparoscopy with the intention of performing a laparoscopic bilateral 
salpingo-oophorectomy.  If clinical findings at laparoscopy are suggestive of 
the presence of an  ovarian  cancer,  or if laparoscopic oophorectomy is  not 
felt  to  be  possible  because  of  technical  difficulties,  a  laparotomy  is 
undertaken.
Laparoscopy - The  procedure  is carried  out using  the surgeon’s  preferred 
technique.  A thorough  inspection  of the  whole  of the  abdominal  cavity  is 
performed  before  aspirating  any  free  fluid  that  is  present  and/or  taking 
peritoneal  washings.  If  technically  possible  and  in  the  absence  of  any 
features suggestive of ovarian cancer, a bilateral salpingo-oophorectomy is 
performed. Care is taken to ensure removal of the entire ovary on each side. 
The  operative  specimen  is  placed  inside  a  bag  prior to  removal  from  the 
abdominal cavity in  order to minimise the risk of spillage of cyst contents if 
cyst rupture occurs during this  process.  Aspiration  of ovarian  cysts should 
be avoided  since a stage  1A cancer may be unwittingly be converted to a 
stage  1C.  When  a  histopathological  diagnosis  of ovarian  cancer  is  made
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following  a  laparoscopic  bilateral  salpingo-oophorectomy  a  formal  staging 
laparotomy is performed within 2 weeks of initial surgery.
Laparotomy -  If there  is a clinical  suspicion  of ovarian cancer the surgeon 
carries out the laparotomy according to their usual practice in order to stage 
the disease and remove all macroscopic disease where possible.
Details of all surgical procedures undertaken to investigate screening results 
is  collected  including  the  operative  procedure,  the  surgical  findings,  the 
histopathological  findings,  details  of  the  postoperative  course  and  any 
complications.
12.8  Conservative management
A  large  number  of  asymptomatic  benign  adnexal  masses  are  detected 
especially  in  the  ultrasound  arm  of  the  trial.  In  women  who  have  had 
previous  hysterectomy,  there  is  an  increased  chance  of  adhesions  and 
peritoneal  pseudo  cysts  being  reported  as  ‘multilocular  adnexal  cysts’. 
Following clinical assessment, investigation and discussion with the woman, 
if  the  plan  is  made  to  avoid  surgery  and  manage  conservatively,  then 
women  are  followed  by  a  repeat transvaginal  scan  and  possibly  a  serum 
CA125 assessment in three months. They are returned to annual screening 
if the findings are unchanged at review. At subsequent screens, no action is 
taken  if there  is  no  change  in  the  size  or character of the  adnexal  lesion 
detected.
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12.9  Follow-up
The  primary  ends  points  of  the  trial  are  ovarian  cancer  diagnosis  and 
mortality.  In  a  previous  OCS  trial,  the  National  Health  Service  Central 
Register  ascertainment  in  1999  was  found  to  be  incomplete  and  direct 
follow-up  provided  additional  information.166  Hence  trial  follow  up  includes 
postal questionnaire and flagging via the Office of National Statistics.
All  volunteers  are  sent  a  postal  questionnaire  3.5  and  7  years  from  the 
randomisation  date.  The  questionnaire  asks  for  details  of  any 
gynaecological  procedures,  cancer  diagnosis  or  serious  illness  since 
recruitment  and  contact  details  of the  clinician  who  treated  the  condition. 
Further details of these procedures are then be obtained as appropriate.  In 
order to assess contamination, the follow up questionnaire also asks women 
in  the  control  group  if they  have  undergone  a  pelvic  ultrasound  scan  or 
CA125 test since randomisation and if so the reason for the test.
All volunteers were asked for consent for their contact details to be sent to 
the Office of National Statistics (ONS) for England and Wales or the Cancer 
Registry of Northern  Ireland  depending  upon their place of residence.  The 
computerised  entry  for  each  subject  at  the  registry  is  ‘flagged’  to  prompt 
notification to the CC of deaths and all  new cancer diagnoses in the study 
population.
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12.10  Confirmation of outcome
Where  any  method  of  follow  up  raises  the  possibility  of  ovarian  cancer 
further information is requested from the GP and/or hospital where treatment 
is  provided.  In  addition,  to  ensure  that all  deaths from  ovarian  cancer are 
documented,  a  copy  of  the  death  certificate  is  requested  for  all  study 
participants who die during follow up.  In addition, survival at end of study for 
participants  with  a  confirmed  diagnosis  of  ovarian  cancer  will  initially  be 
confirmed  from  the final  postal  questionnaire.  For participants who  do  not 
return the questionnaire further inquiries will be made via the GP to establish 
their status.  An  independent  outcomes  committee  reviews each  case  and 
confirms diagnosis and mortality due to OC.
12.11  Sample Size
The  proposed  sample  size  of  200,000  is  based  on  primary  comparison 
between the control group and the two screened groups combined with the 
primary  outcome  measure  mortality  from  ovarian  cancer.  There  are 
approximately 37 deaths from ovarian cancer per 100,000 women aged 50- 
74  per year.  Assuming  an  attrition  rate  of 4%  per  year  (75%  of  patients 
followed  up for the full  7  year period)  gives  a  mean  of 6  person  years of 
observation for each  patient randomised,  and thus an expected  number of 
deaths from ovarian cancer in the control group of 222 per 100,000 women 
randomised.  The event of interest,  death from ovarian cancer,  is rare and 
so it is assumed that the observed number of deaths in each group follows a
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Poisson  distribution.  Under  these  assumptions,  a  total  sample  size  of 
200,000 (100,000 controls, 50,000 in each screening group) would give 80% 
power  at  the  (two-sided)  5%  significance  level  to  detect  a  reduction  in 
mortality due to screening of 25% (167 deaths in the screening groups), and 
over 90% power to detect a reduction of 30% (155 deaths in the screening 
groups).  Comparisons  between  the  multimodal  and  control  groups  and 
between the ultrasound and control groups are also of primary interest. With 
the above assumptions, the trial will have 80% power at the (two-sided) 5% 
significance  level  to  detect  a  30%  reduction  in  mortality  compared  to  the 
control group and  63%  power to detect a 25%  reduction.  It is  important to 
note  that  if one  comparison  is  significant  and  the  other  is  not,  this  result 
does  not necessarily  imply that one  method  is significantly  better than  the 
other. Only the direct comparison between the two methods will address this 
issue. The trial has at least 70% power to detect a difference in OC mortality 
between the two screening arms of 30% or more. However, if as anticipated 
the difference in  OC mortality between the two screened groups is modest 
then this study will  have limited  power to detect such differences e.g.  35% 
power to detect a difference of the order of 20%.  The choice  of screening 
strategy will then be based on other outcome measures such as sensitivity, 
positive predictive value, morbidity, quality of life, and health economics.
At  the  end  of  recruitment,  the  original  power  calculation  was  reviewed. 
Deaths  in  any  particular year from  ovarian  cancer occur largely  in women 
diagnosed with the disease  in the  preceding 2-3 years.  Based on eligibility 
criteria women  with  ovarian  cancer cannot join  the trial.  Hence one of the
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concerns was that this will result in a reduction in the number of deaths from 
ovarian  cancer  in  the  early  years  of  the  trial  when  compared  to  the 
anticipated  numbers  adopted  in  the  original  power calculations,  which  did 
not factor in this effect. This could have two possible effects
(1)  Decline  in the  number of control  group deaths,  particularly during the 
initial years,  resulting  in  a  reduction of anticipated events (deaths from 
ovarian cancer) at the end of the 7 years follow up.
(2)  A  reduction  in  mortality  differences  between  the  screen  and  control 
groups, if the primary analysis is performed  1   year after the last screen. 
As women usually die about 2-3 years after initial diagnosis, a sufficient 
period  of  time  may  not  have  passed  to  demonstrate  the  efficacy  of 
screening.
Hence, the expected  number of control group deaths was recalculated with 
more precision taking into consideration several factors.
(1)  Firstly,  the  mortality  rate  for  ovarian  cancer  used  initially  was  an 
average value that covered the entire age range.  However as the age 
distribution of the recruited 202,638 women  is now known,  age-group 
specific mortality rates were used.
(2)  Linked to the above,  it was now possible to calculate the numbers of 
women in each respective age group as the trial progresses, reflecting 
the increasing age of the women.
(3)  The original calculations employed an average 4% annual attrition rate 
for the trial. This is very conservative because women remain flagged 
with  the  ONS  even  if they  have  withdrawn  from  participating  in  the
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screening.  Death  and  cancer registration  information  continues to  be 
available  until  censorship.  All women  effectively contribute to the trial 
(at  least  with  regard  to  this  main  outcome  measure)  unless  they 
actually  die,  whereupon  they  are  of  course  then  unable  to  die  of 
ovarian cancer.  So in  place of an attrition factor one instead  needs to 
adjust for a mortality factor of deaths from other causes that reduces 
the effective population at risk from ovarian cancer.
(4)  Finally, it is necessary to account for the reduction in deaths due to the 
eligibility criteria, as discussed.
Table  12-1  Power values for tests of control versus screen combined  is for 
the test of the control group  mortality versus the screen groups combined, 
and  has power values  based  on  the  7,  8  and  9 year control deaths totals 
compared  against a  range of potential  mortality reductions from screening 
(15-50%).  If the true mortality reduction is of the order of 30% then a power 
value of 0.888 suggests that 7 seven years might be sufficient.
Table 12-1 Power values for tests of control versus screen combined
Mortality
reduction
7 years total 8 years total 9 years total
C deaths: 193.1 C deaths: 231.8 C deaths: 271.4
S
deaths
Power
S
deaths
Power
S
deaths
Power
15% 164.1 0.334 197 0.388 230.7 0.443
20% 154.5 0.543 185.44 0.62 217.1 0.689
25% 144.8 0.745 173.9 0.818 203.6 0.873
30% 135.2 0.888 162.3 0.936 190 0.964
40% 115.9 0.991 139.1 0.997 162.8 0.999
50% 96.6 1 115.9 1 135.7 1
C=control group; S= Screen groups combined
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In  Table  12-2 the  power values for comparison  between the control group 
and  an  individual  screening  arm  is  presented.  Inevitably  with  a  reduced 
sample  size  (approx.  50,000  compared  to  100,000)  this  means  reduced 
power values.  The  7-year value  for a  30%  reduction  of 0.722  may  not be 
considered high enough and even possibly the 8-year value of 0.795 either. 
Given that this comparison is important to assess whether individually each 
of the arms shows an effect than the arms combined, these results suggest 
that at least 9 years from randomisation maybe appropriate.
Table 12-2: Power values for tests of control versus individual screen
Mortality
reduction
7 years total 8 years total 9 years total
C deaths: 193.1 C deaths: 231.8 C deaths: 271.4
S
deaths
Power S
deaths
Power S
deaths
Power
15% 82.1 0.241 98.5 0.278 115.3 0.317
20% 77.2 0.391 92.7 0.453 108.6 0.511
25% 72.4 0.562 86.9 0.638 101.8 0.704
30% 67.6 0.722 81.1 0.795 95.0 0.852
40% 57.9 0.926 69.5 0.961 81.4 0.980
50% 48.3 0.989 58.0 0.996 67.9 0.999
C=control group; S= Individual screen groups
The plan is to screen women in the study arms for 6 years and then to build 
in the possibility of extending follow up for each woman in the cohort from 7 
to  9  years  from  date  of  randomisation.  Recruitment  was  completed  in 
September 2005  and  in  Oct 2010,  as  initially envisaged  screening  will  be 
complete. Follow up for each woman will continue to the end of 9 years from 
date of randomisation such that the last woman  randomised is censored in 
October 2014. Depending on the mortality reduction achieved in either of the
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screen  arms,  the  study  may  reveal  a  mortality difference from  as early as 
2011.
12.12  Secondary objectives
12.12.1  Performance characteristics of the two screening strategies
Sensitivity, specificity and positive predictive value will be estimated for each 
screen  (Table  3).  The screening  strategy  includes the screening tests,  the 
screening algorithms,  clinical evaluation and culminates in either surgery or 
a  return  to  annual  screening.  The  primary  analysis  of  performance 
characteristics will therefore  be  based  on women who  have surgery  in the 
trial as  a  result of screen  positive findings.  The  outcome  measure for this 
primary analysis will be primary ovarian cancer. Sensitivity will be calculated 
in  the standard  fashion  as the  ratio  of screen  detected  cases to all  cases 
found through  some  interval  usually a year after a screen  as well as from 
date of randomisation.  Performance characteristics for detection of primary 
invasive epithelial ovarian cancer will be calculated separately.
Table 12-3: Performance characteristics of the screening strategies
Surgery in the trial 
following screen 
positive findings
Primary
ovarian
cancer*
Primary  ovarian 
cancer* not 
diagnosed
Performance
characteristics
Yes a b* Sensitivity = a/(a+c) 
Specificity = d/(c+d) 
PPV = a/(a+b)
No c d
"Includes all malignant ovarian neoplasms
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12.12.2  Physical  morbidity  resulting  from  surgical  intervention 
attributable to screening
The safety risk is not associated with the screening procedures themselves 
but with the surgical investigation of abnormal screen results by laparoscopy 
or laparotomy.  All  serious  adverse  reactions  that are  possibly trial  related 
are documented. They are broadly defined as any untoward deviations from 
baseline  health  that  are  possibly  related  to  recruitment,  screening  and 
surgery within UKCTOCS. Suspected serious adverse reactions (SSAR) are 
known complications of the procedures undertaken in the trial and are listed 
in Appendix  1.  An Adverse  Reaction  is a  SUSAR  (Suspected  Unexpected 
Serious  Adverse  Reactions)  if  its  nature  and/or  severity  is  not  consistent 
with  known  complications  of the  surgical  or screening  procedure  or if it  is 
fatal  or  life-threatening.  An  independent  Data  Monitoring  and  Ethics 
Committee (DMEC) examine all SUSARs and complications. The SUSARs 
are  also  reported  annually  to  the  Multicentre  Research  Ethics  Committee 
that monitors the trial.
The excess surgical morbidity and mortality in the trial will be calculated on 
the assumption that all operations for cancer and 25% of operations for false 
positive  results would  ultimately  have  been  required  regardless of the trial. 
Data  obtained  through  the  follow  up  questionnaire  on  the  incidence  of 
gynaecological  surgery  for  benign  indications  in  the  control  arm  will  help 
refine this calculation.
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12.12.3  Feasibility of screening, as reflected by compliance rates 
with annual screening
There  will  inevitably  be  less  than  complete  compliance  with  annual 
screening. The rate of compliance is an important end point of the study as it 
has  implications  for  the  feasibility  of  introducing  a  national  screening 
programme.  In the  initial  randomised  control trial 99.3%  and  96.8%  of the 
volunteers  who  underwent  an  initial  screen  following  randomisation, 
attended  for their 2n d   and  3rd   annual  screens  respectively.8  The  proposed 
trial  will  involve  6  screens  but  it  is  reasonable  to  anticipate  an  overall 
compliance  with  screening  in  excess  of 75%.  Our  estimates  allow  for  an 
annual attrition rate of 4%, which translates to an overall compliance with 6 
annual screens of 78%.
12.12.4  Psychological consequences of screening
The  overall  aim  of the  quality  of  life  study  is  to  assess  the  psychosocial 
factors affecting behavioural and emotional responses to OC screening.  It is 
coordinated  by  the  Psychosocial  Oncology  Group,  Brighton  and  Sussex 
Medical School.
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12.12.5  Resource  implications  of  screening  and  the  resulting 
interventions
The  trial  is  powered  for  primary  clinical  end-points  and  consequently  the 
analysis for the economic end-points  is within these constraints.  Statistical 
analysis  will  however  be  undertaken  on  the  calculated  cost-effectiveness 
ratios that are crucial to the trial. The economic evaluation will include both a 
within  trial  analysis  and  a  modelling  analysis.  The  analysis  will  be 
undertaken by the group at the Department of Social Policy, London School 
of Economics, London.
12.13  Serum bank
Women  have  provided  written  consent to  use  of their serum  samples  for 
ethically  approved  secondary  studies,  the  focus  of  which  is  the  early 
detection  and  treatment  of  disease.  A  baseline  serum  sample  has  been 
stored for all participants and serial samples are being stored in the 50,000 
women in the multimodal group who have annual screening.
12.14  Study organisation
The  study  was  designed  and  is  coordinated  by  the  Department  of 
Gynaecological Oncology, located initially at Queen Mary University London 
and  since  April  2004  at  University  College  London  (UCL).  It  is  conducted 
through  13  regional  trial  centres  (RCs)  in  England,  Wales,  and  Northern
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Ireland  which  are  mainly  located  in  NHS  Trusts  (Figure 4).  UCL  are  legal 
sponsors for the trial.
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Figure 12-4: UKCTOCS Organisation
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12.14.1  Coordinating Centre (CC) Team
The  coordinating  centre  consists  of  a  clinical  trials  unit  located  in  the 
Gynaecological  Cancer  Research  Centre  (GCRC)  and  a  tumour  marker 
laboratory  located  in  the Translational  Research  Laboratory.  The CC team 
at GCRC  is  responsible for implementation  and  day to day  running  of the 
trial. The team is lead by the clinician (trial coordinator) who is author of this 
thesis and  includes a data manager,  a senior research  nurse,  a laboratory 
manager, two postdoctoral  research fellows,  a clinical fellow and a team of 
clerical, secretarial and laboratory staff. The main principles underlying ttrial 
organisation  and  running  are  maximum  centralisation,  immediate 
engagement with problems, lateral thinking, and finding solutions. No aspect 
of the study was considered too trivial for senior input.
All  trial  documentation,  applications  for  ethical  approval,  reports  to 
overseeing  committees  and  organisation  of  trial  meetings  are  the 
responsibility of the  CC  as are data  analyses and  monitoring.  Recruitment 
and  screening  is  centrally  organised  through  the  custom-built  data 
management  system  (DMS)  described  below.  There  is  regular  weekly 
monitoring of all trial activities to ensure adherence to protocol. This includes 
clinical assessment of screen  positives,  trial surgery and  cancer diagnosis. 
This  is  done  by  a  series  of database  checks  (fail-safe  procedures),  close
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liaison  with  the  RC  teams  and  direct  communication  with  the  trial 
participants. Follow up is entirely the responsibility of the CC team.
12.14.2  Regional Centres
At the  RCs,  there  is a  dedicated trial team  consisting of a  research  nurse, 
phlebotomist,  clerk,  and  ultrasonographers  led  by  a  consultant  clinician 
(Lead  Researcher).  Recruitment of the trial participants and performance of 
the  screening  tests  are  the  responsibility  of  the  RC.  The  team  arranges 
clinical  evaluation  of women  confirmed  to  have  abnormalities  on  Level  2 
screens and arranges for referral to the appropriate NHS clinic if surgery is 
appropriate.  Copies  of  all  documentation  are  forward  to  the  CC  for  data 
entry  expect  for  ultrasound  results  which  are  entered  live  over  the  web. 
There  are  regular  meetings  of  all  the  RC  teams  at  the  CC  once  a  year. 
Regular visits of RCs by CC staff are undertaken.
12.14.3  Data Management System (DMS)
The  trial  DMS  is  based  on  an  earlier  prototype  which  was  extensively 
revised  and  further developed  by  the  author working  with  the  commercial 
company Xchanging. It includes a web browser and high security encryption 
which  allows live data entry from the  RCs and the laboratory and  makes it
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possible to  run  the trial  centrally from  the  CC.  All trial  clinics  (recruitment, 
phlebotomy, and ultrasound) at the RCs are set up on the DMS.
The  main  functions of the  DMS  are  invitation  of women whose details are 
uploaded from electronic files provided by participating PCTs; scheduling of 
recruitment  appointments  at  the  appropriate  RCs  when  acceptances  are 
logged on the system; automated checking for a complete dataset following 
scanning  of  recruitment  datasheets;  randomisation  of  eligible  women; 
scheduling  of screening  appointments,  classification  of serum  CA125  and 
ultrasound results, assignment of follow up as per screening algorithms with 
scheduling into appropriate clinics.
Automated letter printing includes invitation letters to join study, appointment 
letters to all trial clinics,  requests for further data when minimum dataset is 
incomplete;  confirmation  of  randomisation  with  notification  of  individual 
general practitioners, screen results and follow-up plan. There are numerous 
failsafe  measures  set  up  such  as  automatic  prompts  for  overdue  screen 
results.
The functionality  incorporates  download  of contact details  to  the  Office  of 
National  Statistics  (ONS)  for flagging;  upload  of cancer  registrations  files 
from  ONS  and weekly downloads of data to Quality of Life Study team  so 
that screening events can  be followed  up. The DMS maintains an  interface
12-130
MD thesis UMUKCTOCS -  TRIAL DESIGN AND ORGANISATION
with  the  laboratory which  makes  possible tracking  of serum  samples from 
RC phlebotomy clinics via processing in the central laboratory to storage in 
the biorepository.  For women  in the multimodal group,  requests for CA125 
assays  of appropriate  samples  are  generated  and  the  results  are  directly 
uploaded from the CA125 analyser.
Using the web browser function, staff at the RCs are able to log acceptance 
of  invitations,  edit  volunteer  contact  details  and  withdraw  volunteers; 
maintain  trial  clinics  (cancel  clinics  over  holidays  and  reschedule 
appointments) and enter data (attendance at clinics, date/time blood sample 
taken, details of ultrasound scan performed).
The security of the DMS is ensured by server & client certificates; username 
/passwords stored  within  SQL  and  on Win2K server domain.  The  DMS  is 
upgraded on a regular basis to accommodate protocol development.
12.14.4  Serum bank
Serum  samples  are  shipped  overnight  in  the  Grienger  gel  tubes  and 
processed  the  next day  in  the central  UKCTOCS  laboratory.  A novel semi 
automated  system  aliquots serum  in  500  micro  litre  straws which  are then 
heat sealed and bar coded and stored in special containers in liquid nitrogen 
tanks. The tanks once filled and shipped off site to a cryonic biorepository.
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Figure 12-5: Novel storage solutions for the UKCTOCS serum bank
12.14.5  Committee Structure
There  are  two  committees  comprised  of  UKCTOCS  researchers  whose 
focus  is  implementation.  Three  mainly  external  committees  oversee 
progress,  monitor  safety,  of  volunteers  and  data,  and  confirm  outcomes 
(Figure 12-4).
Trial Management Committee (TMC)
This  committee  oversees the  implementation  of the  trial.  It consists  of the 
principle  investigators,  trial  coordinators  of  both  the  main  trial  and  the 
Quality of Life study, three RC lead  researchers and the CC data manager, 
statistician and research fellows.  It meets formally twice a year with frequent 
email discussions as issues arise.
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Ultrasound Sub-committee
The  committee  consists  of  UKCTOCS  researchers  with  a  particular 
expertise in ultrasound or its delivery. The main purpose of the committee is 
to  oversee  the  ultrasound  arm  of  the  trial  and  to  monitor  adherence  to 
protocol,  develop  quality  assurance,  advice  on  the  logistics  of  ultrasound 
delivery,  training  of  staff  and  solutions  for  sustaining  a  high  standard  of 
scanning in the trial.
Trial Steering Committee (TSC)
The trial  steering  committee  provides overall  supervision  and  ensures that 
the  trial  is  conducted  to  the  rigorous  standards  set  out  in  the  MRC 
Guidelines for Good Clinical Practice. In its deliberations, the rights and well­
being  of the trial  participants are the  most important consideration.  Its  role 
includes monitoring progress and adherence to protocol. The TSC evaluates 
reports from  DM EC based on efficacy and safety analyses and determines 
what  constitutes  the  minimal  important  difference  for  the  futility  analysis. 
UKCTOCS  TSC  has five  independent members  including the chair.  Three 
observers from the funding bodies attend the meetings.
Data Monitoring and Ethics Committee (DMEC)
The  safety  committee  includes  four  experts  (gynaecological  oncologists, 
epidemiologist and senior scientist)  not directly affiliated with  UKCTOCS.  It 
monitors the  trial  and  reports to  the  TSC.  The  safety  committee's  primary
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responsibility is to safeguard the well-being of patients enrolled in the trial. It 
reviews  all  adverse  reactions/complications  and  complaints.  It  monitors 
performance of RCs, recruitment, compliance with screening, logistic issues 
with delivery of the screening,  performance characteristics of the screening 
strategies  and  supports/makes  recommendations  for  protocol  changes 
including  recommendations  for  early  dissemination  of  results.  The  trial 
coordinator  and  lead  statistician  report  to  DMEC  which  reviews  the  trial 
every 6-12 months.
Outcomes Committee
The  committee  consists  of  a  independent  gynaecological  oncology 
pathologist,  gynaecological  oncologist  and  an  epidemiologist.  The  main 
purpose of the committee  is to review each ovarian cancer case in the trial 
to confirm the diagnosis and/or death is due to ovarian cancer.
12.15  Discussion
The UKCTOCS trial  represents a major commitment of resources from the 
Medical Research Council and the Department of Health, UK. The design is 
a three arm  randomised controlled trial that allows for direct comparison of 
the control group with  the two screening  groups combined  as well  as with 
each  of the screening groups alone.  The sample size has been  chosen to 
ensure a valid scientific assessment of impact of the screening strategies on
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ovarian cancer mortality while comprehensively addressing the questions of 
performance  characteristics  of  the  strategies,  cost,  physical  and 
psychological morbidity and compliance.
An  RCT of OCS  is  also  underway  as  part of the  PLCO  trial158.  The  main 
differences are that  in  the  latter only the  primary screen  (combined  serum 
CA125  and  ultrasound)  is  under  the  purview  of  the  trial.  Women  with 
abnormalities  detected  are  then  referred  to  their  personal  physicians.  In 
UKCTOCS,  there  is  a  well-defined  screening  strategy  which  includes 
screening  algorithms  with  first  and  second  lines  tests,  clinical  evaluation 
within the trial for women  requiring  assessment and finally surgery.  This  is 
similar to the NHS cervical screening programme in the UK. 78,237 women 
aged  55-74  were  recruited  into  PLCO  with  28,816  undergoing  prevalence 
screen.  133  Overall  each  woman  will  have  6  screens  and  follow  up for  13 
years.  In  UKCTOCS,  100,000  women  will  undergo  6  annual  screens  and 
follow up will be for 7-9 years from randomisation so that there is no dilution 
of the screening effect.
The  results  of  UKCTOCS  will  provide  essential  information  about  the 
benefits and adverse effects of OC screening.  If the study does not reveal a 
reduction  in  OC  mortality  attributable  to  screening,  then  it will  provide  an 
evidence  base for discouraging  the  introduction  of population  screening.  If 
the study reveals a mortality benefit from screening an informed debate will
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be possible about the wisdom or otherwise of introducing an OC screening 
programme in clinical practice and about the optimal screening strategy. The 
debate will  need  to consider the size  of the  mortality  benefit,  physical and 
psychological  morbidity,  compliance,  cost,  and  logistic  issues  related  to 
delivery of the screening strategies. Without evidence from a well-designed 
trial such a debate will not be possible.
The  trial  provides  a  great  resource  as  the  serum  bank  amassed  for  the 
duration  of  the  trial  may  prove  invaluable  for  discovery  of  novel  tumour 
markers for pre-clinical detection of ovarian cancer.
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13  UKCTOCS - RECRUITMENT OF 200,000 WOMEN
13.1  Introduction
Randomised  controlled  trials  (RCTs)  are  widely  accepted  as  the  gold 
standard  for  evaluating  healthcare  interventions.  However,  less  than  one 
third  (31%)  of  UK  Medical  Research  Council  (MRC)  and  NHS  Health 
Technology  Assessment  (HTA)  Programme  funded  multicentre  RCTs 
recruiting  between  1994  and  2002  achieved  their  original  recruitment 
target.1 6 7  This  has significant implications in  lost opportunity costs for trials 
that fail to complete and cost, inconvenience and loss of statistical power for 
completed trials168. In this respect,  UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS, www.ukctocs.org) is a success story.  Funded jointly 
by  MRC,  NHS  R&D  and  Cancer  Research  UK  (CR-UK),  it  completed 
recruitment in  September 2005 to  become the world’s  largest  randomised 
control  trial.  This  chapter  describes  the  challenges  of  recruiting  200,000 
women together with the innovative solutions that made it possible.
13.2  Methods
As  described  in  the  previous  chapter,  the  design  of  UKCTOCS  involves 
recruitment of 200,000 women  randomised to annual screening with serum 
CA  125  (50,000);  transvaginal  ultrasound  (50,000)  or  no  intervention 
(100,000). Screening is for 6 years and all women are followed up by postal 
questionnaire and through flagging via the Office of National Statistics.
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13.2.1  Ethics
Ethical  approval  was  obtained  from  the  Multicentre  Research  Ethics 
Committees (North West) and site specific approval from the Local Regional 
Ethics Committees for each of the participating Regional Centres (RCs) and 
their associated  Primary  Care  Trusts  (PCTs).  Approval  was  also  obtained 
from  the  Caldicott  Guardians  of  each  of  the  participating  PCTs.  Written 
consent was obtained from all women who were recruited.
13.2.2  Coordinating Centre (CC)
Invitation,  recruitment  and  randomisation  was  centrally  organised  through 
the data management system (DMS). The CC team ensured that adequate 
numbers of women were invited in a timely manner such that appointments 
at the  recruitment clinics at the  RCs were booked.  Recruitment rates were 
closely monitored and close liaison was maintained with the RC teams.
13.2.3  Regional centres (RCs)
12  regional centres were set up with a target recruitment of 16,667 women 
over the  course  of  3  years.  The  number of centres  was  decided  on  cost 
efficiency  and  optimal  logistic feasibility.  Key factors determining  the  latter 
were  the number of women who could be recruited in a week by a full time 
research  nurse;  the  maximum  number  of  ultrasound  scans  that  could  be 
performed  in  a  year  by  a  full  time  ultrasonographer  using  one  ultrasound
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machine; the number of screen abnormalities and surgical referrals a centre 
could  manage without significant impact on the  routine NHS work;  and the 
space requirements for running such a trial. All RCs identified a designated 
trial area which  included a waiting  room and separate rooms for interviews 
and phlebotomy.
13.2.4  Database management system (DMS)
The customised database management system (DMS) has been described 
in  the  pervious  chapter.  Key  features  supporting  recruitment  and 
randomisation  are  automated  processes  for  invitation,  scheduling  of 
appointments to  recruitment clinics  at  RCs,  checking  of eligibility following 
scanning  of  the  recruitment  datasheets  into  the  system,  randomisation, 
generation  of  requests  when  data  incomplete  and  printing  of  letters  to 
participants  and  their  GPs.  A  web  browser  and  high  security  encryption 
enables all trial staff whether located at the CC,  RC or the central laboratory 
to enter and see live data at all times. This feature supports rescheduling of 
appointments whether women ring the CC or the RC.
In  addition,  specialised  software was commissioned  from the  NHS so that 
women aged between 50 and 74 years could be randomly chosen from the 
age/sex registers held  by their PCT and their contact details,  date of birth, 
NHS  number,  and  GP details could  then  be downloaded  to the  CC  as an 
electronic file.  The software ensured that the women were then flagged  on
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the  PCT  register  such  that  their  details  were  not  included  in  future 
downloads.
13.2.5  Invitation
Electronic  files  with  details  of  all  General  Practitioners  (GPs)  working  in 
participating  PCTs  were  uploaded  into  the trial  DMS.  A  letter was  sent to 
each of them with information about the study.
Electronic files containing details of 2,000 -  10,000 women were requested 
on  a  regular basis from  each  of the  participating  PCTs  by the  CC.  These 
files  were  uploaded  into  the  trial  DMS.  Women  were  then  sent  personal 
invitations  to  join  the  study  along  with  a  brochure  outlining  the  trial 
objectives,  design  and  inclusion/ exclusion  criteria.  Women  were  asked  to 
return the tear away slip (Figure  13-1) using the freepost address provided. 
The  slip  had  each  individual’s  study  number  and  details  pre-printed.  This 
maximised  efficiency  and  minimised  errors when  the  returned  information 
was logged on to the DMS by RC staff via the web browser.
13.2.6  Recruitment
The recruitment clinic profile was set up on the DMS for all RCs. The DMS 
every  night automatically  scheduled  recruitment clinic appointments at the 
appropriate  centre  for  women  who  accepted  invitations.  Recruitment 
appointment letters were printed and sent to the women along with a
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WE  WOULD  BE  VERY  GRATEFUL  IF  YOU  WOULD  RETURN 
THIS SLIP
Ref: {Volunteer Reference No}
I {volunteer name} of {volunteer address}
1 .1  would like to take part in the UKCTOCS study.  □
2 .1  cannot take part because
More than one person in my family has ovarian cancer □
I am currently being treated for cancer  □
I had ovarian cancer □
I had both my ovaries removed  □
I am still having periods  □
I am taking part in another ovarian cancer screening trial  □
3 .1  do not wish to participate in this study □
Signed..............................
Date..................................
Figure 13-1: Reply slip returned by women
detailed  trial  information  sheet from  the  CC.  Appointments  were  made  6 
weeks  in  advance  to  allow  adequate  time  for  rescheduling.  Women  were 
able to ring either the RC or the CC to change appointments.
At the  recruitment appointment, women  completed  a one page  recruitment 
questionnaire,  which  included  information  regarding  eligibility.  Those  who 
were  willing  to  participate  in  the  psychosocial  study  were  given  a  set  of 
baseline  quality  of  life  questionnaires  to  complete  and  return  to  the 
researchers  in  a  pre-paid  envelope.  Written  consent  included  separate 
consents for the main trial and the psychosocial study and a data protection 
form.  All volunteers  provided  a  baseline serum  sample that was sent over 
night  to  the  central  laboratory  at  the  CC  for  storage  (Figure  13-2). 
Attendance at the recruitment clinic was  recorded on the DMS in  real time 
over the web browser.
13-141
MD thesis UMUKCTOCS -RECRUITMENT AND RANDOMISATION
Health Authority (HA) download
Personal information of women aged 50-74 from 27 PCTs 
from England, Wales and Northern Ireland
Invitation
Letter of invitation and Freepost address provided for returning the reply
Eligibility confirmed
Women contacted 
for clarification
Randomisation
Computer software
Incomplete datasheet or 
ineligible
Consent logged and Recruitment datasheet scanned into DMS
Control group
No screening
Multimodal group
Screening with CA125
Ultrasound group
Screening with TVS
Invitation to recruitment
All replies data based on to DMS including ‘No’ and ‘Ineligible’ 
Those who wished to participate and were eligible sent an appointment to 
attend a recruitment clinic at their local RC
Completion of recruitment datasheet
(data captured on height, weight, origin, past history of cancer, 
family history of ovarian and breast cancer, age at menarche, 
last menstrual period date, hysterectomy, sterilisation)
5 minute interview with research nurse 
when baseline datasheet checked and consent taken
7 minutes information video 
Group discussion lead by research nurse
Blood taken
(transported overnight to laboratory at CC)
Recruitment visit
Figure 13-2: UKCTOCS Recruitment flow chart
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13.2.7  Randomisation
The completed questionnaire and copies of the consent were sent in weekly 
batches to the CC. At the coordinating centre, the recruitment questionnaire 
was  scanned  electronically  using  computerised  intelligent  character  and 
optical mark reading software (TeleForm) allowing  rapid  and  accurate data 
entry. Any inconsistency or information that was not recognised by the data 
capture software was verified manually by trained data entry staff, who also 
validated  computer-interpreted  data  and  checked  each  questionnaire  to 
confirm whether signed consent for follow up has been granted.
The  DMS  checked  if  the  eligibility  data  was  complete.  When  data  was 
incomplete,  women  were  placed  ‘on  hold’  and  letters  sent  to  the  women 
requesting further information. If the Volunteer was placed ‘on hold’ because 
12  months  had  not  lapsed  from  her  last  menstrual  period  or start date  of 
hormone  replacement  therapy,  she  was  informed  and  included  in  the 
randomisation  process  when  12  months  have  elapsed  from  the  relevant 
date.  The  DMS  generated  lists  of  women  who  had  a  family  history 
suggestive  of  ‘increased  risk  of  ovarian  cancer1 .  Such  women  were 
individually contacted  and eligibility confirmed.  If they fulfilled  criteria which 
put them  at  ‘increased  risk’  for familial  cancer,  their GP  was  sent a  letter 
requesting that the individual be referred to the Clinical Genetics department 
for risk assessment.
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Once  the  DMS  confirmed  eligibility,  participants  were  randomised  to  the 
control  group,  multimodal  (CA125)  group,  or  ultrasound  group. 
Randomisation was carried out as follows:
1. The DMS allocated a  set of 32 random numbers to each RC
2. The lowest 8 were allocated to the M-group, the next 8 to the U-group and 
the remaining 16 to the C-group.
3. Each successive Volunteer within the RC was randomly allocated one of 
the random numbers and hence randomised into a group
4. When all 32 random  numbers had been used up a further set of 32 were 
generated.
The  actual  randomisation  was  accomplished  by  using  the  Visual  Basic 
Randomisation statement and the Rnd function. Once the woman had been 
randomised,  the  date  of  randomisation  was  stored  on  the  database.  The 
system  then  automatically  printed  letters  to  the  woman  and  her  GP 
confirming eligibility and randomisation status.
13.2.8  Complaints
All  complaints  were  lodged  and  monitored  centrally.  A  designated  CC 
person wrote to each woman directly after investigating the issues raised. All 
suggestions by the women were explored and trial logistics amended when 
appropriate and possible.
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13.3  Results
Prior  to  the  start  of  the  trial,  12  Gynaecological  Oncology  departments 
expressed  interest  in  participating.  However,  in  the  set  up  phase,  the 
Scottish  centres  and  two  of  the  English  centres  were  unable  to  secure 
support from  their respective Trust management boards.  Key  issues were 
space and retirement of the local principle investigator. Various possibilities 
were explored  and  after much  negotiation,  new trial centres were finalised 
at Cardiff,  North  Wales,  Manchester,  and  Derby  (Figure  13-3).  In  2003,  a 
13th  centre  became possible through  a combination  of circumstances:  the 
determination  of  the  investigators  to  build  a  safety  net,  the  particular 
centre’s  expertise  in  OC  screening  acquired  through  participation  in  a 
previous trial and Cancer Research  UK’s willingness to support one further 
centre with  additional funds.  No  overall  recruitment target was set for this 
centre.  Instead,  it was agreed that this centre should  have the same target 
monthly recruitment rate as the other centres.
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Regional Centre Start date End date
Gateshead 18-Apr-01 28-Sep-05
Bart's, London 17-Jun-01 14-Sep-05
Nottingham 16-Jul-01 07-Jul-05
Liverpool 23-Jul-01 29-Sep-05
Portsmouth 11-Sep-01 31-Aug-05
Royal  Free, 
London
22-Oct-01 08-Sep-05
Bristol 24-Oct-01 29-Sep-05
Belfast 11-Mar-02 29-Sep-05
Cardiff 22-Apr-02 08-Sep-05
North Wales 27-May-02 29-Sep-05
Manchester 10-Jun-02 28-Sep-05
Derby 16-Sep-02 29-Sep-05
Middlesbrough 10-Feb-03 29-Sep-05
UKCTOCS -1 3  Trial Centres, 27 Primary Care
Trusts
Belfast City Hospital 
Belfast
Liverpool Women’s Hospital 
Liverpool
Llandudno General Hospital 
North Wales
University of Wales College of 
Medicine Cardiff
St Michael's Hospital, 
Bristol
St Mary’s Hospital 
Portsmouth
Queen Elizabeth Hospital 
Gateshead
James Cook University 
Hospital, Middlesbrough
St Mary’s Hospital 
Manchester
Derby City Hospital 
Derby
Nottingham City Hospital, 
Nottingham
Barts, London 
Royal Free, London
Figure 13-3: Location of UKCTOCS trial centres and start and end dates of recruitment
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Caldicott Guardians for 5 PCTs refused access to contact details of women 
on their age/sex register.  On exploring their concerns,  it became clear they 
were willing to allow access but would not give permission for electronic files 
with contact details of the women to be sent to the CC. A compromise was 
negotiated  whereby  study  invitations  and  brochures  were  sent  in  sealed 
franked  envelopes  to  the  PCT.  PCT  staff then  stuck  address  labels  and 
forwarded  the  mail  to  the  women.  The  women  wrote  to  the  CC  with  their 
contact  details  if they  wished  to  participate.  As  it was  essential  to  obtain 
NHS numbers and most women did  not know the correct number, the PCT 
agreed to print this on a corner of the address label. Women were asked to 
copy this on to their reply slip.  The  DMS  programme was altered  to allow 
manually entry of data and CC staffing reorganised.
The  RCs  were  set  up  in  a  staggered  fashion  (Figure  13-3).  In  order  to 
maximise efficiency, women were invited to participate at a centre 3 months 
prior to the start date of recruitment.  Invitations were sent such that at the 
minimum  about  1500  women  were  awaiting  recruitment  when  a  centre 
began.  In order to maximise efficiency,  RC trial staff started their posts two 
weeks prior to start of recruitment.  Training  both  at the CC  and  at the  RC 
was organised during this period and all trial documentation was delivered. 
The senior nurse from the  CC  participated  in  the first recruitment clinic at 
each centre.
There was national media coverage when the trial was launched. In addition 
as  each  RC  came  on  line  and  women  in  the  surrounding  areas  received
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invitations to the trial, press releases, interviews on local radio and articles in 
local newspapers were organised. This was cost free. The impact of OC on 
women’s lives, the benefits of the study, the major components of the study, 
the  main  inclusion  criteria  were  emphasised.  A  website  www.ukctocs.org 
was  set  up  where  both  public  and  health  personnel  could  obtain  detailed 
information about the trial.
The target of 16,667 women in 3 years meant a weekly target of 120 women 
per week (based  on  44 working weeks  in  a  year).  The  RCs would  need  a 
minimum of 5 recruitment clinics a week, with 24 women  recruited  in each. 
In  order to  make  this  feasible  and  sustainable  and  to  ensure  that women 
were well  informed  about all aspects of the trial,  it was decided to make  a 
ten  minute  information  video  about the  trial.  It showed  a  group  of women 
(CC  staff and volunteers) attending for trial  recruitment with  one of the CC 
staff explaining the key aspects of the trial and taking questions.  The video 
was made by an experienced  BBC producer.  Funding for making the video 
and for providing video players and TVs to each  RC  had to  be found from 
sources outside the grant.
At  recruitment  clinics,  appointment  slots  were  set  up  such  that  6  women 
attended together for a 45 minute appointment. After viewing the trial video, 
the research nurse led a group discussion.  She then spent 5 minutes alone 
with  each  woman.  A  clerk  assisted  her  by  documenting  attendance  ‘live’ 
over  the  web  browser  and  assisting  the  women  in  completing  their 
recruitment  data  sheet.  To  facilitate  recruitment,  the  data  sheets for each
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clinic were  pre-printed  at the CC with the volunteer’s details and  delivered 
two weeks ahead of the clinic along with barcoded labels.
There was close monitoring of acceptance rates and it was clear within the 
first  6  months  that  these  were  below  the  estimated  66%.  Measures  to 
improve acceptance  rates were explored  including simplifying the invitation 
letter and instituting local publicity.  It was soon clear that instead of 300000, 
it would  be  necessary  to  invite  about  1.2  million  women.  Early  in  the  trial 
measures were  instituted  to  ensure  savings were  made  that would  defray 
some of these costs.  The  MRC  board was  appraised well  in  advance and 
towards the end of recruitment awarded an extension and a supplementary 
grant.
Overall invitations were sent to 1,243,312 women,  1,079,515 directly by the 
CC and  163,797 by the PCTs covered by the RCs at Liverpool,  Belfast and 
for  a  few  months  Gateshead.  The  acceptance  rate  varied  between  from 
19% in East London (Barts) to 32% at Portsmouth. Overall 290,947 (26% of 
women excluding those who replied they were ineligible) replied they would 
like to participate in the RCT (Table 13-1). These women were sent detailed 
information about the trial and a recruitment appointment. 74743 withdrew or 
did not attend the appointment (Table 13-1).
There was weekly monitoring of recruitment figures. It became apparent that 
the  number  of women  who  failed  to  attend  appointments  varied  between 
centres.  To  maintain  recruitment,  the  number of women  booked  into  a 45
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minute  appointment slot was  increased  at each  centre  to  compensate  for 
this so that an average of 100 women attended recruitment each week. The 
median time from  recruitment to randomisation of a woman was  12.3 days 
(25th  centile  8.5  days;  75th  centile  15.5  days).  The  median  number  of 
women  randomised  per  month  was  4018  (mean  3861)  (Figure  4).  There 
were  dips  in  numbers  randomised  in  August  and  January  each  year 
following the holidays. The breakdown of randomisation by RCs is shown in 
Table 13-2 .
In 2001, the MRC published the  Human Tissue and  Biological Samples for 
use in  Research - Operational and  Ethical guidelines.  In response to this,  it 
was felt that more  information should  be provided to women about storage 
of excess serum samples for future studies and that the new MRC consent 
form should be adopted. Following ethical approval trial documentation was 
changed and the 50,000 women who had already been recruited were sent 
the  additional  information  with  the  option  to  withdraw.  None  took  up  the 
option to withdraw. A ticker tape was added to the video which emphasised 
that excess serum would be stored for future ethically approved secondary 
studies.
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Table 13-1: Acceptances rates
Regional Centre Invited
All acceptances 
including those 
known to be 
ineligible
Acceptance rate 
including known 
ineligibles
Ineligible at 
invitation*
Acceptance rate 
excluding women 
known to be 
ineligible**
Gateshead 109054 33651 30.86% 8874 24.73%
Gateshead (PCT invited) *** 13000 1324 10.18%
Bart’s 166988 39949 23.92% 10269 18.94%
Liverpool*** 63987 14855 23.22%
Nottingham 77013 28924 37.56% 6999 33.62%
Manchester 133609 35109 26.28% 8938 20.99%
Derby 65445 24895 38.04% 5093 35.27%
Royal Free 133868 31171 23.28% 6415 21.03%
Portsmouth 95144 36490 38.35% 8738 32.12%
Bristol 74970 28613 38.17% 5703 33.07%
Belfast*** 86810 16975 19.55%
Cardiff 96610 32710 33.86% 8753 27.27%
North Wales 73993 26666 36.04% 5134 31.27%
Middleborough 52823 16905 32.00% 3274 27.51%
Overall total 1243312 368237 25.34%
Total/  Average  excluding 
Belfast and Liverpool
1079515 335083 31.04% 78190 25.66%
*T
* *
lis data is not complete as only an unknown proportion of ineligible women reply. 
Ineligible women not included in numerator or denominator 
Due to the manner invitations are sent, only eligible women reply
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Table 13-2: Recruitment and randomisation per year at each UKCTOCS regional centre
Regional
Centre
No of 
PCTs
No of GP 
practices
Number of women randomised %
of target
No of years 
of active 
recruitment 2001 2002 2003 2004 2005 Total
Gateshead 3 252 2243 6119 4551 1850 2558 17321 103.92% 3.9
Bart’s 3 454 1639 6808 4671 4575 2081 19774 118.64% 4.2
Liverpool 3 191 1107 4102 2060 23* 2800 10092 60.55% 2.5
Nottingham 1 195 1641 5084 4877 3721 1455 16778 100.67% 3.9
Manchester 5 385 1 2666 5792 4995 3068 16522 99.13% 4.0
Derby 1 139 3 1513 5015 4472 3626 14929 89.57% 3.0
Royal Free 3 502 474 3777 4370 3981 4289 16891 101.34% 3.9
Portsmouth 2 291 945 4662 5392 4942 3246 19187 115.12% 3.5
Bristol 1 178 428 4132 4171 3777 4020 16528 99.17% 3.4
Belfast 2 148 3309 3302 3837 3137 13585 81.51% 3.3
Cardiff 1 198 2 2879 4831 4671 4368 16751 100.50% 3.2
North Wales 1 167 1919 4340 4201 3892 14352 86.11% 3.0
Middlesbrough 1 86 3 3 4138 3785 1999 9928 None set 2.6
Total 27 3186 8486 46973 57510 48830 40839 202638 101.32% 45.4
‘Recruitment was suspended due to staffing issues
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Figure 13-4: Number of women randomised per month into UKCTOCS
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33154
256893
ACCEPTED
290,047
\ ’
RANDOMISATION
202,638
No reply 
(647017)
Withdrew from 
study (74743)
Decided 
not to join 
study 
(97415)
Ineligible at 
invitation 
(78190)
Not recruited as target 
reached (10189)
Control
Group
(101359)
Multimodal
Group
(50640)
Ultrasound
Group
(50639)
ATTENDED RECRUITMENT 
205208
Contact details of 1,084,656 women received 
as electronic file from PCT and loaded onto
Invitation sent directly to 1,079,515 
5141 women not sent invitations
163,797 letters mailed by 
PCTs for Liverpool and 
Belfast and initially for 
Gateshead
Datasheet incomplete (450) 
Consent form not properly 
signed (298)
Withdrew from study (360)
Not eligible (1369)
Note that final status of women  is in  red and adding all numbers in  red will 
equal number of women invited
Figure 13-5: Status of all women at the end of recruitment
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Between  17th April 2001  and 29th  September 2005,  205208 women  (71% 
of those who initially accepted the invitation) attended for recruitment (Figure 
13-5).  The  median  time  in  days  from  recruitment  to  randomisation  was 
12.31  (25th, 75th  quartiles 4.56 and 11.9) days. Confirmation of eligibility and 
randomisation was completed on 21st October 2005. 202,638 women were 
finally randomised.  10,184 women who accepted the invitation could not be 
recruited due to target recruitment being achieved (Figure 13-5).
During  2001  and  2005  when  recruitment  was  underway,  265  written 
complaints were  received.  Of these,  98 were  related  to  recruitment issues 
(Table  13-3).  Useful  suggestions  made  such  as  incorporating  a  clear 
statement on the appointment letter that the visit would take a minimum of 
an hour, the need for better sign posting etc were immediately implemented.
Subject of complaint 2001 2002 2003 2004 2005 Total
Invitation to trial 0 6 13 8 5 32
Trial Information 1 7 11 6 3 28
Recruitment visit 1 4 4 5 3 17
Randomisation to control 
group 0 3 10 6 2 21
Total 2 20 38 25 13 98
able  13-3  Summary  of  complaints  related o  inviltation
recruitment
192624 serum samples were obtained  at recruitment and stored for use  in 
future studies.
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13.4  Discussion
A total of 205,208 women attended for recruitment at 13 centres in the  UK 
between  April  2001  and  September  2005.  202,638  were  randomised, 
making  UKCTOCS the  largest ever RCT  undertaken.  Next in  size  are  the 
UK Single Flexible Sigmoidoscopy screening trial (FLEXISIG) with  170,432 
men  and women169 and the Women’s  Health  Initiative  prevention trial with 
161,808  postmenopausal  women170.  The  only  trial  to  report  on  larger 
numbers of participants is the UK Trial of Early Detection of Breast Cancer 
(TEDBC) set up in  1979 which  involved 236,103 women.  However TEDBC 
was  a  non-randomised  study  with  108,980  women  recruited  to  the  study 
arm and a comparison group of 127,487.1 7 1
UKCTOCS  is the  largest OC  screening  trial.  Given  the  size  and  the  RCT 
design,  it should answer definitively whether screening will have a mortality 
impact.  The  largest  OCS  trial  reported  so  far  involved  51,500  Japanese 
women  who  underwent a transvaginal  scan  during  annual  cervical  cancer 
screening. The authors noted that the percentage of Stage I ovarian cancer 
cases  treated  in  the  department  increased  after  introduction  of screening 
from 29.7% to 58.8% 10 The lack of a control group, the wide age  range of 
participants, the low numbers of OC detected and the lack of data on screen 
negative cancers  made  it impossible to draw any definitive conclusions.  In 
an earlier RCT of OCS involving 22,000 volunteers, women with OC  in the 
screened arm were noted to have a survival benefit8. The size and design of 
UKCTOCS  should  also  make  it  possible  to  address  comprehensively
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performance  characteristics  of  the  screening  strategies,  physical  and 
psychological morbidity, cost, acceptability and compliance.
The  OCS  component of the general  population  Prostate,  Lung,  Colorectal 
and  Ovarian  (PLCO)  Cancer  Screening  Trial  in  the  US  will  probably  be 
larger  then  the  Japanese  cohort.  The  number  of  women  eligible  for  the 
ovarian  arm  of this  trial  is  not yet clear.  Between  autumn  1993  and  June 
2001  (8.3 years) 78,237 women aged 55-74 were recruited via 10 centres. A 
proportion are not eligible for the OC screening arm as they had previously 
undergone bilateral oophorectomy172. The OC prevalence screen in the trial 
involved  28,816  women133.  There  has  been  discussion  with  the  PLCO 
investigators  and  in  principle  a  meta-analysis  of  the  two  trials  has  been 
agreed.  No other trials are underway in the general population.  In the high- 
risk  population  however,  several  smaller  single  arm  trials  are  underway. 
These  will  not  address  the  core  issue  of  impact  of  OCS  on  disease 
mortality.173
The  plan  was  to  set  up  12  regional  trial  centres  (RC)  in  the  UK  in  a 
staggered  fashion  over  the  course  of  12  months.  It  has  been  suggested 
based on anecdotal data that staggering recruitment may help to prevent fall 
in  recruitment  with  time.168  11  centres  commenced  recruitment  within  14 
months of start of recruitment with the 12th  starting recruitment at 17 months. 
The key reason for the 5 month delay was that 4 of the pre-identified 12 RCs 
dropped out. As a result, negotiations and approvals had to recommence to 
set up four new RCs. A recent review of UK multicentre trials reported that in
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20%  of trials,  a  proportion  of pre-identified  centres did  not participate  and 
45% of trials had to recruit new centres.167  It is important in the planning of 
multicentre trials, that the list of pre-identified centres outnumbers that finally 
required  especially  if  centres  have  to  make  significant  long  term 
infrastructure commitments. The review found no common reason for the fall 
out.  In UKCTOCS, the main issue were inability of hospital management to 
commit  to  space  requirements  for  the  10-year  lifespan  of  the  trial  and 
retirement of key clinicians. Space to run clinical trials is increasingly difficult 
to find  in the current NHS and will  be even  more so as Trusts use  Private 
Funding  Initiatives  to  modernise  their  hospitals.  It  is  vital  that trialists  and 
funding  agencies  such  as  the  MRC  and  Cancer  Research  UK  (CR  UK) 
highlight  this  issue.  Support  from  the  Department  of  Health  and  the  UK 
Clinical  Research  Network  for  dedicated  clinical  research  facilities  in 
teaching  and  large district hospitals  is  essential  if multicentre  clinical trials 
are to continue. In this context, the Welcome Trust Clinical Research Facility 
in  Manchester  (one  of  five  such  facilities  in  the  UK)  which  hosts  the 
UKCTOCS Manchester provides a valuable model of a joint NHS/academic 
environment,  staffed  and  equipped  to  promote  high  quality  studies 
(www.crf.man.ac.uk).
The  negotiations and effort involved  in setting  up an additional  13th centre 
paid  dividends  when  one  of the  initial  12  centres  was  forced  to  suspend 
recruitment for over a year due to staffing issues (Table 2). Grant funding for 
clinical trials  in  the  UK leave  little  leeway for such  problems which  though 
unpredictable,  have  been  reported  frequently.168  Investigators  should
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prepare  and  budget  contingency  plans  in  case  of poor  recruitment at the 
start  of  trials  which  funding  agencies  and  sponsors  should  be  willing  to 
release with if recruitment falters.
Trial  centres  need  to  be  chosen  such  that  they  are  able  to  recruit  a 
representative  group  of women.  Equally  important they  need  to  have  the 
skills  required  for delivery of the  intervention  and/or treatment.  Centres for 
UKCTOCS  were  chosen  so  that  gynaecological  oncology  expertise  in 
managing ovarian cancer was coupled with geographical location of centres 
so that they covered a representative sample of the UK female population. 
Centres were  planned for England,  Scotland,  Wales,  and  Northern  Ireland 
but  pre-identified  Scottish  centres  dropped  out  mainly  due  to  logistical 
issues.  Participation  was  not  restricted  to  academic  centres.  This  is 
supported by the work of Prescott RJ et al on cancer trials networks.168
Women  aged  50-74  were  randomly  chosen  women  from  the  age/sex 
registers of participating PCTs and sent personal invitations. The alternative 
option would have been to advertise the trial extensively and let women self 
refer.  This  is the  strategy  adopted  by  most  OCS  screening  trials  such  as 
PLCO  trial158,  Bart’s  OCS  trials8  5 1   57,  University  of  Kentucky  Screening 
Trial9.  Women  who  volunteer  to  participate  in  research  are  often  more 
educated and  informed174-176.  It was felt that trial participants may be more 
representative  of the general  population  if all  potentially eligible women  in 
the  target  area  were  invited.  Logistically  this  approach  had  numerous 
advantages:  better control of recruitment rates and  logistics by varying the
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rate of invitation; decreased data entry as electronic files from the PCT were 
directly  uploaded  into  the  DMS;  vastly  improved  accuracy  with  regard  to 
each woman’s NHS number and to a lesser extent contact details of her GP. 
Our experience from previous trials8 57 166 is that most women do not know 
their NHS number.  It is however essential in the UK for flagging women via 
the Office of National Statistics for follow up.  The cost of the flagging study 
is directly correlated to availability of the  NHS  number  of  the  individual. 
Finally this mode of invitation allows data to be gathered on the  number of 
women  invited,  the  variation  in  acceptance  rate  between  regions  and  the 
age  and  deprivation  status  (based  on  postcode)  of  women  who  do  not 
participate.
There was national media coverage when the trial was  launched  and  local 
press releases when each RC started recruitment. This was cost free. Mass 
broadcast  (television  and  radio)  and  print  media  (regional,  city,  and 
neighbourhood newspapers and flyers) are ‘low effort, high yield’ recruitment 
strategies177 used by most trialists178. However, in UKCTOCS a balance had 
to be struck between too much  and too  little  publicity as women could  not 
self  refer  and  could  only  enrol  if  they  received  an  invitation.  Hence  no 
posters and flyers were put up in GP surgeries, well women clinics etc.  It is 
possible  that such  additional  measures  might  have  increased  acceptance 
rates.
In  UKCTOCS,  permission  was  requested  from  Caldicott  Guardians  (data 
controllers  for  PCTs)  for  an  electronic  file  with  contact  details  of women
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aged  50-74  on  the  age  /sex  register  so  that  the  CC  could  send  a 
personalised invitation. There was disagreement among the data controllers 
on  interpretation  of  the  Data  Protection  Act  1998 
(www.informationcommissioner.gov.uk).  There  is  a  research  exemption  in 
this  act  which  allows  processing  of  personal  data  if  it  is  necessary  for 
medical research and undertaken by a health professional. The majority (22) 
of  Caldicott  Guardians  felt  that  the  trial  request  fulfilled  this  criterion. 
However, Caldicott Guardians for 5 PCTs refused permission. The requests 
relate  to  2000/2001.  Since  then  there  has  been  increasing  guidance 
provided by the Department of Health (DoH) on the conduct of clinical trials. 
It is essential that clear guidance about the 1998 Act as it relates to research 
is circulated to data controllers by the DoH and there is a forum for appeals 
and  discussions.  32  women  of  the  1.2  million  invited  complained  about 
being sent an invitation. The low complaint rate suggests that British women 
are supportive of use of their personal data for invitation to trials.
Barbara Farrell lists lateral thinking and a practical business like approach to 
getting the job as essential to managing trials successful.179 For the 5 PCTs, 
an  alternative  plan  was  drawn  up  and  the  DMS  modified.  Trial  invitations 
were  sent  in  sealed  franked  envelopes  to  these  PCTs  whose  staff  then 
stuck address labels and posted them. Women  replied to the CC with their 
contact details if they wished to participate. Acceptance rates at these PCTs 
(Liverpool and  Belfast) were similar to those for PCTs serving  Manchester 
and  Gateshead  (Table  1).  This  suggests  that  the  lack  of  a  personalised 
invitation does not impact on acceptance rate. The main disadvantage was
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that mailing the invitations was dependent on the work priorities of the PCT 
staff  and  often  there  were  significant  delays  which  led  to  underutilised 
recruitment  clinics.  In  addition  the  handwritten  acceptance  sheets  with 
personal  details  required  data  entry  and  all  of  this  resulted  in  additional 
consumable and staff costs.  In these centres,  it is not possible to estimate 
the number of ineligible women in the invited population.
In  UKCTOCS,  individual  GP  practices  were  not  sent  patient  lists  so  that 
women  already  diagnosed  with  ovarian  cancer  or  suffering  from  terminal 
illnesses  could  be  excluded  from  invitation.  One  of the  reasons  sited  for 
requesting GPs to ‘clean up’ lists is concern that trial invitations may cause 
distress  to  women  already  diagnosed  with  ovarian  cancer.  However,  the 
prior experience of the researchers and advice from patient groups such as 
OVACOME  was  that  the  majority  of  women  with  ovarian  cancer  were 
supportive of the research efforts. This was borne out in that only 4 women 
from over 1.2 million invited reported distress on receiving an invite following 
a diagnosis of ovarian cancer. Based on an incidence of 48.9/100000 in this 
population,  about  587  women  with  ovarian  cancer  must  have  been 
contacted.
An  issue  that  is  often  debated  is  whether  acceptance  rates  could  be 
increased by GPs excluding ineligible individuals after checking the lists.  In 
the  FLEXISIG  trial  local  health  authorities  identified  375,744  men  and 
women  aged  between 55 and 64 years.  General practitioners on checking 
the lists identified 7602 (2%) as being ineligible for the trial with the number
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excluded  per  practice  varying  from  0  to  144  (median  11).  85  of the  505 
practices taking  part  in  the  study did  not exclude  any  of their patients.  In 
UKCTOCS,  such an approach would  have involved contacting and getting 
agreement from each of 3186  GP  practices  located  in the 27  participating 
PCTs,  regular  delivery  of  lists  to  the  practices  as  invitations  spanned  3 
years,  checking of the lists by practice staff in a timely manner to maintain 
the recruitment rate. The virtual lack of complaints in UKCTOCS by women 
or GPs after mailing  of over a  million  women  across  England,  Wales and 
Northern  Ireland  and  the  small  number  of  people  excluded  in  FLEXISIG 
after  contacting  505  GP  practices,  seems  to  suggest  that  in  UK  inviting 
women from PCT lists for trials without explicit permission from their GPs is 
acceptable  and  efficient.  The  massive  effort  required  in  ‘cleaning  up  lists’ 
does not seem justified.
Inviting women from the age sex registers  had  not been  piloted during the 
UKCTOCS  pilot.  However,  two  earlier  randomised  control  trials  of  OCS 
using  ultrasound  had  reported  on  acceptance  rates.  Parkes  et  al  in  1994 
reported that 82% of 8678 women,  aged  between  50 and 64 attending for 
NHS breast cancer screening between September 1989 and February 1993 
at Reading England accepted the invitation to participate in an RCT of OCS 
using  transvaginal  ultrasound  1 2 1   Higher  acceptance  rates  can  be 
anticipated for screening trials if invitations are restricted to women regularly 
attending  the  breast  or  cervical  screening  as  these  populations  are  self 
selected  with  regard  to  their  beliefs  in  screening.  However  both  these 
national  screening  programmes  are  limited  to women  aged  below 65  and
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therefore inviting women participating in these national programmes was not 
considered  an  appropriate  option  for  UKCTOCS  where  the  aim  was  to 
screen women aged 50 to 74.
Tabor et  al  published  an  acceptance  rate  of 64.3%  (950  of  1477  eligible 
women) in a population based study of women aged 46 to 65 years living in 
Copenhagen,  Denmark152  and  in  planning  for  UKCTOCS,  this  figure  was 
adopted.  It proved to be an significant overestimate of acceptance rates. A 
four-fold  increase  in  number of women  invited was  required to ensure that 
target recruitment was met.  Of 1,243, 312 women invited to participate in a 
RCT of OCS,  26%  (excluding those  known  to  be  ineligible) answered  that 
they would like to take part, with the highest rates of acceptance (30-32%) in 
Bristol,  Portsmouth,  Nottingham  and  North  Wales  and  the  lowest  rates 
(19%) in  inner city London. This was similar to the  uptake rate of 24% for 
colorectal cancer screening at Dundee180.  However,  in the FLEXISIG trial, 
overall acceptance rates were 55%.  It needs to be clarified that this was in 
response to the question whether they would take up the offer for a bowel 
cancer screening test if invited rather than whether they would participate in 
an  RCT  of  screening.  About  4%  of  invites  were  returned  undelivered  in 
FLEXISIG.  It was not possible to estimate these numbers in  UKCTOCS as 
the envelope did not have the trial address printed on the outside,  a simple 
but  easily  overlooked  point.  Previous  studies  have  shown  that  uptake  of 
screening  is related to socioeconomic deprivation.  It is possible to derive a 
deprivation  index  such  as  Townsend  Index  based  on  2001  Census  data 
using  a  woman’s  postcode.  An  analysis  of  any  association  between
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deprivation, age and distance from the regional centre on acceptance rates 
is underway.
Automated central allocation of regional centre recruitment appointments by 
the  customised  data  management  system  and  close  monitoring  of  under 
filled recruitment clinics ensured that the median number of women recruited 
monthly  was  over 4000  women  once  all  12  centres  were  active  (Figure
13-4).  Meeting recruitment goals for any trial is often more challenging than 
anticipated.  This  is  especially  so  for  longitudinal  RCTs  that  span  many 
years.  Time for the  recruitment phase often  needs to be extended beyond 
original plans by an average of 27%.  In UKCTOCS, it was originally planned 
that each of 12 RCs would have 3 years to recruit the target population i.e.. 
200,000 women would  be  recruited  in  36  centre years.  It took 45.4  centre 
years to recruit 202,638 women (Table 13-2). This equals a 26% extension 
of the recruitment phase when compared to the original estimate.
In  terms  of time,  recruitment  in  UKCTOCS  took  4.3  years  (May  2001  to 
September  2005),  which  translates  to  an  average  of  47,125  women 
randomised  per  year.  Randomisation  rates  were  exceeded  only  in  the 
FLEXISIG  trial  with  an  annual  randomisation  rate  of 68,173  per year  169. 
However  in  this  trial  participants  were  not  recruited  in  the  usual  manner. 
Individuals who  answered  ‘Yes’ to the  question -  ‘If you were  invited  to  a 
bowel  cancer  screening  test,  would  you  take  up  the  offer?’  were 
randomised.  Individuals were not required to sign consent to participate in a 
RCT or for flagging through ONS181. Only 40,674 of the 170,483 individuals
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who  underwent screening  signed  consent169.  If such  a  design  were  to  be 
adapted for use today, a detailed information leaflet about the trial and clear 
specific  consent  to  participate  in  an  RCT  would  be  required  before 
randomisation  and  flagging  via  the  Office  of  National  Statistics.  However, 
the  design  of  postal  recruitment  of  women  to  the  screening  trial  with 
attendance in person of only those in the study arm is attractive logistically 
and worth exploring further. The highest recruitment rate for a  US trial was 
achieved  by  the  WHI  trial  with  average  annual  recruitment  of  32,362 
women.  On  the  whole,  recruitment to  large  UK  RCTs  seems  to  be  more 
efficient in terms of time and resources than US trials.
With  recruitment  complete  in  UKCTOCS,  the  trial  is  set  to  answer  key 
questions on  impact of screening on ovarian cancer mortality,  physical and 
psychological  morbidity,  compliance,  and  cost.  The  focus  in  the  coming 
years is on ensuring compliance with screening. The serum bank and follow 
up via ONS will allow discovery and validation of novel serum  markers for 
ovarian cancer and other diseases.
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14  BASELINE CHARACTERISTICS 
14.1  Introduction
This  paper  describes  the  characteristics  of  the  women  recruited  to  the 
UKCTOCS trial.
14.2  Methods
At recruitment, the women were asked to complete an 18 item questionnaire 
which  is  2  pages  long  (A4  size).  It  includes  information  regarding  age, 
height, weight, country of  birth, ethnic origin, age at menarche, reproductive 
history  including  treatment  for  infertility  and  sterilization,  date  of  last 
menstrual period,  previous oophorectomy,  previous oral contraceptive  use, 
HRT  use,  previous  hysterectomy,  participation  in  another  ovarian  cancer 
screening trial,  personal  history of cancer and  family  history of breast and 
ovarian  cancer.  At  the  coordinating  centre,  the  recruitment  questionnaire 
was  scanned  electronically  using  computerised  intelligent  character  and 
optical mark reading software (TeleForm) allowing  rapid and accurate data 
entry. Any inconsistency or information that was not recognised by the data 
capture software was verified manually by trained data entry staff, who also 
validated  computer-interpreted  data  and  checked  each  questionnaire  to 
confirm whether signed consent for follow up has been granted. If there was 
any  missing  data  in  the  fields  on  the  data  sheet  that  were  mandatory  to 
confirm eligibility, then the DMS assigned the women to status  ‘incomplete’
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and a letter was sent requesting data.  If there was no response, the woman 
was  contacted  by  phone  call.  No  woman  with  incomplete  data  was 
randomised.
All entries of weight over 180kg and less than 30kg,  height over 210cm and 
less than 75cm and pregnancies >12 were checked against the recruitment 
questionnaire and any data entry errors were corrected.
Analysis  involved  summative  statistics  using  frequency  distributions  and 
median  (quartiles).  Trends and differences  in  baseline characteristics such 
as  OCP  use,  hysterectomy,  tubal  ligation,  no  of  pregnancies,  BMI  were 
explored  between  women  stratified  according  to  year  of  birth  (1925-30; 
1930-35,  1935-40,  1940-45,  1945-50,  1950-55)  and  age  at  randomisation 
(50-54,  55-59, 60-64 and 65 or over). The change in current HRT use over 
time  was  also  assessed  by  considering  the  proportion  (%)  of  women 
randomised  each  month  who  were  using  HRT  when  they  attended  for 
recruitment. 95% confidence intervals for the proportion estimate were used 
to validate any apparent trends. The extent of missing data was known to be 
very  limited  and  so  such  records  were  discarded  in  the  analysis  without 
concern of bias.
14.3  Results
The statistics presented here are based on data collected at recruitment of 
the entire cohort of 202,638  postmenopausal women.  They were  recruited
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between April 2001  and September 2005.  Majority of the women  belonged 
to  cohorts  born  in  1940-45  and  1945-50  (Table  13-4).  Groups  <1000  in 
number are  highlighted  and these groups have  been  omitted from all birth 
cohort analysis
Table  14-1:  Women  grouped  according  to  birth  cohort  and  year  of 
randomisation
Year of birth Year randomised Total
2001 2002 2003 2004 2005
1925-30 435 1325 755 80* 2515
1930-35 1256 6044 6682 8927 3283 26192
1935-40 1831 9457 10427 10401 9336 41452
1940-45 2231 11982 14280 10431 12103 51027
1945-50 2329 14308 17740 11898 9290 55565
1950-55 404 3857 7626 7093 6827 25807
Total 8486 46973 57510 48830 40839 202638
Groups  <1000  in  number  are  highlighted  and  these  groups  have  been 
omitted from all birth cohort analysis
Age at randomisation (yrs)
■   50-55  ■   >65-70
□   >55-60  □   >70-75
□   >60-65  ■   >75
2 women were over 75
Figure 14-1: Age of women on date of randomisation into UKCTOCS
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96.4%  of the women were White with  Black Caribbean  (1823)  and  Indian 
(1180)  forming  the  next  largest ethnic groups  (Table  14-2).  73.6%  of the 
non-white  population  were  recruited  from the  London  centres.  84%  of the 
women were born in England and Wales (Figure 14-3).
Table 14-2: Ethnicity
Ethnicity Number Percent
White 195274 96.4
Black Caribbean 1823 0.9
Indian 1180 0.6
Black African 761 0.4
Chinese 376 0.2
Pakistani 190 0.1
Black other 185 0.1
Bangladeshi 111 0.1
Other 1695 0.8
Not stated 1043 0.5
Total 202638 100
Median height of the trial participants was 162.6cms and median weight was 
67.6kgs.  Median  body mass index was 25.78  (25th,  75th  quartiles 23.3 and 
29.1)  with  little  change  in  women  grouped  by  birth  cohorts  (Figure  14-2). 
57.7% of the women  had a  BMI  of >25 with 20.6% being obese (over 30).
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% of women
100% n
90% L I
80%
70%
60%
50%
40%
30% -
20%
10% /
0%
—
iiu
1925-30 1930-35 1935-40 1940-45 1945-50
□ Obese (>30) 17.7% 19.6% 20.8% 20.8% 20.6%
□  Overweight (25 - 29.9) 38.7% 39.5% 39.4% 37.4% 35.4%
■  Normal (18.5-24.9) 42.4% 39.7% 38.8% 40.9% 43.1%
■  Underweight (<18.5) 1.2% 1.2% 1.0% 0.9% 0.8%
Birth cohort
Figure 14-2: BMI at recruitment in women grouped by age
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Regional
centre
No of 
women
Percent Country recruited
Gateshead 17323 8.5
Bigland 78.1%
St Bart's 19795 9.8
Liverpool 10096 5
Nottingham 16777 8.3
Manchester 16520 8.2
Derby 14925 7.4
Royal Free 16873 8.3
Portsmouth 19185 9.5
Bristol 16540 8.2
Mddesborough 9927 4.9
Cardiff 16751 8.3 Wales 15.4%
North Vteles 14341 7.1
Belfast
13585 6.7
Northern Ireland
6.7%
Country of birth of the women recruited
Elsewhere 6.0% 
Sootland 1.9%
Northern Ireland
Not stated 0.2%
Irish Republic 
1.9%
6.5%
Wales 10.5% (
England 73.1%
Figure 14-3: Place of birth of women randomised to UKCTOCS
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Median  age  at  menarche  was  13.  59.6%  of  the  women  had  used  oral 
contraceptives. When the women were grouped into birth cohorts, over 80% 
of the women born in 1950-55 had used the pill compared to around 22% of 
women  born  in  1925-30.  There was  a  clear trend  of increasing  pill  use  in 
later  birth  cohorts  (Figure  14-4).  The  overall  median  duration  of OCP  use 
was 5 years with little difference between the birth groups.
100-
®  80-
60-
p  40-
o  20-
Women bom before 1930 were no longer eligible after 2004
c -
Quarter the women were randomised to UKCTOCS
Year of birth
    1925-30
    1930-35
1935-40
    1940-45
1945-50 
    1950-55
Figure 14-4: Use of oral contraceptive pill in women grouped by year of 
birth and year randomised
Overall 21%  had  undergone tubal  ligation. Again when  separated  into birth 
cohorts,  women  born  between  1925-30  had  a  6%  rate  which  doubled  to 
12%  in  those  born  between  1930-35.  In  those  born  since  1935,  the  rates 
were similar ranging between 20-25%.
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Figure  14-5:  Tubal  ligation  rates  in  women  grouped  by  year  of  birth 
and year randomised
Overall  the  median  number  of  pregnancies  >6  months  was  2.  69%  of 
women  had  not had a pregnancy <6 months.  There were clear differences 
between the birth cohorts in terms of number of viable pregnancies (Figure 
14-6 and Figure 14-7).
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Missing data 
0%
A. Overall distribution of number of pregnancies > 6 months
16-
14-
10-
2001 2002 2003 2004 2005
YearRandomised
YearofBirth
    1930-35
1935-40
    194045
194550
    1950-55
    192530
B. % of women with >2viable  pregnancies in 
the birth cohorts
* There were only 2595 women in the 1925-30 cohort.
Figure 14-6: Distribution of viable (.>6 months) pregnancies
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2001
I
2002
I
2003
r
2005
Year of birth
    1925-30
    1930-35
1935-40
    1940-45
1945-50 
    1950-55
Year Randomised
B.  % of women with  1  or more  pregnancy  less than  6 
months in the birth cohorts
Figure 14-7:  Pregnancies below 6 months
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18.9% of women  had undergone hysterectomy with conservation of at least 
one ovary. When the birth cohorts were examined separately and over time, 
in women born in  1950-55, the hysterectomy rate at recruitment fell steadily 
through  2001  to  2005.  This  trend  although  less  pronounced  was  also 
apparent in those born in 1945-1950 (Figure 14-8).
Year of Birth
    1925-30
    1930-35
1935-40
    1940-45
1945-50 
    1950-55
3 0 -
2 5 -
1
2 O
20 -
C 3
0
1
1 5 -
2002 2003 2004 2005 2001
Year Randomised
Figure  14-8:  Hysterectomy  rates  in  women  with  ovarian  conservation 
grouped by year of birth and year randomised.
All  women  were  postmenopausal  as  defined  by  eligibility  criteria.  Women 
who  had  a  hysterectomy  (38,120);  missing  data  (4)  and  those with  age  of
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menopause <stated age of menarche (100) were excluded. In the remaining 
164,324  women,  the  median  age  at  menopause  was  50.66  years  (mean 
50.35;  SD 4.32; 25th, 75th quartiles 48.15 and 53.15).  If the women on HRT 
at recruitment (27,577 were excluded), the median age at menopause in the 
remaining  137,059 women was 50.5 years (mean  50.2;  SD 4.83;  25th,  75th  
quartiles 48 and 52.95) (Figure 14-9).
15.000-
Mean = 50.3516 
Std.  Dev. = 4.92361 
N =  164,324
12,000-
9 ,0 00-
U .
6,000-
3 ,0 00-
50 60 70 80 10 20 30 40
Age at Menopause (years)
Figure 14-9: Age at menopause in women with an intact uterus
Overall  18.75%  (38002)  of  women  were  using  hormone  replacement 
therapy  (HRT)  at  recruitment.  The  median  duration  of HRT  use was  8.15 
years (mean 8.8; SD 5.72; 25th, 75th quartiles 4.5 and 12) years.
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2,000-
1,5 0 0 -
Mean = 8.7565 
Std.  Dev.  = 5.49493 
N = 37,954 5 0 0 -
10 30 -10 0 20 40
Length of HRT use (years)
48  women  who  recorded  over 40  years  of  HRT  use  have  been  excluded 
from this graph.
Figure 14-10: Length of HRT use in women on HRT at recruitment
Between  April  2001  and  June  2002,  the  average  proportion  of  women 
randomised per month using  HT at recruitment was 28% with a slight initial 
upward trend with time. This was followed by a clear downward trend in HT 
use starting  in July 2002,  coinciding with the publication of the WHI  interim 
results.  From  February to September 2005, the proportion of women  using 
HT  was  between  10-11%  (averaged  10.9%).  The  downward  trend  was 
confirmed in the age-adjusted proportion  (with 95% confidence intervals) of 
women  randomised  per month  using  HT at recruitment for the entire study
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period  (Figure  13-17)).  For all  age  groups,  there was a  decline  in  HT  use 
from July 2002, although this decline was less pronounced for women over 
the age of 65. There was reduction in HT use with increasing age.
-  -  Upper 95% Cl
HRT use - all women
-  -  Lower 95% Cl
/  / /  /  /  /
D a ta
MWS  CSM  UK WHI
Figure  14-11:  Proportion  of women  randomised  each  year using  HRT 
in  the  birth  cohorts  and  proportion  randomised  each  month  in  each 
age group using HRT
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YearofBirth
    1925-30
    1930-35
1935-40
    1940-45
1945-50 
    1950-55
Year Randomised
-% HT use in women aged 50-54 
-% HT use in women aged 55-59 
• % HT use in women aged 60-64 
■% HT use in women aged over 65
25 00%
20.00%
500%
0.00%
j '   jy   j?  j*  j *   v   y   y  y  J - J?  J 1   /
Month of recruitment
Figure 14-12: Percentage of women randomised each month using HRT
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Women  with  a  personal  history  of  ovarian  cancer  were  ineligible  for 
participation  in  the  trial.  6%  of women  had  previously  had  a  cancer other 
than  ovary or skin with  3.78% of women  reporting  previous breast cancer. 
4.53% of women  had a family history of ovarian cancer with  1.56% having 
mothers who suffered from the disease. 22.2% had a family history of breast 
cancer with a maternal history of breast cancer noted in 6.41% (Table 14-3).
Total number of women 202638 women
No  of 
women
%
Hysterectomy 38210 18.86%
Tubal ligation 43135 21.29%
Fertility treatment 6629 3.27%
OCP use 120737 59.58%
Current HRT use 38002 18.75%
Personal history of cancer 12094 5.97%
Breast cancer 7658 3.78%
Bowel cancer 773 0.38%
Lung cancer 106 0.05%
Other cancer 3557 1.76%
Maternal history of cancer 16025
Ovarian cancer - mother 3035 1.50%
Breast cancer -mother 12863 6.35%
Mother - both 127 0.06%
Family history of ovarian cancer 9186 4.53%
Relatives with Ovarian Cancer
1 9029 4.46%
2 143 0.07%
>2 14 0.01%
Family history of breast cancer 44992 22.20%
No of relatives with breast cancer
1 36965 18.24%
2 6460 3.19%
>2 1585 0.78%
Table 14-3 : Gynaecological history and personal and family history of 
cancer
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All  mandatory data fields were complete in women  randomised to the trial. 
Table 14-4 shows the percentage of missing information in each of the non­
mandatory data fields. This ranges between 0.16 (country of birth) to  1.5% 
(years  of  pill  use).  A  variety  of  criteria  used  to  estimate  erroneous  data, 
suggests that it is about 0.5%  (Table  14-5).  On  checking  recruitment data 
sheets,  majority  of the  278  women  who  stated  their first  period  occurred 
over the age of 19, had entered in this field the age at their last period.
Non mandatory fields on the 
recruitment data sheet
No of women with 
missing data (%)
Ethnicitv 1043 (0.51)
Years of Pill use in 120737 who 
noted they had used OCP
1811  (1.5)
Pregnancies <6 months 2674(1.32)
Pregnancies >6 months 596 (0.29)
Age at first period 1083 (0.53)
Country of birth 318(0.16)
Height 502 (0.52)
Weight 765 (0.38)
Table 14-4: No of women with missing data in the non mandatory fields 
in the recruitment data sheet
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Data fields on
recruitment
datasheet
No  with 
possible 
erroneous 
data
Total
(No randomised 
- No with 
missing data)
%
error
Reason data considered possibly 
erroneous
No of Pregnancies 
<6 months
7 199964 0.004 No of entries with over 12 in this category
No of Pregnancies 
>6 months
21 202042 0.01 No of entries with over 12 in this category
Age at first period* 322 201555 0.16 <8 years and >19 - some of this data is 
correct
Height 818 202136 0.4 >210 cms and <120 cms
Weight 853 201873 0.42 <40kgs and >140kgs
Yrs of HRT use 48 38002 0.13 In those who admitted to HRT use, usage for 
>40 years
Yrs from LMP 346 202634 0.17 Yrs from LMP greater than 50 yrs or before 
born
All  weights  over  180kg  and  less  than  30kg,  heights  over 210cm  and  less than  75cm  and  pregnancies  >12  have  been 
checked against the recruitment questionnaire and any data entry errors have been corrected.
*For the erroneous age at first period, majority of the women have filled in their age at last period
Table 14-5: No of women with possibly erroneous data in the non-mandatory fields in the recruitment data sheet
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14.4  Discussion
202,638  postmenopausal  women  aged  50-74  years  from  the  general 
population residing in 27 participating primary care trusts in England, Wales 
and  Northern  Ireland  volunteered  to  participate  in  UKCTOCS  and  were 
randomised. The baseline data collected at recruitment in this large national 
cohort of women provides useful information about trends in older women in 
the UK.  However,  it is important to note that this cohort consists of women 
willing to  participate  in  an  RCT of ovarian  cancer screening.  Women who 
volunteer  to  participate  in  research  are  usually  more  educated  and 
informed174-176.  Less  important,  as a  result of exclusion criteria of the trial, 
the cohort does  not contain women who have had  bilateral oophorectomy, 
previous ovarian cancer, an active malignancy or who are at risk of familial 
ovarian cancer.
The median  age was 60.6 years with  11%  over the age of 70.  The  mean 
age  of women  recruited  to  the  Million  Women  Study  (MWS),  a  large  UK 
based general population questionnaire study was lower (57.4 years) as the 
study  involved recruitment through the NHS breast screening programme of 
women aged 50 to 64 years.182 Women participating in the Women’s Health 
Initiative,  an  RCT of HRT based  in the US  had a mean age of 63.3+/- 7.1, 
again reflecting the eligibility criterion which was age 50 - 79 years.  183 The 
age differences are important when comparing baseline data between these 
studies.
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In  UKCTOCS,  7.4%  of  participants  were  born  outside  the  UK  which 
compares  well  with  UK  census  data  from  April  2001  which  reported  that 
8.3%  of the  population was  born  overseas  (www.statistics.gov.uk).  96.4% 
of the women were white versus 92.1% of the population in the 2001  census 
(www.statistics.qov.uk).  Black Caribbeans and Indians were the next largest 
ethnic  groups.  Most  of  the  non  white  population  were  recruited  from  the 
London  centres.  Resources  were  not  available  for  specific  efforts  to 
encourage  greater  participation  of women  from  ethnic  minorities.  The  trial 
design involved inviting women and since over 1.2 million women were sent 
invitations,  it  was  not  possible  to  use  a  language  other  than  English. 
Interpreters  were  arranged  to  facilitate  recruitment  but women  needed  to 
inform the  centre  ahead  of the appointment.  Ethnicity was  not recorded  in 
the MWS.  But in the WHI study, where special efforts were made to recruit 
women from  ethnic minorities  by publicising the trial  in ethnic newspapers, 
newsletters, television and radio channels,  18.5 % of participants were from 
ethnic minorities  (versus 20%  in the  US  population).183 There  is increasing 
evidence  that  racial  and  ethnic  minorities  are  as  willing  as  whites  to 
participate  in  health  research. What is required are steps to ensure that all 
groups  have  greater  access to  health  research,  rather than  try  to  change 
minority attitudes.184 This was also  noted  in the  Birmingham  Rehabilitation 
Uptake  Maximisation  (BRUM)  study,  an  RCT  comparing  a  home-based 
with  a  hospital-based cardiac rehabilitation  programme.  Significantly more 
patients  of  South  Asian  ethnicity  were  excluded  as  they  were  ineligible 
based  on  language  (i.e.  the  inability  to  speak  English  or  Punjabi).
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However,  of  those  eligible,  similar  proportions  were  recruited  from  the 
different ethnic groups (white, South Asian and other). The primary reason 
for  ineligibility  was  the  inability  to  support  the  range  of  minority 
languages.185  However they  have  been  reports that trials that included  an 
invasive arm enrolled fewer minority participants than expected.186
Median self reported height of the trial participants was 163 cms and median 
weight was  66  kgs.  The  correlation  between  BMI  based  on  self-reported 
height and weight and that based on measured height and weight is typically 
greater  than  O.9.187  The  median  body  mass  index  in  the  trial  was  25.8. 
Overall 37% of the women were overweight (BMI >25) and 21% were obese 
(BMI>30)  as  per  WHO  criteria.188  Although  these  figures  are  high,  the 
UKCTOCS cohort seems to be  less obese that the UK population.  31% of 
women in UK aged 55 to 64 are reported to be obese189 when compared to 
20.7%  of  UKCTOCS  women  in  the  same  age  group.  There  was  little 
change in BMI patterns between the birth cohorts and in women grouped by 
aged.  In the WHI clinical trial, three quarters of the women were overweight 
or  obese.  The  problems  of overweight  and  obesity  have  achieved  global 
recognition  only during the past 10 years.190 It is now well established that 
obese persons have diminished life expectancy.  New evidence is emerging 
that even moderate elevations in BMI confer an increased risk of death. The 
risk of death in participants in the US NIH-AARP Diet and Health Study who 
were overweight at the age of 50 was 20 to 40 percent higher than that of 
those who had a normal BMI at that age.1 9 1   It will be possible in due course 
to estimate the impact of BMI on mortality in the UKCTOCS cohort.
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Between  the  birth  cohorts,  there  are  clear differences  in  the  reproductive 
choices that these women made, with earlier birth cohorts reporting less use 
of the  pill,  more viable  pregnancies,  fewer  pregnancies  <6  months and  a 
lower rate of tubal ligation. While the absolute rates cannot be extrapolated 
to the general  population,  the differences  between the birth  cohorts  in this 
large cohort of women are probably reflective of trends in the population.
18.9% of women had undergone hysterectomy with conservation of at least 
one  ovary.  At first glance,  this  is  lower than  the  25.1%  hysterectomy  rate 
noted  in the Million Women  Study (MWS).  However once account is taken 
of the  7.4%  of women  in  MWS  who  reported  having  undergone  bilateral 
oophorectomy,  the  rates  are  remarkably  similar.182  The  Royal  College  of 
Obstetrics and Gynaecology estimates that 20% of women in the UK have a 
hysterectomy usually for benign conditions by the age of sixty.192  When the 
UKCTOCS birth cohorts were examined separately and over time, in women 
born in 1950-55, the hysterectomy rate at recruitment fell steadily from about 
28.5%  in  2001  to  16.3%  in  2005  (Figure  14-8).  In  the  eighties  the 
hysterectomy  trends  were  increasing.  From  1987  to  1992  in  Finland  the 
hysterectomy  rate  increased  by  22%,  from  340  to  414  per  100,000 
females.193  However  since  then  the  hysterectomy  rates  for  benign 
indications has been declining as a result of better medical management of 
menorrhagia  using  oral  medication  and the  hormone-releasing  intrauterine 
system and conservative surgical options for a variety of benign conditions. 
In California, there has been a significant decline, in the hysterectomy rates
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for benign indications from 4.01  per 1,000 women in 1994 to 3.41  per 1,000 
women  in  2003194  while  in  Western  Australia,  the  age-standardised 
hysterectomy rate decreased 23% from 6.6 per 1000 woman-years in 1981 
to  4.8  per  1000  woman-years  in  2003.  The  age  when  the  UKCTOCS 
women  underwent hysterectomy was not elicited.  In the UK VALUE survey 
of hysterectomies,  the  median  age  at hysterectomy (both with  and without 
conservation  of  ovaries)  was  found  to  be  45,  with  dysfunctional  uterine 
bleeding  being  the  most  common  indication.195  Given  that  the 
hysterectomies  in  the  UKCTOCS  women  were  for  benign  disease  and 
associated with conservation  of at least one ovary,  it can  be surmised that 
the  majority of the women  may  underwent the operation  prior to their mid 
forties. Women  in the  birth  cohort 1950-55 would  have been  in their early 
forties  in  the  1990s  and  the  decreasing  hysterectomy  rates  noted  in  this 
birth cohort are probably a reflection of the international trends.
137,059 women were  neither on  HRT at recruitment nor had  undergone a 
hysterectomy. The median age at natural menopause in this group was 50.5 
years  (25th,  75th   quartiles  48  and  52.95).  This  is  in  keeping  with  the 
estimated  average  age  at  natural  menopause  in  Western  countries  of 
between 50 and 51  years.196 Recent  estimates from various countries have 
ranged  from  median  age  at  natural  menopause  in  Puerto  Rica  of  51.3 
years197,  in Spain of 51.7 years, and  in the U.S.  of  52.6 years.198 A more 
detailed  analysis  of the effects  of parity,  deprivation  and  other factors  on 
menopausal age should be possible.
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The  proportion  of women  using  HT at recruitment was 29%  between April 
2001  and June 2002. However from July 2002 there was a steady decline in 
women using HT and by February 2005 to September 2005 only 10-11 % of 
newly recruited women were  using  HT. While the absolute rates of HT use 
may  not  apply  to  the  UK  female  population,  given  the  large  size  of  this 
national cohort and the pronounced decline in HT use, the trend observed is 
probably representative of a general trend in the UK. This cohort of women 
seem similar in  current HT use to those who  participated  in the  MWS.  In 
MWS women were recruited between 1996 and 2001  and the overall rate of 
current HT use at recruitment was 33%199 which is similar to the 35% overall 
rate of current HT  use  in  postmenopausal women  aged  50-64  recruited  in 
2001  to UKCTOCS.  The cohort itself was fairly homogenous as there was 
no change over time  in the  proportion  of recruited women with  a  personal 
history of breast cancer, number of relatives with breast or ovarian cancer or 
hysterectomy. As variation in the proportion of women in various age groups 
over  time  could  impact  on  HT  use,  the  age  groups  were  examined 
separately.  The  decline  in  HT  use from  July  2002  was  present  in  all  age 
groups.
Similar  downward  trends  have  been  reported  from  the  USA200-202  and 
Europe203-205  in  the  period  2002-2003  immediately  following  publication  of 
the trial  results.  Studies  reported  a  decline  in  HT  prescribing  in  the  USA 
from 14.6% in September 1999 to 7.9% in June 2002 in women aged 40-80 
years202;  The Netherlands from  10.7%  in 2000 to 8.7%  in 2003  in women 
aged 45-69 years 203 and  in  Hong  Kong from  12.2%  in the second  half of
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2000 to 4.5% by the first half of 2003 in women aged 50 or above206.  In an 
observational  cohort  study  of  postmenopausal  US  women  aged  50-74 
undergoing  mammography  an  18%  decline  in  HT  use  per  quarter  was 
documented  during  July  2002  and  May  2003201.  The  UKCTOCS  data 
shows a smaller rate of decline in the UK, but one that continued to fall until 
February 2005 when it stabilized. An annual report on prescription costs for 
England by the Department of Health support these findings.  In 2001, there 
were  6.3  million  HT  prescriptions dispensed  in  England  and  by 2004,  this 
had fallen to 3.8 million207.
The  timelines  suggest that the  decline  is  related  to  the  publication  of the 
WHI  and  MWS results.  In the  USA,  the dissemination of the WHI  HT trial 
results had an  immediate impact on the discontinuation of HT200.  Our data 
suggests that in the UK, the publication of the US study was followed  by a 
gradual  decline  in  HT  use which  fell  more  steeply  after publication  of the 
British  MWS  in August 2003.  The difference in  impact of the two trials on 
HT  use  was  also  noted  in  the  Netherlands  with  a  modest  decline  in  HT 
prescribing after the publication of the WHI study, followed by a dramatic fall 
in the prescribing of HT after release of results from the MWS203.
Reports from small longitudinal cohort studies support the decline in HT use 
to  be  related  to  the  WHI  trial208  209.  The  decline  was,  however  less 
pronounced in Germany where in a survey of 8,380 women (mean age 56.1 
years) only 25.7% reported stopping HT in response to the WHI results210 as
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opposed to 40% and 60%  in the  reports from  New Zealand209 and  USA208 
respectively.
A number of factors may have contributed to this decline.  Media coverage 
of  the  WHI  study  had  a  significant  influence  on  women’s  use  of  HT211. 
There was a  misunderstanding  about the magnitude of risks and  benefits. 
The original publication and most of the ensuing publicity from WHI phrased 
the  risks  as  a  percent  increase  (or  decrease)  of  the  relative  risk.  For 
example, there was a 24% increased relative risk of breast cancer per year 
in  the  HT  group.  The  general  public,  not  understanding  the  concept  of 
relative  risk,  interpreted  this  statement  as  a  24%  chance  of  developing 
breast  cancer  each  year  on  HT212.  An  evaluation  study  of  educational 
intervention  on  HT  continuation  rate  in  Slovenia  confirmed  that  the  main 
reason  for discontinuing  HT  was  fear of breast  cancer,  intensified  by  the 
media213.  A  recent  Cochrane  review  identified  five  studies that evaluated 
health care utilization before and after media coverage of specific events214. 
Each found  changes in  utilization: favourable publicity was associated with 
higher  use,  unfavourable  publicity  with  lower  use.  The  Cochrane  review 
concluded  that  media  reports  played  an  important  role  in  influencing  the 
public's use of health care interventions. Media coverage as distinct from the 
scientific importance of the work also plays an important role in transmitting 
knowledge to the scientific community215.  In addition, guidance circulated by 
most  health  care  providers  about  the  implications  for  prescribing  HT 
probably contributed to the observed changes216 as did the advice given by 
physicians as women who continued to taking  HT did so  largely based  on
14-192
MD thesis UMUKCTOCS - BASELINE CHARACTERISTICS
their physician’s advice217.  Interrelated with all of this,  reduced promotion of 
HT by the pharmaceutical companies may have further played a role in the 
decline in prescriptions218.
The large cohort size makes it possible to explore numerous other variables. 
However,  in an effort to maintain the focus of the trial,  ensure good quality 
data  and  complete  recruitment  in  the  stipulated  time  period,  we  have  not 
captured  detailed  medical  history  or  information  on  lifestyle  and  socio­
demographic factors.  More  information  is  being  collected  via the follow up 
questionnaires  which  women  receive  in  the  course  of  the  trial  and  this 
should make it address issues that are more specific.
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15  SUMMARY
This thesis spans work done over eight years from June 1997 to December 
2005. A lot has been achieved during this long journey and the stage is now 
set to definitively answer the question -  Will ovarian cancer screening save 
lives?’
The first step involved literature review and refining the ROC algorithm using 
ultrasound  data  from  the  initial  trial  of  22,000  women.  There  were  1219 
scans available from 741 women who underwent a second line test due to a 
serum  CA125  measurement  of  >30  U/l.  A  database  was  built,  a 
classification  system  proposed,  data  entry  mostly from  hand  written  cards 
supervised,  missing  outcomes chased  by writing to GPs and doctors,  data 
repeatedly  audited  and  finally  analysis done.  This  resulted  in  alteration  of 
the ROC algorithm so that ovarian morphology was used instead of volume 
to interpret scans.
At this point the pilot RCT of 13,582 postmenopausal women was underway 
and the refined ROC algorithm incorporating the new ultrasound criteria was 
implemented.  Day to day work  involved  managing the women  detected  to 
have  screen  abnormalities  on  the  trial  and  addressing  the  various  logistic 
issues  involved  in  running  the  pilot  RCT.  Collection  of  outcome  data 
involved  follow  up  postal  questionnaires to  all  22,000 women.  Preliminary 
analysis  revealed  that screening with the  ROC algorithm was feasible and 
could  achieve  high  specificity and  positive  predictive value.  This data was
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used to inform the UKCTOCS trial design.  Final analysis of the prevalence 
screening was completed and published in 2005.
Meanwhile in  1999, work was underway writing a project grant to the MRC, 
CRUK,  and  Department of Health for a definitive ovarian cancer screening 
RCT of 200,000 women.  It was decided this should include a head to head 
comparison  of  both  OCS  strategies  -  multimodal  and  ultrasound.  Specific 
aspects  that  were  the  remit  of the  researcher were  literature  review;  the 
screening  strategy  in  the  ultrasound  arm,  estimating  outcomes  based  on 
known performance characteristics of the screening strategies and detailed 
planning  of the  logistics  of the  proposed  trial.  The  grant was  awarded  in 
2000  and  as  trial  coordinator  implementation  of  the  project  was  the 
researcher’s remit.
The trial was set up between late 2000 and 2002. Tasks involved:
1)  Writing  up  the  detailed  trial  protocol  and  numerous  standard 
operating  procedures  for  each  aspect  of  the  trial  from  labelling 
samples to surgery.
2)  Setting  up  transparent,  robust and  sustainable financial  processes 
for managing the grant income; accurate forecasting of expenditure 
as  it evolved  and  changed  over the  course  of the  12 years of the 
trial.
3)  Separate  negotiations  with  the  Department  of  Health  to  finalise  a 
process for efficient transfer of subvention to the RCs.
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4)  Negotiation  with  the  lead  researchers  of  initially  17  Trusts.  This 
involved  drawing  up and  providing  accurate forecasts for finances, 
staffing,  space  and  support for the  duration  of the  trial  that  leads 
could use to negotiate with their Trust Boards.  Finally 13 RCs were 
set up.  In 2000, there were no standard contracts or processes and 
these had to be drafted and legal advice sought.
5)  Approval from MREC,  13 LRECs and 13 R&D departments.
6)  Approval from  Caldicott guardians from 27  PCTs for permission  to
use data from their age sex registers to invite the women.
7)  Approval  for the  flagging  study  from  the  ethics  committees  of the 
Office of National  Statistics for England  and Wales and  protracted 
negotiations for the same for Northern  Ireland which  lasted  almost 
six years.
8)  Recruitment and training of the coordinating centre team which was 
built up from  3 [Prof Jacobs, the trial manager and the researcher] 
to the current 20 -  this involved writing job descriptions, advertising, 
short listing, appointing, induction and training.  In the first two years, 
there  was  significant  turn  over  of  clerical,  nursing  and  laboratory 
staff.  In  addition,  the  trial  manager who  had  been  involved  in  the 
pilot RCT left and moved abroad.
9)  Setting  up  of  a  new  laboratory  for  processing  and  analysing  the 
blood samples
10)  Changing the method of analysis of serum CA125 - It was clear that 
it would not be possible to analyse the large number of samples for 
serum  CA125  using  the  original  radioimmunoassay.  The
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introduction  of  an  enzyme  linked  immunoassay  using  a  semi 
automated  platform  meant that 6000  samples  from  the  pilot  RCT 
had  to  be  re-assayed  so  that  a  correction  factor  could  be  was 
calculated for incorporation into the ROC algorithm.
11)  Setting up a novel system for storage of the serum. Various options 
were explored  to ensure  high  throughput,  maximum efficiency and 
long term viability of the samples for future research.  Finally a semi 
automated  system  using  straws  and  storing  the  samples  in  liquid 
nitrogen tanks was set up.  In the initial phase they were numerous 
training issues and problems with the using the system.
12)  Setting up a cryostore of liquid nitrogen tanks. This turned out to be 
a  huge  issue for the first 5 years due to the problems with  space. 
Lateral  thinking  and  intense  negotiations  with  Estates  led  to  a 
temporary  solution  through  building  a  large  shed  on  the  QMUL 
college grounds. In 2004 on transfer of the CC to UCL, this task was 
handed  over  to  a  commercial  organisation  with  off  site  storage 
facilities.
13)  Assisting  the  RC  leads  with  setting  up  the  local  centres  and 
recruiting, and training the staff.
14)  Setting up the logistics of daily transport of blood samples from the 
13 RCs to the coordinating centre laboratory, weekly transfer of all 
documentation  to  and  from  the  RCs,  regular  delivery  of 
consumables including venepuncture equipment to RCs.
15)  Putting  in  place  high  throughput  procedures  for  sending  out 
thousands  of  letters  to  women  every  day.  This  involved
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procurement  of  high  specification  printers,  a  machine  for  stuffing 
envelops, a franking machine and contracts with the Royal Mail.
16)  Tendering in Europe for 13 ultrasound machines and going through 
a  detailed  procurement  process.  Writing  up  the  tender documents 
was one of the most challenging tasks faced.
17)  Organising maintenance contracts for the core equipment
18)  Organising the printing and delivery of thousands of trial brochures, 
patient  information  sheets,  and  site-specific  consent  forms.  The 
challenge  was  in  getting  the  lowest  price  which  meant  large 
volumes but working within the constraints of storage space.
19)  Writing the transcript and assisting in the shooting and editing of the 
trial information video
20)  Setting up of the various overseeing committees - DMEC, TSC and 
Outcomes Committee, all of whom had independent members who 
needed to be updated on a regular basis on study progress.
21)  Setting  up the database  management system  that underpins all of 
UKCTOCS.  The  DMS  was  built by  a  commercial  organisation  but 
input from the researcher was significant. The technical specification 
document alone that was drawn up ran into hundreds of pages. The 
system was tested at each stage as it was built and  arrangements 
made for data from various sources such as the Office of National 
Statistics,  PCTs,  the  CA125  analyser to  be directly  uploaded  into 
the system
22)  Setting  up  of data  transfer between  the  main  UKCTOCS trial  and 
the Psychosocial Study at the University of Sussex.
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23)  Organisation  of  publicity  as  the  main  trial  and  then  each  of  the 
centres  went  live.  This  required  coordination  with  various  funding 
agencies  and  Trust  press  officers to  ensure  everyone  was  aware 
and there were processes in place to handle the ensuing enquiries.
24)  Putting in place robust procedures for documenting and responding 
to complaints and reporting adverse events.
In addition,  the researcher directly set up and  ran the  RC at Barts and the 
London which involved a whole series of separate tasks - local negotiations, 
recruiting  staff,  managing  the  logistics  and  being  directly  involved  in  the 
clinical assessment of women from this centre.
Recruitment commenced  in April 2001  with  13  RCs set up  in  a staggered 
fashion.  This  phase  involved  continuous  monitoring  of  targets  to  ensure 
issues  were  addressed  in  real  time,  fine-tuning  of  invitation  rates  and 
appointments  to  accommodate  regional  variations  in  response  and 
attendance respectively, site visits to RCs to help resolve various issues that 
arose  in  the  initial  phase,  organisation  of team  meetings and  continuously 
working on team building and motivation. The  DMS was repeatedly refined 
in  response to  new needs and the operating  protocols regularly revised.  In 
response  to  new  MRC  guidelines  on  consent,  patient  information  and 
consent forms were revised and 50,000 women who had been randomised 
contacted  again  to  clarify  further  issues  with  regard  to  ONS  flagging, 
secondary studies and stored samples. In April 2004, the department moved 
from QMUL to UCL. Many of the processes that were in place, had to be set
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up again especially documentation, contracts, and logistics of transport. The 
biggest  task  was  setting  up  a  new  laboratory.  However,  by  this  time  an 
extremely  competent  laboratory  manager was  in  post who  took  over the 
brunt of this task.
1248453 invitations were sent.  31% of women accepted the invitation. The 
acceptance  rate  varied  between  24%  in  East  London  (Bart’s)  to  38%  at 
Portsmouth.  Between  April  2001  and  September  2005,  205,208  women 
attended for recruitment.  202,638 participants were randomised to the trial, 
making  it  the  largest  randomised  control  trial  ever  undertaken.  10189 
women  could  not be  recruited  into the trial despite wishing to take  part as 
the recruitment target was met.
Good quality data with  minimal errors or missing  information was collected 
at recruitment.  Analysis of this  data  revealed  a wealth  of information  both 
about trends  in  use  of reproductive  options  like the  oral  contraceptive  pill, 
tubal ligation in women belonging to different birth cohorts as well as trends 
in practices like HRT use which changed over the course of the recruitment 
period.
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16  FUTURE DIRECTIONS
The  UKCTOCS  trial  is  poised  to  answer the  crucial  question  of whether 
screening  can  impact on  ovarian  cancer mortality.  The focus in the next 5 
years  is  to  ensure  that  annual  screening  continues  to  be  organised 
efficiently and high levels of compliance are maintained. It is anticipated that 
the first results will be available in 2012 when each woman has been in the 
trial for 7 years post randomisation.  Once a mortality impact is established, 
detailed  information  collected  on  compliance,  cost,  psychological  and 
physical morbidity and the performance characteristics of the two screening 
strategies  will  provide  the  basis  for  the  NHS  to  implement  an  OCS 
programme.
One  of  the  main  challenges  in  setting  up  any  screening  programme  is 
quality  assurance.  This  is  especially  as  issue  when  the  strategy  involves 
screening tests such as ultrasound which have a definite subjective element. 
Work is underway to develop a well defined rigorous and sustainable quality 
assurance  programme  for  ovarian  ultrasound  together with  a  web  based 
training  and  accreditation  process.  The  work  is the  basis  of a  future  PhD 
which the researcher is supervising.
The serum bank together with follow up of all women in  UKCTOCS via the 
Office of National Statistics provides unique opportunities to improve on the 
currently  available  tests  through  discovery  of novel  biomarkers  for cancer 
screening.  Well  characterized  serum  samples  are  now  available  from
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women  many  years  ahead  of  their  cancer  diagnosis.  Projects  already 
underway include
1)  An  MRC  funded  biomarker  discovery  project  using  a  variety  of 
proteomic  technologies  for early  detection  of ovarian,  breast,  and 
other  cancers.  This  involves  collaborations  with  the  proteomics 
group  in  UCL,  Reading  University  and  National  Cancer  Institute 
laboratories in Washington,  US and bioinformatics support from the 
computer science department at Royal Holloway University, UK.
2)  An  NIH funded project in collaboration with  Pittsburgh  University in 
the US using high through put multiplex antibody assays to explore 
use  of  marker  panels  for  screening  for  ovarian  and  pancreatic 
cancer.
Integral to any screening  programme  is defining the target population with 
increased disease prevalence increasing the positive predictive value of the 
screening strategy. The data collected from women in the UKCTOCS cohort 
together  with  the  serum  samples  provides  the  opportunity  to  refine  risk 
assessment in the general population. Projects are underway to predict risk 
for  ovarian  and  breast  cancer  using  novel  strategies  which  include 
assessment of free  circulating  methylated  DNA in the serum.  This work is 
based  on an entirely new model of carcinogenesis proposed  by the group
i.e.  that tumour cells arise from  stem  cells whose  potential to differentiate 
has  been  irreversibly destroyed  by  means of CpG  island  methylation  and 
that  high  cell  turnover  and  lysis  leads  to  this  hypermethylated  tumour- 
derived  DNA in the blood stream.219 220 Work is also underway to built risk
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prediction models for breast and endometrial cancer using hormone profile 
including  oestrogen  bioactivity  and  ultrasound  data  of  ovarian  size  and 
endometrial thickness and morphology.
In  addition,  the  plan  is  to  approach  women  in  the  multimodal  arm  of 
UKCTOCS who have a blood test every year for consent to store DNA. This 
germline DNA would enable further refinement of risk prediction using single 
nucleotide  polymorphisms  for  a  number  of  common  diseases.  An 
international consortium (The Ovarian Cancer Association Consortium) has 
been  set-up  by the  researchers  involving  15  groups  across  USA,  Europe, 
and  Australia  for  a  case  control  study  involving  10,000  ovarian  cancer 
patients  and  matched  controls.  It  is  anticipated  that  UKCTOCS  would 
contribute towards this  and  other similar efforts to assess  risk  in  common 
cancers  like  breast  and  colon  as  well  as  common  diseases  such  as 
coronary heart disease.
The cohort also provides a unique opportunity to prospectively explore the 
role of symptoms in ovarian cancer by carrying out a symptom survey of the 
entire cohort. An MRC studentship has been awarded for this and a large 
study is being designed. Projects to further explore some of the findings 
noted in this thesis are also underway such as survey on management of 
menopausal symptoms given the falling trend noted in the UKCTOCS 
cohort of HRT use. Studies of risk prediction in other common diseases 
such as coronary heart disease are being explored.
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17.3  Oral presentations I published abstracts
The  role of ultrasonography in  a  multimodal screening  strategy for ovarian 
cancer.  Poster at British  Gynaecological Cancer Society Annual Meeting at 
Bristol on 8th  Nov, 1997.
The  role of ultrasonography in  a  multimodal screening strategy for ovarian 
cancer.  William  Harvey  Day,  St  Bartholomew’s  and  the  Royal  London 
School of Medicine and Dentistry at London on 20th  Oct, 1998.
Risk of Ovarian Cancer Algorithm (ROCA) for the Early Detection of Ovarian 
Cancer XXVIII International Society for Oncodevelopmental Biology Meeting 
at Munich on  9th  September 2000
Screening  for  Ovarian  Cancer  National  Screening  Committee  Meeting  on 
Screening for late onset genetic disorders -  breast ovarian cancer at Cardiff 
on 10th  November 2000.
Further  thoughts  on  ovarian  cancer  screening  Gynaecological  Oncology 
meeting  -  Cervical  and  Ovarian  Cancer  at  St  George’s  Hospital  Medical 
School on 24th  November 2000
Developments in screening and preoperative diagnosis of ovarian cancer at 
Regional  Scientific  Meeting  of  Association  of  Clinical  Biochemists  at 
Edinburgh on 6th  March 2001
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Screening  for  Ovarian  Cancer  Principle  and  practice  of  screening  in 
obstetrics and gynaecology at North West Wales NHS Trust on 30th  March 
2001.
Screening for Ovarian  Cancer Gynaecological  Ultrasound  Course at Royal 
College of Obstetricians and Gynaecologists on 19th  September 2001.
Screening for Ovarian  Cancer The silent disease -  Ovarian  Cancer at the 
Royal Surrey County Hospital NHS Trust on 24th  September 2001
Sonography  in  ovarian  cancer screening  -  Review and  update  of ongoing 
trials at 4th Annual International Ovarian Cancer Screening Meeting at Fred 
Hutchinson Cancer Research Centre, Seattle on 7th  November 2001.
Evaluation of sonography data in ovarian cancer screening trials 4th Annual 
International Ovarian Cancer Screening Meeting at Fred Hutchinson Cancer 
Research Centre, Seattle on 7th  November 2001.
Screening  for  Ovarian  Cancer  Screening  in  Gynaecological  Oncology  at 
Sint-Augustine Hospital, Antwerp  on 7th  November 2001.
Screening for Ovarian Cancer European Society of Urogenital Radiology at 
Genoa on 17th  June 2002
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Screening for Ovarian Cancer Key advances in the effective management of 
Ovarian Cancer at Royal College of Physicians 2002
Ovarian  cancer  screening  4th  Ovarian  Cancer  Research  Symposium  at 
Swedish Medical Centre, Seattle on 19th  September 2002.
Progress in  Screening for Ovarian Cancer All  India Congress of Obstetrics 
and Gynaecology at Bangalore  on 8th  January 2003.
Current  ovarian  cancer  screening  trials  Helene  Harris  Memorial  Trust 
Meeting at Stratford on Avon on 27th  March 2003
Prevalence  screening  for  ovarian  cancer  using  Risk  of  Ovarian  Cancer 
Algorithm  European Society of Gynaecological Oncology at Brussels on 7th  
April 2003.
Screening  for  Ovarian  Cancer  at  the  Gynaecology  Nursing  Forum 
Conference of Royal College of Nursing at Leeds on 8th  May 2003.
Screening  for  Ovarian  Cancer  -   Current  Trials  at  the  Annual  Joint 
Gynaecology Oncology Meeting at Institute of Molecular Medicine at Oxford 
on 15th  October 2003.
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United  Kingdom  Familial  Ovarian  Cancer  Screening  Study  at  Annual 
Meeting of the Traveller's Society at Bart's and the London NHS Trust on 3rd  
Nov 2003.
Screening  for  Sporadic  Ovarian  Cancer  at  the  13th   Annual  Meeting  in 
Honour of Professor Per Kolstad,  Norwegian  Radium  Hospital,  Oslo on  5th  
Dec 2003.
Will  ovarian  cancer screening  save  lives?  at 25th  Anniversary  Meeting  of 
British Gynaecological Cancer Society at Royal College of Obstetricians and 
Gynaecologists on 20th  May 2004.
UK  Collaborative  Trial  of  Ovarian  Cancer  Screening  at  the  10th  Biennial 
IGCS Meeting at Edinburgh on 3rd  Oct 2004.
Ovarian  cancer  Will  screening  impact  on  mortality?  at  The  Practical 
Management of Ovarian Cancer meeting at London on 9th  March 2005.
Ovarian  Cancer  Screening  Trials  at  the  Cancer  Ideas  Workshop  at 
University College London on 21s t April 2005.
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